Conf idential and Proprietary – Property of Ultragenyx Pharmaceutical Inc.  CLINICAL STUDY PROTOCOL  
IND NUMBER: 17190  
EUDRACT NUMBER: 2016 -001057- 40 
 
A Phase 1/2, Open-Label Safety and Dose -Finding Study of Adeno -Associated Virus (AAV) 
Serotype 8 (AAV8) -Mediated Gene Transfer of Human Ornithine Transcarbamylase (OTC) in 
Adults with Late -Onset OTC Deficiency  
  
 Protocol Number: 301OTC01  
Sponsor:  Ultragenyx Pharmaceutical Inc. 
840 Memorial Drive  
Cambridge, MA 02139  
Sponsor Contact:  Ana Cristina Puga, MD, PhD Vice President, Clinical Development  
Ultragenyx Pharmaceutical  
Telephone:  
Medical Monitor:  
Medical Director, Pharmacovigilance PPD 
929 North Front Street  
Wilmington, NC 28401  
Telephone:  
Version of Protocol:  06 
Date of Protocol:  Amendment 5: 25 February 2020  
Amendment 4: 11 June 2019  
Amendment 3: 07 February 2017  
Amendment 2: 20 December 2016  
Amendment 1: 18 August 2016  
Original: 29 March 2016  
 
CONFIDENTIAL  
All financial and nonfinancial support for this study will be provided by Ultragenyx Pharmaceutical 
Inc. The concepts and information contained in this document or generated during the study are 
considered proprietary and may not be disclosed in whole or in part without the expressed, written 
consent of Ultragenyx Pharmaceutical.  
The study will be conducted according to the International Council for Harmonisation harmonised tripartite guideline E6(R2): Good Clinical Practice.  
 

Ultragenyx Pharmaceutical Inc. 
Protocol: 30 I OTCO I DTX301 
Protocol Approval 
Study Title A Phase 1/2, Open-Label Safety and Dose-Finding Study of Adeno-Associated 
Virus (AA V) Serotype 8 (AA V8)-Mediated Gene Transfer of Human 
Omithine Transcarbamylase (OTC) in Adults with Late-Onset OTC 
Deficiency 
Protocol Number 3010TC01 
Protocol Version 06 
Protocol Date Amendment 5: 25 February 2020 
Amendment 4: 11 June 2019 
Amendment 3: 07 February 2017 
Amendment 2: 20 December 2016 
Amendment 1: 18 August 2016 
Original: 29 March 2016 
Protocol accepted and approved by: 
Sponsor Signatory 
Ana Cristina Puga, MD, PhD 
Date 
Page 2 of123 
Version 06 25 February 2020 

Ultragenyx Pharmaceutical Inc.  DTX301  
Protocol: 301OTC01   
Page 3 of 126 
Version 06   25 February 2020 Table of Contents  
Table  of Contents ....................................................................................................................... 3  
List of Tables  .............................................................................................................................. 8  
List of Figures ............................................................................................................................ 8  
Protocol Synopsis..................................................................................................................... 10  
List of Abbreviations ................................................................................................................ 25  
1 Introduction ...................................................................................................................... 27  
1.1 Adeno- Associated Viral  Vectors  ............................................................................. 29  
1.2 Selection of the AA V Clinical Candidate  ................................................................ 30  
1.3 Study Rationale ....................................................................................................... 31  
1.3.1  Design Rationale ...................................................................................... 31  
1.3.2  Dosing Rationale ..................................................................................... 34  
2 Study Objectives and Endpoints ....................................................................................... 37  
3 Investigational Plan  .......................................................................................................... 39  
3.1 Study Overview ...................................................................................................... 39  
3.2 Overall Study Duration and Follow- Up .................................................................. 40  
3.2.1  Screening Period ...................................................................................... 42  
3.2.2  Baseline Period  ........................................................................................ 43  
3.2.2.1  Baseline Visit – Day 0 ............................................................................. 43  
3.2.2.2  Baseline – Day 1  ...................................................................................... 43  
3.2.3  Treatment Period  ...................................................................................... 44  
3.2.3.1  Hom e or Clinic Visits  .............................................................................. 44  
3.2.3.2  Outpatient Clinic or Home Health Service Visits  .................................... 45  
3.2.3.3  Inpatient Visits  ......................................................................................... 45  
3.2.4  Tapering of Ammonia Scavenger Therapy .............................................. 45  
3.2.5  Modification of Dietary Restrictions  ....................................................... 47  
3.2.6  Occurrence of Hyperammonemia and Hyperammonemic Crisis (HAC) 48  
3.2.7  Safety Stopping Criteria ........................................................................... 48  
3.2.8  End of Study ............................................................................................ 49  
4 Subject Selection  .............................................................................................................. 49  
Ultragenyx Pharmaceutical Inc.  DTX301  
Protocol: 301OTC01   
Page 4 of 126 
Version 06   25 February 2020 4.1 Inclusion Criteria  .................................................................................................... 49  
4.2 Exclusion Criteria  ................................................................................................... 51  
5 Screening and Randomization Procedures ....................................................................... 53  
5.1 Subject Screening.................................................................................................... 53  
5.2 Subject Randomization  ........................................................................................... 53  
6 Study Treatment  ............................................................................................................... 54  
6.1 Identity of DTX301 ................................................................................................ 54  
6.1.1  Description of DTX301  ........................................................................... 54  
6.1.2  Components Used for Manufacturing DTX301 ...................................... 54  
6.2 Management of Clinical Supplies ........................................................................... 54  
6.2.1  Packaging and Labeling ........................................................................... 54  
6.2.2  Storage of Study Product ......................................................................... 55  
6.2.2.1  Storage of DTX301 .................................................................................. 55  
6.2.3  Study Product Accountability  .................................................................. 55  
6.2.4  Transmission of Infectious Agents ........................................................... 55  
6.2.5  Exposure to Radiation  .............................................................................. 55  
6.3 Treatment Schedule and Administration  ................................................................. 56  
6.3.1  Administration of [1 -13C]Sodium Acetate  ............................................... 56  
6.3.2  Administration of DTX301 ...................................................................... 56  
6.3.3  Treatment Compliance  ............................................................................. 57  
6.4 Prior and Concomitant Therapy .............................................................................. 57  
6.4.1  Permitted Medications  ............................................................................. 57  
6.4.2  Prohibited Medications  ............................................................................ 58  
7 Withdrawal of Subjects From the Study ........................................................................... 59  
7.1 Study Withdrawal  .................................................................................................... 59  
7.2 Subject Replacem ent ............................................................................................... 59  
8 Study Assessments and Procedures  .................................................................................. 60  
8.1 Efficacy Assessments .............................................................................................. 60  
8.1.1  Ureagenesis  .............................................................................................. 60  
8.1.2  Plasma Ammonia Area Under the Curve from Time Zero to 24 Hours .. 60  
8.2 Safety Assessments  ................................................................................................. 60  
Ultragenyx Pharmaceutical Inc.  DTX301  
Protocol: 301OTC01   
Page 5 of 126 
Version 06   25 February 2020 8.2.1  Physical Examination  .............................................................................. 61  
8.2.2  Vital Sign Measurements  ......................................................................... 61  
8.2.3  Electrocard iograms .................................................................................. 62  
8.2.4  Clinical Laboratory Analyses ................................................................... 62  
8.2.4.1  Clinical Laboratory Parameters  ............................................................... 63  
8.2.4.1.1  Elevation of Liver Function Tests ................................................ 65  
8.2.4.1.2  Treatment for Possible Vector -Induced Hepatitis ........................ 66  
8.2.5  Other Laboratory Parameters  ................................................................... 68  
8.2.5.1  Neutralizing Antibodies to Adeno- Associated Virus Serotype 8  ............. 68  
8.2.5.2  Adeno- Associated V irus Serotype 8 Binding Antibody Immunoglobulin 
G Assay  .................................................................................................... 68  
8.2.5.3  Anti-Ornithine Transcarbamylase Antibody Assay ................................. 68  
8.2.5.4  Viral S hedding ......................................................................................... 68  
8.3 Pharmacokinetics and Pharmacodynamic Assessments  ......................................... 69  
8.3.1  Ureagenesis  .............................................................................................. 69  
8.3.2  Plasma Ammonia Area Under the Curve from Time Zero to 24 Hours .. 69  
8.3.3  Orotic Acid Excretion  .............................................................................. 70  
8.4 Quality -of-Life Assessment  .................................................................................... 70  
8.4.1  PROMIS Questionnaire  ........................................................................... 70  
8.5 Neuropsychological Tests  ....................................................................................... 70  
8.5.1  Intelligence  .............................................................................................. 71  
8.5.2  Motor Function ........................................................................................ 72  
8.5.2.1   ............................................................ 72  
8.5.3  Executive Function .................................................................................. 72  
8.5.3.1  ................. 72  
8.5.4  Memory  .................................................................................................... 72  
8.5.4.1   
 ........................................ 72  
8.6 Genotyping .............................................................................................................. 73  
8.6.1  Ornithine Transcarbamylase Genotyping  ................................................ 73  
8.7 Other Assessments  .................................................................................................. 73  
8.7.1  Demographic, Medical, and Ornithine Transcarbamylase Deficiency 
History Assessments ................................................................................ 73  
8.7.2  Ammonia Scavenger Use and Dietary Protein Intake ............................. 73  

Ultragenyx Pharmaceutical Inc.  DTX301  
Protocol: 301OTC01   
Page 6 of 126 
Version 06   25 February 2020 9 Safety Monitoring and Reporting ..................................................................................... 74  
9.1 Adverse Events and Serious Adverse Events ......................................................... 74  
9.1.1  Definitions  ............................................................................................... 74  
9.1.1.1  Adverse Events ........................................................................................ 74  
9.1.1.2  Serious Adverse Events  ........................................................................... 75  
9.1.2  Safety Reporting ...................................................................................... 75  
9.1.2.1  Adverse Events ........................................................................................ 75  
9.1.2.2  Serious Adverse Events  ........................................................................... 76  
9.1.2.2.1  Expedited Reporting .................................................................... 77  
9.1.3  Assessment of Severity/Toxicity  ............................................................. 77  
9.1.4  Assessment of Causality  .......................................................................... 78  
9.1.5  Follow-Up of Subjects Reporting Adverse Events .................................. 79  
9.2 Procedures for Handling Special Situations ........................................................... 79  
9.2.1  Pregnancy ................................................................................................ 79  
9.2.2  Treatment Noncompliance ....................................................................... 80  
9.2.2.1  Overdose Management  ............................................................................ 80  
9.2.2.2  Medication Errors  .................................................................................... 80  
9.3 Data Monitoring Committee  ................................................................................... 81  
10 Statistical and Ana lytical Plan  .......................................................................................... 81  
10.1  Dose -Finding Algorithm and Process ..................................................................... 81  
10.2  Primary Endpoints .................................................................................................. 82  
10.3  Secondary Endpoints .............................................................................................. 82  
10.4  Exploratory Endpoints  ............................................................................................ 82  
10.5  Statistical Analysis Methodology  ........................................................................... 82  
10.5.1  Determination of the Optimal Biological Dose  ....................................... 83  
10.5.2  Efficacy Analysis  ..................................................................................... 85  
10.5.2.1  Ureagenesis  .............................................................................................. 85  
10.5.2.2  Plasma Ammonia Area Under the Curve from Time Zero to 24 Hours .. 86  
10.5.3  Safety Analyses  ........................................................................................ 86  
10.5.3.1  Adverse Events ........................................................................................ 86  
10.5.3.2  Physical Examination Findings ............................................................... 86  
10.5.3.3  Vital Sign Measurements  ......................................................................... 86  
Ultragenyx Pharmaceutical Inc.  DTX301  
Protocol: 301OTC01   
Page 7 of 126 
Version 06   25 February 2020 10.5.3.4  Electrocardiogram Results  ....................................................................... 86  
10.5.3.5  Clinical Laboratory Assessment Results  ................................................. 87  
10.5.3.6  Other Laboratory Results ......................................................................... 87  
10.5.4  Neuropsychological Tests  ........................................................................ 87  
10.5.5  Quality -of-Life Assessment  ..................................................................... 87  
10.5.6  Other Analyses  ......................................................................................... 87  
10.5.7  Interim Analysis  ....................................................................................... 87  
10.6  Data Quality Assurance ........................................................................................... 88 
10.6.1  Data Management  .................................................................................... 88  
11 Ethics  ................................................................................................................................ 89  
11.1  Institutional Review Board, Independent Ethics Committee, and Institutional 
Biosafety Committee  ....................................................................................... 89  
11.2  Ethical Conduct of the Study .................................................................................. 90  
11.3  Subject Information and Consent ........................................................................... 90  
12 Investigator’s Obligations ................................................................................................ 90  
12.1  Confidentiality  ........................................................................................................ 91  
12.2  Financial Disclosure and Obligations ..................................................................... 91  
12.3  Investigator Documentation .................................................................................... 91  
12.4  Study Conduct ......................................................................................................... 92  
12.5  Adherence to Protocol ............................................................................................ 92  
12.6  Adverse Events and Study Report Requirements ................................................... 92  
12.7  Investigator’s Final Report ..................................................................................... 93  
12.8  Record Retention .................................................................................................... 93  
12.9  Publications ............................................................................................................. 93  
13 Study Management ........................................................................................................... 93  
13.1  Monitoring .............................................................................................................. 93  
13.1.1  Monitoring of the Study ........................................................................... 93  
13.1.2  Inspection of Records .............................................................................. 94  
13.2  Management of Protocol Amendments and Deviations.......................................... 94  
13.2.1  Modification of the Protocol .................................................................... 94  
13.2.2  Protocol Deviations ................................................................................. 94  
Ultragenyx Pharmaceutical Inc.  DTX301  
Protocol: 301OTC01   
Page 8 of 126 
Version 06   25 February 2020 13.3  Study Termination  ................................................................................................... 95  
13.4  Final Report ............................................................................................................ 95  
14 Reference List ................................................................................................................... 97  
15 Appendices ..................................................................................................................... 103  
15.1  Appendix: Schedules of Events ............................................................................ 103  
15.2  Quality of Life Questionnaire  ............................................................................... 112 
15.2.1  PROMIS Questionnaire  ......................................................................... 112 
15.3  Protocol Amendment History and Summary of Changes ..................................... 116 
15.3.1  Amendment 1 (dated 18 August 2016) .................................................. 116 
15.3.2  Amendment 2 (dated 20 December 2016) ............................................. 117 
15.3.3  Amendment 3 (dated 07 February 2017) ............................................... 118 
15.3.4  Amendment 4 (dated 11 June 2019) ...................................................... 119 
15.3.5  Amendment 5 (dated 25 February 2020) ............................................... 121  
 
List of Tables  
Table  8-1  Clinical Laboratory Parameters  ...................................................................... 64  
Table  9-1  PPD PVG Contact Information for SAE Reporting ....................................... 76  
Table  9-2  General Guidelines for Grading Events not Captured by the CTCAE ........... 78  
Table  15-1  Schedule of Events – Outpatient, Home Health Services, and Inpatient Clinic 
Visits  ............................................................................................................. 104  
Table  15-2  Schedule of Events – Clinic or Home Visits During the Initial 12 -Week 
Treatment Period  ............................................................................................ 111 
 
List of Figures  
Figure 1-1  Overview of the Urea Cycle  ........................................................................... 27  
Figure 3-1  Study Design ................................................................................................... 41  
Figure 10-1   
 .................................................................... 84  

Ultragenyx Pharmaceutical Inc.  DTX301  
Protocol: 301OTC01   
Page 9 of 126 
Version 06   25 February 2020 Figure 10-2   
............................................................................................. 85 
 

Ultragenyx Pharmaceutical Inc.  DTX301  
Protocol: 301OTC01   
Page 10 of 126 
Version 06   25 February 2020 Protocol Synopsis  
Protocol Number:  301OTC01 
Title: A Phase 1/2, Open -Label Safety and Dose -Finding Study of Adeno -Associated 
Virus (AAV) Serotype 8 (AAV8) -Mediated Gene Transfer of Human Ornithine 
Transcarbamylase (OTC) in Adults with Late -Onset OTC Deficiency  
Sponsor:  Ultragenyx Pharmaceutical Inc.  
840 Memorial Drive  
Cambridge, MA 02139  
Study Phase:  Phase 1/2  
Sample Size:  The study is anticipated to enroll up to 18  subjects  
Study Sites:  Approximately 20 global study sites  
Indication:  OTC deficiency  
Primary Objective:  • To determine the safety of sin gle intravenous (IV) doses of DTX301 in 
adults with late -onset OTC deficiency.  
Secondary 
Objectives:  • To establish a dose of DTX301 that has a meaningful increase in the rate of ureagenesis to allow further clinical development.  
• To evaluate the efficacy of  single IV doses of DTX301 in adults with 
late-onset OTC deficiency, in the setting of tapering or discontinuing 
ammonia scavenger medications.  
Exploratory Objectives:  • To assess the impact of DTX301, by dose, on the number of hyperammonemic crises during the study.  
• To evaluate the effect of DTX301, by dose, on urinary orotic acid levels.  
• To evaluate the effect of DTX301, by dose, on plasma glutamine and glutamate levels.  
• To assess the impact of DTX301, by dose, on the subject’s neuropsychological functioni ng. 
• To assess the impact of DTX301, by dose, on the subject’s quality of life (QoL).  
• To assess the impact of DTX301, by dose, on the use of ammonia scavengers.  
• To assess the impact of DTX301, by dose, on dietary protein restriction.  
• To describe the immune response to AAV8 capsid proteins after IV 
administration of DTX301.  
• To describe the immune response to OTC after IV administration of DTX301.  
Primary Endpoints:  • The incidence of adverse events (AEs), treatment- emergent adverse events 
(TEAEs), and serious adverse events (SAEs) for each dosing cohort, 
assessed by severity and relationship to study product.  
Ultragenyx Pharmaceutical Inc.  DTX301  
Protocol: 301OTC01   
Page 11 of 126 
Version 06   25 February 2020 Secondary 
Endpoints:  • The change from baseline in the rate of ureagenesis (as measured by the 
generation of [13C]urea over 4 hours) as determined by gas c hromatography 
mass spectrometry over time to 52  weeks after the IV administration of 
DTX301.  
• The change from baseline (Day 0) in plasma ammonia area under the curve 
from time zero to 24 hours (AUC 0-24) over time to 52  weeks after IV 
administration of DTX30 1 in the setting of tapering or discontinuing 
ammonia scavenger medications.  
Exploratory 
Endpoints:  • The number of hyperammonemi c crises  observed for each dose over time to 
52 weeks after IV administration of DTX301.  
• The change from baseline in urinary orotic acid excretion over time to 52 weeks after IV administration of DTX301.  
• The change from baseline in serum glutamine and glutamate over time to 52 weeks after IV administration of DTX301.  
• Changes in responses to the  
 
 Working Memory Index (WMI), will be summarized by 
dose level of DTX301.  
• Responses to the Patient -Reported Outcomes Measurement Information 
System (PROMIS
®) questionnaire, summarized by dose level of DTX301 
over time to Week 52.  
• Use of ammonia scavengers, summarized by dose level of DTX301.  
• Change in dietary protein intake, summarized by dose level of DTX301.  
• The development of neutralizing antibodies to AAV8 (as determined by a cell-based assay), summarized by time point and dose level of DTX301.  
• The development of anti -AAV8 binding antibodies (as determined by 
enzyme- linked immunosorbent assay [ELISA]), summarized by time point 
and dose level of DTX301.  
• The development of anti -OTC antibodies (as determined by ELISA), 
summarized by time point and dose level of DTX301.  
Subject Population:  Inclusion Criteria  
Each subject must meet all of the following criteria at Screening to be enrolled in 
this study: 
1. Willing and able to provide written informed consent.  
2. Males and females ≥  18 years of age with documented diagnosis of 
late-onset (defined as first manifestation of signs and symptoms at 
> 30 days of age) OTC  deficiency, confirmed via enzymatic, biochemical, 
or molecular testing. This may include identification of a pathogenic mutation, pedigree analysis, liver OTC activity that is <  20% of normal 
activity, or elevated urinary orotate (>  20 µmol/ mmol creatinine) after an 
allopurinol challenge test.  
3. Documented history of ≥  1 symptomatic hyperammonemia event with 

Ultragenyx Pharmaceutical Inc.  DTX301  
Protocol: 301OTC01   
Page 12 of 126 
Version 06   25 February 2020 ammonia ≥  100 µmol/L.  
4. Subject’s OTC deficiency is stable as evidenced by either a) no clinical 
symptoms of hyperammonemia OR b) plasma ammonia level 
< 100 µmol/L within the 4 -week period preceding the Screening visit.  
5. Subject’s plasma ammonia level on Day 1 (predose) is < 100 µmol/L, for 
patients who historically maintain normal ammonia levels, and the subject 
is clinically stable; O R subject’s plasma ammonia level on Day 1 
(predose) is <  200 µmol/L, for patients who historically are not able to 
fully control ammonia levels with baseline management, and the subject is 
clinically stable. If the Day 1 (predose) ammonia level is inconsistent with 
the subject’s clinical status, the ammonia level may  be repeated to ensure 
accurate results.  
6. On ongoing daily stable  dose of ammonia scavenger therapy for 
≥ 4 weeks.  
7. No known allergic reaction to any component of DTX301.  
8. Willing and able to comply with study procedures and requirements, including periodic inpatient hospitalizations, frequent blood draws, and 
urine collections over a 24 -hour period.  
9. Hematology and coagulation panel results are within the normal range or, if outside the normal range, deemed not clinically significant in the opinion of the investigator.  
10. Males and all females of childbearing potential must be willing to use 
effective contraception at the time of administration of gene transfer and 
for the 52  weeks following administration of DTX301 to prevent the 
potential transmission of the AA V vector. For male subjects, appropriate 
contraceptive methods include the use of a condom with spermicide. For female subjects, appropriate contraceptive methods include the use of a condom with spermicide plus at least 1 of the following:  
a. Oral contracept ives, other hormonal contraceptives (vaginal products, 
skin patches, or implanted or injectable products), or mechanical products such as an intrauterine device;  
b. Use of a diaphragm or cervical/vault cap;  
c. Previous female sterilization (surgical bilateral oo phorectomy [with or 
without hysterectomy] or tubal ligation) at least 6 weeks prior to DTX301 administration. In case of an oophorectomy alone, the reproductive status of the subject must have been confirmed by follow -up hormone level assessment.  
NOTE:  Abstinence is an acceptable form of birth control; however, appropriate 
contraception must be used if the subject becomes sexually active. Abstinence is 
defined as sexual inactivity consistent with the preferred and usual lifestyle of the subject. Periodic ab stinence (calendar, symptothermal, post -ovulation 
methods), withdrawal (coitus interruptus), spermicides only, and lactational amenorrhea methods are not acceptable methods of contraception.
 A condom 
with spermicide is required to be used by all sexually a ctive vasectomized males 
Ultragenyx Pharmaceutical Inc.  DTX301  
Protocol: 301OTC01   
Page 13 of 126 
Version 06   25 February 2020 in the study in order to prevent potential transmission of the vector via seminal 
fluid.  
 
NOTE:  Females of childbearing potential are defined as all females 
physiologically capable of becoming pregnant, unless they are using highly  
effective methods of contraception for the duration of the study.  
Females are considered post -menopausal and not of childbearing potential if they 
have had 12 months of natural (spontaneous) amenorrhea with an appropriate 
clinical profile (eg, age appropr iate, history of vasomotor symptoms) or have had 
surgical bilateral oophorectomy (with or without hysterectomy) or tubal ligation 
at least 6  weeks prior to enrollment. In the case of oophorectomy alone, only 
when the reproductive status of the woman has been confirmed by follow up 
hormone level assessment is she considered not of childbearing potential.  
Exclusion Criteria:  
Subjects meeting any of the following criteria at Screening will be excluded from the study: 
1. At Screening or Baseline (Day 0), plasma ammonia level ≥ 100 µmol/L 
for patients who historically maintain normal ammonia levels; OR plasma 
ammonia level ≥ 200 µmol/L for patients who historically are not able to 
fully control ammonia levels with baseline management; OR signs and 
symptoms of hypera mmonemia, with documented elevated ammonia 
level, during the 4- week period preceding Day 0. If the ammonia level is 
inconsistent with the subject’s clinical status, the ammonia level may be repeated to ensure accurate results . 
2. Liver transplant, including hepatocyte cell therapy/transplant.  
3. History of liver disease as evidenced by any of the following: portal 
hypertension, ascites, splenomegaly, esophageal varices, hepatic 
encephalopathy, or a liver biopsy with evidence of stage 3 fibrosis.  
4. Significant hepat ic inflammation or cirrhosis as evidenced by imaging or 
any of the following laboratory abnormalities: alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > the upper limit of normal (ULN), total bilirubin >  1.5 × ULN, alkaline phosphatase > 2.5 × ULN.  
5. Serum creatinine > 2.0 mg/dL.  
6. Evidence of active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection, documented by current use of antiviral therapy for HBV or HCV 
or by hepatitis B surface antigen (HBsAg) or HCV RNA positivity. 
NOTE: Subjects with a history of HCV infection must have 
documentation of 2 negative viral assays by polymerase chain reaction 
(PCR), collected at least 6 months apart, to be considered negative for 
HCV. Subjects with a history of HCV infection who test positive for HCV 
RNA at Screening can be rescreened once, after they have been treated and have documentation of at least 2 negative samples collected at least 6 months apart.  
7. History of human immunodeficiency virus (HIV) infection AND any of 
the following: CD4+ c ell count <  350 cells/mm3, change in antiretroviral 
Ultragenyx Pharmaceutical Inc.  DTX301  
Protocol: 301OTC01   
Page 14 of 126 
Version 06   25 February 2020 therapy regimen within 6 months prior to Day 0, or plasma viral load 
> 200 copies/mL, documented on 2 separate occasions, as measured by 
PCR.  
8. Active infection (viral or bacterial).  
9. Anti-AAV8 neutralizing antibody titer ≥  1:5. 
10. Participation (current or previous) in another gene transfer study.  
11. Participation in another investigational medicine study within 3  months of 
Screening.  
12. History of a malignancy for which the subject has received treatment in 
the past  2 years except for prostate cancer treated with watchful waiting or 
surgically removed non -melanoma skin cancer.  
13. Has a positive serum pregnancy test at Screening (females of childbearing 
potential only), a positive urine pregnancy test at Baseline (Day 0;  females 
of childbearing potential only), or is nursing.  
14. Has any other significant medical condition that the investigator feels 
would be a risk to the subject or would impede the study.  
Study Design:  This is a Phase 1/2, open -label, single arm, multicent er, safety and dose -finding 
study of DTX301 in adults with late -onset OTC deficiency. The primary 
objective of the study is to determine the safety of single IV doses of DTX301. A key element  of the study is the identification of  the optimal biological dos e 
(OBD) of DTX301 . The secondary objectives of the study are the assessment of 
rate of ureagenesis, reflecting the direct in vivo  efficiency of the urea cycle and 
the assessment of plasma ammonia (AUC
0-24), reflecting clinical metabolic 
control. The target  for DTX301 is to achieve a rate for ureagenesis of 
approximately 300 µmol/kg/hr (±10%), which is the approximate rate of ureagenesis in healthy adults.  
Eligible subjects will receive a single IV infusion of DTX301. Three subjects  
will be enrolled in Coho rt 1 and a minimum of 2  to 3 subjects will be enrolled in 
each subsequent cohort. Dose escalation will be conducted according to a model that uses the collected data to predict the safety profile of the dose in order to 
determine the OBD. There will be a m inimum of 12 weeks between the dosing 
of the last subject in one dosing cohort and the first subject in the next dosing 
cohort followed by data monitoring committee (DMC) review of a dosing cohort up to Cohort 3. Dosing of additional subjects as expansion of Cohort 3, and 
initiation of Cohort 4 (Dosing Process Optimization) may occur in parallel, 
following the DMC review of a minimum of 12 weeks of data from the initial 3 
subjects in Cohort 3. A continual reassessment method (CRM) will be used for dose finding to discover the OBD of DTX301. Cohort 4 is intended to dose at 
OBD.  
Subjects will be followed for 52 weeks after dosing. After completion of this 
study, subjects will be asked to enroll in a 4 -year extension study to evaluate the 
long-term (a total of 5 years  after dosing ) safety and efficacy  of DTX301.  
Study 
Methodology:  Screening Period  
After a subject has provided written informed consent, the investigator or other 
Ultragenyx Pharmaceutical Inc.  DTX301  
Protocol: 301OTC01   
Page 15 of 126 
Version 06   25 February 2020 qualified study personnel will determine if the subject is eligible for the study. 
This will be accomplished by reviewing the inclusion and exclusion criteria and 
completing all of the screening assessments. Screening assessments may be 
performed on more than 1 day; all assessments must be completed and results 
available and reviewed prior  to Day  0. 
Screening Assessments: Demographic data; OTC and general medical history; prior medications, therapies, and procedures; use of ammonia scavengers; dietary 
protein restrictions; vital sign measurements; height and weight will be recorded. 
A 12 -lead electrocardiogram (ECG) and a complete physical examination will be 
performed. Blood samples will be collected for HBV, HCV, and HIV status; serum pregnancy test (females of childbearing potential only); AAV8 neutralizing antibody testing; AAV8 binding antibody immunoglobulin G (IgG) 
testing, and clinical laboratory assessments (clinical chemistry , plasma ammonia 
[STAT sample] , hematology, urinalysis, and coagulation panel). Adverse events 
and SAEs will be monitored after the subject has provided written informed 
consent.  
Subjects will be administered [1 -
13C]sodium acetate orally. Blood samples for 
determination of ureagenesis will be collected, via an indwelling catheter, before dosing (time 0) and at approximately 0.5, 1, 1.5, 2, 3, and 4  hours after dosing 
with [1 -
13C]sodium acetate.  During Screening, assessment of rate of ureagenesis 
may be repeated if discrepant with subject’s clinical status and severity.  
Subjects participating in Cohort 4 (Dosing Process Optimization) will start the prophylactic cor ticosteroid regimen at least 5 days prior to dosing with DTX301.  
The subject must be assessed as clinically and metabolically stable, and 
intercurrent illnesses (eg, viral infection) or concomitant medications known to affects transaminases, be excluded. A t any time after in itiation  of prophylactic 
corticosteroid regimen, additional assessments of plasma ammonia levels, amino acid profiles or any other biomarker to assess subject safety and clinical status 
may be performed, at the discretion of the investigator  and as clinically 
indicated . 
Day 0 – Baseline Measurements  
Subjects will be admitted on Day 0 for the baseline determination of the 
following: plasma ammonia ( AUC
0-24) and urinary orotic acid levels over 
24 hours.  
Prior to the determination of plasma  ammonia AUC 0-24, blood samples will be 
collected for OTC genotyping, AAV8 neutralizing antibody testing, AAV8 binding antibody IgG testing, anti -OTC antibody testing, amino acid panel, and 
clinical laboratory assessments (clinical chemistry , plasma ammoni a [STAT 
sample] , hematology, urinalysis, and coagulation panel). Saliva, urine, and stool 
samples will be collected to provide a baseline for assessment of viral shedding. 
A urine pregnancy test will be performed on all female subjects of childbearing 
potential. An ECG and a targeted physical examination will be performed. Vital 
sign measurements and weight will be recorded. Adverse events and SAEs will 
be monitored; concomitant medications, therapies, and procedures, use of ammonia scavengers and dietary p rotein restrictions will be recorded.  
Ultragenyx Pharmaceutical Inc.  DTX301  
Protocol: 301OTC01   
Page 16 of 126 
Version 06   25 February 2020 Subjects participating in Cohort 4 (Dosing Process Optimization) will start the 
prophylactic corticosteroid regimen at least 5 days prior to dosing with DTX301.  
The subject will complete the PROMIS questionnaire to eva luate QoL prior to 
the neuropsychological tests.  
The subject’s plasma ammonia level should be < 100 µmol/L or within the range 
of historical ammonia levels obtained when the subject was clinically stable in 
order to perform the neuropsychological tests. The study site may use the time 0 (T 0) plasma ammonia sample (from AUC
0-24 plasma ammonia) analyzed by the 
local laboratory (STAT sample) to determine the subject’s plasma ammonia level. The result must be available prior to initiating the tests. If the amm onia 
level is inconsistent with  the subject’s clinical status, the ammonia level may be 
repeated to ensure accurate results.  If the subject is deemed clinically unstable, 
the neuropsychological tests will be held . Subjects, in a nonfasted state, will 
compl ete the following neuropsychological tests: 
IQ:  
Motor Function :  
Executive Function :  
Memor y:  
Blood samples will be collected for the determination of plasma ammonia (AUC
0-24) at time 0 and at approximately 2, 4, 8, 12, 16, 20, and 24  hours. Urine 
will be collected for the determination of orotic acid at time 0 and at 
approximately 6,  12, 18, and 24 hours (relative to the start of plasma ammonia 
determination). Urine orotic acid concentration will be standardized to urine 
creatinine concentration.  
Day 1 – Determination of Plasma Ammonia, Ureagenesis , and DTX301 
Infusion  
The subject’s plasma ammonia level should  be < 100 µmol/L or within the range 
of historical ammonia levels obtained when the subject was clinically stable in 
order to receive [1 -13C]sodium acetate and DTX301. The 24 -hour time poi nt 
(T 24) from the local laboratory (STAT sample) for (AUC 0-24) of plasma 
ammonia can be used and the result available prior to administering 
[1-13C]sodium acetate.  If the ammonia level is inconsistent with the subject’s 
clinical status, the ammonia level may be repeated to ensure accurate results.  If 
the subject is deemed clinically unstable, administration of [1 -13C]sodium acetate 
will be held . Subjects will be administered [1 -13C]sodium acetate orally 
(morning of Day 1). Blood samples for determination o f ureagenesis will be 
collected, via an indwelling catheter, before dosing (time 0) and at approximately 0.5, 1, 1.5, 2, 3, and 4  hours after dosing with [1 -
13C]sodium acetate.  
Prior to the preparation of DTX301, a blood sample will be collected for clinic al 
chemistry (including liver function tests)  and vital sign measurements will be 
recorded. Adverse events and SAEs will be monitored; concomitant medications, 
therapies, and procedures, use of ammonia scavengers and dietary protein 

Ultragenyx Pharmaceutical Inc.  DTX301  
Protocol: 301OTC01   
Page 17 of 126 
Version 06   25 February 2020 restrictions will be re corded. Prior to the start of DTX301 infusion, the study site 
must confirm that the subject’s plasma ammonia level on Day 1 (predose) is 
< 100 µmol/L for patients who historically maintain normal ammonia levels, and 
the subject is clinically stable; O R subject’s plasma ammonia level on Day 1 
(predose) is < 200 µmol/L, for patients who historically are not able to fully 
control ammonia levels with baseline management, and the subject is clinically 
stable. If the Day 1 (predose) ammonia level is inconsistent with the subject’s 
clinical status, the ammonia level may be repeated to ensure accurate results.  
NOTE: If the subject is deemed clinically unstable, dosing will be held, and the 
subject can be rescreened once the subject is determined to be clinically stable . 
The 24 -hour time point ( time 24) from local laboratory (STAT sample) for 
(AUC 0-24) of plasma ammonia can serve as the DTX301 predose plasma 
ammonia result, if drawn within 12 hours of dosing with DTX301. If not, a new plasma ammonia (STAT sample) is t o be collected prior to dosing with DTX301.  
Subjects will receive a single IV infusion of DTX301. The start of DTX301 
infusion should be after all samples and procedures specified for Day 0 and 
Day 1 (predose) have been completed. Subjects will be discharged after a 
24-hour observation period.  
After dosing with DTX301, a blood sample will be collected for clinical 
laboratory assessments (clinical chemistry [including liver function tests]) at 
approximately 0.5, 4, 8, and 22 hours after the start of infusion . A second sample 
for liver function tests only will be collected and sent to the local laboratory 
(STAT sample). Vital sign measurements will be recorded at 5  minutes after the 
start of infusion, and at approximately 0.5, 1,  2, 4, 6, 8, and 22 hours after  the 
start of infusion. An ECG will be performed at 1 hour after the start of infusion.  
A single sample for plasma ammonia (STAT sample at local laboratory) will be collected and reviewed prior to discharging the subject.  
Subjects treated in Cohort 4 (Dosing Process Optimization) will utilize an 
alternative regimen of corticosteroids, aiming at prophylaxis of vector -induced 
hepatitis. Therefore, oral prednisone (or prednisolone) will be initiated before 
dosing with DTX301, sustained for 4 weeks, followed by  tapering.  At any time 
after in itiation  of prophylactic corticosteroid regimen, additional assessments of 
plasma ammonia levels, amino acid profiles or any other biomarker to assess 
subject safety and clinical status may be performed, at the discretion of the 
investigator  and as clinically indicated . 
Clinic or Home Visits  
Subjects will be asked to provide samples for clinical chemistry approximately 
every 4 days through Week 12 of the study. One sample for LFTs is collected as 
part of clinical chemistry and  sent to the central laboratory for analysis. A second 
sample for LFTs only is collected and sent to the local laboratory (STAT sample).  Through Week 12, one sample for spot ammonia will be collected 
approximately once per week and sent to the local labora tory (STAT sample). If 
subjects cannot visit the study site in person, subjects may have the option of being visited by clinically trained and qualified personnel (if available) 
approximately every 4 days at their home through Week 12; the exception being required study site visits when the subject must visit the study site in person.  At 
any point between scheduled visits, additional unscheduled assessment of LFTs, 
Ultragenyx Pharmaceutical Inc.  DTX301  
Protocol: 301OTC01   
Page 18 of 126 
Version 06   25 February 2020 plasma ammonia, or any other biomarker to assess subject safety and clinical 
status may be performed, at the discretion of the investigator.   
Weeks 2, 4, 10, 16, 20, and 36 (Outpatient Clinic Visit ) (Table  15-1) 
Where available, agreed upon by the investigator and allowed by local 
regulation, an outpatient clinic visit may take place as home health services. 
Week 20 visit is a mandatory outpatient clinic visit for all subjects  
(Table  15-1). 
Weeks 6, 12, and 24 (Inpatient Visit)  (Table  15-1) 
Subjects will be dischar ged following completion of all assessments, including 
plasma ammonia (AUC 0-24), urinary orotic acid levels over 24 hours, and 
ureagenesis. Subjects will be housed for approximately 28 hours . 
End of Study (Week 5 2)/Early Withdrawal Visit (Inpatient Visit)  
A comprehensive visit will occur at Week 52  (Table  15-1). Subjects will be 
dischar ged following completion of all assessments, including plasma  ammonia 
(AUC 0-24), urinary orotic acid levels over 24 hours, ureagenesis , and 
neuropsychological tests. Subjects will be housed for approximately 28 hours. Following completion of the Week 52 visit, subjects will be asked to enroll in a 
4-year extension study to evaluate the long -term (a total of 5  years  after dosing ) 
safety and efficacy of DTX301.   
Ultragenyx Pharmaceutical Inc.  DTX301  
Protocol: 301OTC01   
Page 19 of 126 
Version 06   25 February 2020 Tapering of 
Ammonia 
Scavenger Therapy  
and Protein -
Restricted Diet: There are multiple types of ammonia scavenger medications available globally 
and patients with OTC deficiency typical ly have a personalized prescription of 
one or more ammonia scavenger medications to optimize the management of 
their disease.  Adjustments to ammonia scavenger therapy may be considered 
following the Week 12 and Week 24 visits. Changes to baseline treatment  (ie, 
ammonia scavenger therapy and protein- restricted diet) cannot occur until there 
is evidence of transgene expression reflected  by continued evidence of metabolic 
stability with ammonia levels in the normal range  or improved ammonia control 
if subjects  have a history of ammonia levels above the upper limit of normal and 
supported by improvement in clinical signs and symptoms. The subject must be 
clinically stable and under good metabolic control before changes can be initiated or progressed. The risks o f making adjustments to baseline treatment on 
their own, without express guidance from the site, will be reinforced with the subject at site visits.  
Changes to baseline treatment cannot occur while the subject is treated with corticosteroids or within a 2- week period of completing a corticosteroid taper.  
Modification of ammonia scavenger therapy cannot occur at the same time as 
changes in protein- restricted diet. Once medications or diet are adjusted or 
discontinued , the subject must demonstrate good metab olic control prior to 
adjustments in the other type of baseline treatment.  
Modification of baseline treatment will be individualized, dependent on the clinical judgment of the investigator, and based on review of the totality of 
longitudinal clinical and laboratory data for each subject, including spot plasma 
ammonia levels, plasma ammonia (AUC
0-24), subject clinical 
stability/asymptomatic status, neurocognitive status, and subject- reported 
outcomes . Rate of ureagenesis cannot be used for decision -making i n 
modification of ammonia scavenger therapy or protein -restricted diet  and 
results will not be made available to the investigative sites until the end of 
the study . During periods of adjustment to baseline treatment , subject s will be 
closely monitored.  
At any time after modification and/or discontinuation of ammonia scavenger 
therapy, reinstitution of therapy may take place based on the subject’s  clinical 
and metabolic status (elevated ammonia levels or signs and symptoms consistent 
with hyperammonemia), and under evaluation of the investigator.   
Ultragenyx Pharmaceutical Inc.  DTX301  
Protocol: 301OTC01  
Page 20 of 126 
Version 06  25 February 2020 Tapering of 
Ammonia 
Scavenger Therapy and Protein -
Restricted Diet (continued):  Reinstitution of a mmonia scavenger therapy should be consider ed if:  
1.Subjects demonstrate 2 or more documented consecutive laboratory
results of hyperammonemia ( plasma ammonia level ≥ 100 µmol/L) .
NOTE: If the subject is clinically stable, spot ammonia may be repeatedif discre
pant with subject’s clinical status and severity, OR
2.Subjects demonstrate upward trending plasma  ammonia levels l ess than
100 µmol/L  and associated with clinical signs or symptoms suggestive
of worsening underlying  disease , OR
3.Subjects experience a time of increased metabolic demand, such as
intercurrent viral infection, treatment with steroids, hyperammonemia,or hy perammonemic crisis.
Learnings from this study will allow for the development of a more standardized protocol for tapering ammonia scavenger medications in future studies of DTX301.  
Occurrence of 
Hyperammonemia 
and Hyperammonemia Crisis (HAC) Consistent with the Urea Cycle Disorder s Consorti u m (UCDC), we have defined 
hyperammonemic crisis (HAC) in this study as an episode of signs and 
symptoms
 as
sociate d with hype rammonemia (such as frequent vomiting, nausea, 
headache
, lethargy, irritability, combativeness,  and somnolence), with 
documente d e levate d ammonia levels ( ≥ 100 µmol/L) and requirin g medical 
i
ntervention [Kent and Holt 2017; Longo and Holt 2017 ; Diaz  2019 ]. 
On-study ma
nagement of hyperammonemia plasma level or hyperammonemic 
crises ma
y include, but is not limited to, intravenous hydration, discontinuatio n 
of all dietary p
rotein intake, increase in ammoni a scavenger th erapy, 
hemodialysis in addition to treatment of underlying inciting illness or event (eg, 
acute infection, sepsis,  bleeding, drug-related, etc. ). Comprehensive, 
internat
ionally accepted guide lines for  management of urea cycle disorders are 
recommended [ Häberle 2012 ; Häberle 2019 ]. 
Because there is a wide spectrum of presentati on and sever ity of symptomatic 
hyperammonemia events, investigator judgment needs to be exercised and each 
subject’s management individualized (Section
 3.2.4). 
Ultragenyx Pharmaceutical Inc.  DTX301  
Protocol: 301OTC01   
Page 21 of 126 
Version 06   25 February 2020 Treatment for 
Vector- Induced 
Hepatitis:  The investigator, in conjunction with the Ultragenyx Pharmaceutical medical lead will consider starting oral steroid treatment, per protocol, for possible 
vector -induced hepatitis when a subject’s ALT is greater than the ULN and is 
considered by the investigator to be related to treatment with DTX301. The 
subject must be assessed as clinically and metabolically stable, and intercurrent 
illnesses (eg, viral infection) or concomitant medications known to affect 
transaminases, be excluded.   
Repeat liver function testing for confirmation of results should be considered to 
inform the use of steroid treatment. If repeat testing is deemed necessary, every 
effort should be made to repeat the testing within 24 hours from receipt of test 
results indicating elevated ALT.  
At any point between scheduled visits, additional, unscheduled assessments for LFTs, plasma ammonia or any other biomarker t o assess subject safety and 
clinical status may be performed, at the discretion of the investigator.  
Changes to baseline treatment (ammonia scavenger medications and protein -
restricted diet) cannot occur while the subject is treated with corticosteroids o r 
within a 2 -week period of completing a corticosteroid taper.    
Based on available evidence, it is expected that vector -induced hepatitis will be 
self-limiting. Therefore, oral prednisone (or prednisolone) will be used per the 
American Association for the  Study of Liver Disease guidelines in Cohorts 1  to 
3, with a slight modification: 
• Week 1: prednisone 60 mg/day  
• Week 2: prednisone 40 mg/day  
• Week 3 and Week 4: prednisone 30 mg/day  
• Week 5 and thereafter: Prednisone will be tapered by 5  mg/week until 
liver e nzymes return to baseline levels.  
Cohort 4 (Dosing Process Optimization) will utilize an alternative regimen of 
corticosteroids, aiming at prophylaxis of vector -induced hepatitis. Therefore, oral 
prednisone (or prednisolone) will be initiated before dosing with DTX301, 
sustained for 4 weeks, followed by tapering as described below. Prophylactic 
corticosteroid regimens are in use for gene transfer therapies [Audentes 2017 Clinicaltrials.gov identifier: [STUDY_ID_REMOVED] ; Abeona Therapeutics 2016 
ClinicalTrials.gov  identifier: [STUDY_ID_REMOVED]].   
• At least 5 days prior to administration of DTX301: prednisone 
60 mg/day  
• Study Day 1 (Week 1) through Week 4: prednisone 60  mg/day  
• Study Week 5 through Week 8, tapering every 5 days:  
• Prednisone 40 mg/day for 5 days, followed by prednisone 
30 mg/day for 5 days, prednisone 20 mg/day for 5 days, 
prednisone 10 mg/day for 5 days, prednisone 5 mg/day for 5 days, and prednisone 5 mg every other day for 5 days  
Ultragenyx Pharmaceutical Inc.  DTX301  
Protocol: 301OTC01   
Page 22 of 126 
Version 06   25 February 2020 At any time after in itiation  of prophylactic corticosteroid regimen, additiona l 
assessments of plasma ammonia levels, amino acid profiles or any other 
biomarker to assess subject safety and clinical status may be performed, at the discretion of the investigator  and as clinically indicated . 
Utilization of prednisone (or prednisolone)  after dosing and after completion of 
the prophylactic regimen, remains available to all subjects when a subject’s ALT is greater than the ULN and is considered by the investigator to be related to treatment with DTX301.  
Safety Stopping 
Criteria:  Enrollme nt will be stopped and the regulators will be notified if, at any time 
during the study, any of the following occur:  
• Death of a subject following administration of DTX301  
• An event with an intensity of ≥ Grade 3 (according to the Common 
Terminology Criteria for Adverse Events), but excluding hyperammonemic crise s, develops following administration of DTX301  
• Occurrence of a hepatic malignancy following administration of DTX301  
Abnormal clinically signific ant laboratory values (clinical chemistry , plasma 
ammonia , hematology, urinalysis, and coagulation panel ) as assessed by the 
investigator will be considered AEs. Laboratory values that meet any of the 
above criteria will result in a pause in enrollment until the DMC reviews the data 
and provides a recommendation for subsequent study conduct.  
Any event that meets any of the above criteria will be reported immediately and 
captured as an AE/SAE in the electronic case report form (eCRF), as appropriate. 
Enrollm ent and dosing will be temporarily suspended until the situation can be 
assessed and risks to the subjects mitigated. If an investigator reports an AE/SAE 
that meets any of the study stopping criteria, the DMC will meet on an ad hoc 
basis to review and ass ess the event. If study enrollment is suspended, all 
subjects who have been enrolled will remain in the study and will continue to be monitored through their completion or withdrawal from the study.  
All AEs will be graded according to the most current ver sion of the National 
Cancer Institute Common Terminology Criteria for Adverse Events.  
Efficacy 
Assessments: Efficacy assessments include:  
The rate of ureagenesis, as measured by the generation of [13C]urea over 4  hours, 
will be determined by GCMS at Screening, on Day 1 and at 6, 12, 20, 24, and 52 weeks after IV administration of DTX301. During Screening, assessment of 
rate of ureagenesis may be repeated if discrepant with subject’s clinical status and severity.  
The change from Baseline (Day 0) in AUC
0-24 plasma ammonia  at 6, 12, 24, and 
52 weeks after IV administration of DTX301.  
Ultragenyx Pharmaceutical Inc.  DTX301  
Protocol: 301OTC01   
Page 23 of 126 
Version 06   25 February 2020 Safety 
Assessments: Safety assessments will include the following: AEs, SAEs, complete and targeted 
physical examination findings, vital sign measurements, ECG results, clinical  
laboratory assessments (clinical chemistry, plasma ammonia, hematology,  
urinalysis, and coagulation panel), viral shedding, measurement of neutralizing antibody titer to AAV8, measurement of AAV8 binding antibodies, and 
measurement of anti -OTC antibodies.  
Pharmacokinetic/ 
Pharmacodynamic Assessments: Ureagenesis  
The conversion of the stable isotope [1 -13C]sodium acetate to [13C]urea will be 
determined by GCMS. Blood samples will be collected in precooled heparinized 
tubes before dosing (time  0) and at app roximately 0.5, 1, 1.5, 2, 3, and 4  hours 
after [1 -13C]sodium acetate is administered orally at Screening, Baseline (Day 1), 
and over time to Week 52 after administration of DTX301. Blood samples will 
be immediately centrifuged to separate the plasma, which will be stored frozen 
at -70°C until shipped for analysis.  During Screening, assessment of rate of 
ureagenesis may be repeated if discrepant with subject’s clinical status and 
severity.  
Plasma Ammonia  
The AUC 0-24 of plasma ammonia will be determined at Baseline (Day 0) and 
over time to Week 52 after administration of DTX301. Two samples  (one 
analyzed at the local laboratory [STAT sample], and the other analyzed at the central laboratory) will be collected at time  0 and at approximately  2, 4, 6, 8, 10, 
12, 16, 20, and 24 hours.  
Orotic Acid Excretion  
The excretion of orotic acid will be determined over a 24 -hour period at Baseline 
(Day  0) and over time to Week 52 after administration of DTX301.  
Estimated Study 
Duration:  The duration of the study is defined  for each subject as the date signed written 
informed consent is provided through the visit at Week 52. Subjects will be in the study for approximately 56 weeks (including the screening period).  
After completion of this study, subjects will be asked to enroll in a 4 -year 
extension study to evaluate the long -term (a total of 5 years  after dosing ) safety 
and efficacy of DTX301.  
Study Product, Dose, and Route of Administration:  DTX301 will be administered as a single peripheral IV infusion.  
A continual reassessment method (CRM) will be used to determine the OBD. The following candidate doses may be evaluated to determine the OBD:  
• Dose 1: 2.0  × 10
12 genome copies (GC)/kg  
• Dose 2: 6.0  × 1012 GC/kg  
• Dose 3: 1.0  × 1013 GC/kg  
Based on the results of the CRM, addit ional doses may be considered.  
Statistical Methods:  Determination of the Optimal Biological Dose  
A CRM will be used for dose finding to discover the OBD of DTX301. The 
CRM uses the Bayesian method to model the probability of experiencing a 
Ultragenyx Pharmaceutical Inc.  DTX301  
Protocol: 301OTC01   
Page 24 of 126 
Version 06   25 February 2020 dose-limiting t oxicity (DLT) for each given dose in order to determine the next 
dose. A DLT is defined as any AE/SAE ≥ Grade  3 that is considered related to 
DTX301 by the investigator. Noninformative as well as informative prior 
distributions (ie, historical data) for the model parameters can be used to help 
with the initial modeling of the probability of experiencing a DLT. The OBD is 
defined as the highest dose where the predicted probability of a DLT is less than 
the target toxicity level. Cohort 4 is intended to dose at the OBD. Subjects may 
be assigned in parall el to either expansion of Cohort 3 or Cohort 4, with at least 
1 male subject assigned to each.  
Interim Analysis  
An interim analysis may be conducted when 12 -week data are available for all 
subjects from at least 2 cohorts.  
Safety Analyses  
All statistical a nalyses of safety outcomes will be descriptive. The incidence of 
AEs and TEAEs will be summarized for each dosing cohort by severity and 
relationship to study product. Serious AEs will be presented for each dosing 
cohort by relationship to study product. S ummary tables will present incidence 
estimates and individual event rates by system organ class as well as within each 
system organ class. Subjects experiencing an event more than once with varying 
severity will be counted only once, in the maximum severity within each system organ class and preferred term. For incidence of relationship to study product, 
subjects will be counted only once, in the category of the strongest relationship 
to study product within each system organ class/preferred term.  
Ultragenyx Pharmaceutical Inc.  DTX301  
Protocol: 301OTC01   
Page 25 of 126 
Version 06   25 February 2020 List of Abbreviations  
Abbreviation  Definition  
AAV  adeno -associated virus  
AAV2  adeno -associated virus serotype 2  
AAV8  adeno -associated virus serotype 8  
AE adverse event  
ALT  alanine aminotransferase  
AUC 0-24 area under the curve from time zero to 24 hours  
CFR  Code of Federal Regulations  
CRA  clinical research associate  
CRM  continual reassessment method  
CTCAE  Common Terminology Criteria for Adverse Events  
  
DLT  dose-limiting toxicity  
DMC  data monitoring committee  
ECG  electrocardiogram  
eCRF  electronic case report form  
EDC  electronic data capture  
ELISA  enzyme -linked immunosorbent assay  
FDA  US Food and Drug Administration  
GC genome copies  
GCP  Good Clinical Practice  
HAC  hyperammonemic crisis  
HBV  hepatitis B v irus 
HCV  hepatitis C virus  
IBC institutional biosafety committee  
ICF informed consent form  
ICH International Council for Harmonisation  
IEC independent ethics committee  
IgG immunoglobulin G  
IRB institutional review board  
IV intravenous  
MED  minimal effective dose  
MedDRA  Medical Dictionary for Regulatory Activities  

Ultragenyx Pharmaceutical Inc.  DTX301  
Protocol: 301OTC01   
Page 26 of 126 
Version 06   25 February 2020 Abbreviation  Definition  
MTD  maximum tolerated dose  
NCI National Cancer Institute  
OBD  optimal biological dose  
OTC  ornithine transcarbamylase  
PCR  polymerase chain reaction  
PROMIS  Patient -Reported Outcomes Mea surement Information System  
PVG  pharmacovigilance  
QoL quality of life  
  
SAE  serious adverse event  
SAP statistical analysis plan  
SUSAR  serious, unexpected, suspected adverse drug reaction  
UCD  urea cycle disor der 
UCDC  Urea Cycle Disorders Consortium  
ULN  upper limit of normal  
WAIS -IV Wechsler Adult Intelligence Scale, Fourth Edition  
WASI -II Wechsler Abbreviated Scale of Intelligence, Second Edition  
WMI  Working Memory Index  
 

Ultragenyx Pharmaceutical Inc.  DTX301  
Protocol: 301OTC01   
Page 27 of 126 
Version 06   25 February 2020 1 Introduction  
The urea cycle is a series of biochemical reactions that is responsible for removing excess nitrogen, in 
the form of ammonia, from the body (Figure  1-1). In mammals, ammonia from the breakdown of 
dietary and endogenous protein is converted into urea in the liver; urea is nontoxic, water soluble, and easily excreted in the urine [Deignan  2008 ]. Urea cycle disorders (UCDs) result when there is a 
deficiency of any 1 of the 6 enzymes and 2  transport ers that comprise the urea cycle: 
N-acetylglutamate synthase, carbamyl phosphate synthetase I, ornithine transcarbamylase (OTC), 
argininosuccinate synthetase, argininosuccinate lyase, arginase, citrin, or ornithine translocase 
[Jackson  1986 ]. Clinically, UCDs (which are estimated to affect approximately 1  in 
30,000 individuals worldwide) are characterized by excessive levels of plasma ammonia (hyperammonemia), which is a neurotoxin that can lead to irreversible cognit ive impairment, coma, 
and death in the absence of immediate medical attention [Batshaw 1987; Krivitzky  2009].  
Figure  1-1 Overv iew of the Urea Cycle  
 
Abbreviations: AL, argininosuccinate lyase; ARG, arginase; AS, argininosuccinate synthetase; ATP, adenosine 
triphosphate; CoA, coenzyme A; CPSI, carbamyl phosphate synthetase I; HCO 3, bicarbonate; 
NAG,  N-acetylglutamate synthase; NH 4+, ammonium ion; OTC, ornithine transcarbamylase.  
Ultragenyx Pharmaceutical Inc.  DTX301  
Protocol: 301OTC01   
Page 28 of 126 
Version 06   25 February 2020 Ornithine transcarbamylase deficiency, the most common of the UCDs, is currently estimated to 
occur in up to 1:62,000 live births [Lichter -Konecki  2013]. Orn ithine transcarbamylase deficiency is 
an X-linked disorder that results from mutations in the OTC  gene, affecting the expression or activity 
of the OTC protein [ Caldovic  2015]. A deficiency in OTC activity prevents the normal flux of 
ammonia through the urea cycle and ultimately results in hyperammonemia. Ornithine transcarbamylase deficiency presents as a severe form (ie, complete OTC deficiency) in males shortly 
after birth (neonatal onset; ≤  30 days  of age) or later in life in both males and females (late onset; 
> 30 days of age) with disease that ranges from mild to severe depending on the residual activity of 
OTC [Tuchman  2008a ].  
Males with neonatal -onset OTC deficiency, defined as the onset of signs and symptoms by 30 days of 
age, are typically normal at birth, but become symptomatic and critically ill within 2 to 3 days of initial presentation [ Lichter -Konecki  2013 ]. Without treatment, these patients may fall into a 
hyperammonemic coma and develop severe neurologic abnormalities [Krivitzky  2009]. 
The prognosis of a newborn that falls into a hyperammonemic coma depends on the duration , rather 
than the magnitude, of the elevated ammonia level [Msall  1984]. Despite optimal management, a 
neonate with severe OTC deficiency may only tolerate as much as 1.5 g/kg/day of dietary protein, 
which is the minim um amount of dietary protein needed to grow. In contrast, males with partial OTC 
activity or heterozygous females can present with initial symptoms at any time from infancy through adulthood and are clinically classified as late-onset patients. 
Symptomatic  hyperammonemic events, classified as hyperammonemic crises (HAC) are often 
triggered by acute stressors, most commonly concurrent infection, but can become a life-threatening 
event at any age [Lichter -Konecki  2013; Batshaw 2014 ]. For example, adults with late -onset OTC 
deficiency have become hyperammonemic after crush injury, following surgery, when on a high-protein diet, during the postpartum period, and when treated with chemotherapy, high- dose 
corticosteroids, valproate, or haloperidol [Lichter -Konecki  2013; Batshaw 2014 ]. Consistent with the 
Urea Cycle Disorders Consortium (UCDC) , we have defined hyperammonemic crisis (HAC) in this 
study as an episode of signs and symptoms associated with hyperammonemia (such as frequent vomiting, nausea, headache, lethargy, irritability, combativeness, and somnolence), with documented 
elevated ammonia levels ( ≥ 100 µmol/L) and requiring medical intervention [ Kent and Holt 2017; 
Longo and Holt 2017; Diaz 2019].  
Successful rescue from an initial hyperammonemic crisis does not eliminate the chronic risk patients 
have for developing repeat episodes of hyperammonemi a, which may present as lethargy, seizures, or 
coma. Regardless of the age of onset, neuropsychological complications for all individuals with OTC 
Ultragenyx Pharmaceutical Inc.  DTX301  
Protocol: 301OTC01   
Page 29 of 126 
Version 06   25 February 2020 deficiency typically include developmental delay, learning disabilities, intellectual disability, 
attention d eficit hyperactivity disorder, and executive function deficits.  
The current standard of care for OTC deficiency is to limit dietary protein intake and supplement the diet with a high -energy source, such as glucose [Leonard  2001]. If plasma ammonia is not stabilized 
by dietary restriction alone, ammonia scavengers that promote an alternative pathway of nitrogen removal can be administered [Batshaw 2001; Häberle 2012; Lichter-Konecki  2013; Häberle 2019 ]. 
Ammonia scavengers cannot, however, completely prevent individuals from having hyperammonemic crises [Batshaw 2001 ]. Orthotopic liver transplan tation can correct OTC 
deficiency; however, this is limited by donor availability and is associated with significant risk of morbidity and mortality [ Leonard  2004 ].  
Thus, there remains a significant unmet medical need for a treatment that allows for sustained 
ammonia management and prevention of hyperammonemic crises associated with OTC deficiency.  
1.1 Adeno -Associated Viral Vectors  
Adeno -associated virus (AAV) is a nonenveloped, icosahedral, single-stranded DNA virus. 
Given that wild -type AAV displays wide tissue tropism and is capable of persisting in tissues for long 
durations without pathogenic effects, the use of recombinant AAV vectors has become a popular tool 
for gene delivery. Additionally, recombinant AAV vectors are nonreplicating and the vector genomes 
exist as an episome following tissue transduction, minimizing the risk of insertional mutagenesis 
[Nakai 2001]. Since the first genetic engineering of wild -type AAV as a gene delivery vector in the 
early 1980s, recombinant AAV has shown great promise as an effective and safe gene delivery vehicle for treatment of diseases [Gao 2005].  
Adeno -associated virus serotype 2 (AAV2) was the first AAV that was used for gene transfer 
applications and has been used in numerous studies for a variety of diseases such as 
alpha  1-antitrypsin deficiency, Batten disease, and cystic fibrosis [Mingozzi  2011 ]. In animal mo dels, 
AAV- mediated gene transfer was shown to treat the underlying disease for many years [Snyder  1999; 
Mount  2002; Wang  2005; Nichols 2010 ]. However, in humans, AAV2 -mediated delivery was either 
sub-therapeutic or only lasted a few months [Manno 2003; Manno  2006] . This was attributed to 
several limitations of AAV2 vectors including low transduction efficiency [Yan 2002] , high 
seroprevalence of neutralizing antibodies against AAV2 in humans [Boutin  2010], and  potentially 
destructive T -cell responses to capsids [Gao 2009 ; Vandenberghe  2006; Wang  2007]. 
Additionally,  there has been evidence of B -cell responses against the transgene product in an animal 
model of hemophilia [Herzog 2001].  
Ultragenyx Pharmaceutical Inc.  DTX301  
Protocol: 301OTC01   
Page 30 of 126 
Version 06   25 February 2020 1.2 Selection of the AAV Clinical Candidate  
The host immune response (ie, neutralizing antibodies and T -cell responses) limiting the efficacy of 
AAV2 -mediated gene transfer (Section  1.1) was not predicted in the initial animal studies, due to 
AAV2 not being endemic in the nonhuman animal species under investigation. Novel AAV 
serotypes, isolated from nonhuman primates, are divergent enough from endemic human serotypes to 
circumvent the neutralizing antibodies existing in most human subjects while retaining similar tissue 
tropism [ Gao 2002].  
One of these serotypes, AAV serotype 8 (AAV8), displays strong tropism for the liver [ Gao 2002] 
and has been tested extensively as a vector for gene transfer in nonclinical and clinical models of 
hemophilia [Davidoff  2005; Jiang  2006 ; Nathwani  2006; Nathwani  2007; Nathwani  2011a ].  
These studies have shown that AAV8 has clear advantages over AAV2 that include the following: excellent transduction efficiency; liver -specific tropism; stable transgene expression; a lack of 
hepatotoxicity as measured by peak serum aminotransferases; a lack of liver histopathology findings; a lack of T -cell activation to the transgene product; and low levels of pre -existing neutralizing 
antibodies in human populations, minimizing their inhibition of in vivo transduction. Furthermore, in 
clinical studies, AAV8 has shown impressive efficacy and safety for the treatment of hemophilia B 
[Nathwani  2011a ; Nathwani  2014] and is currently being studied for the treatment of glycogen 
storage disease type Ia ([STUDY_ID_REMOVED]), hemophilia A ([STUDY_ID_REMOVED]), hemophilia B ([STUDY_ID_REMOVED] and [STUDY_ID_REMOVED]), X -linked retinoschisis ([STUDY_ID_REMOVED]), human 
immunodeficiency virus -1 ([STUDY_ID_REMOVED]), X -linked retinitis pigmentosa ([STUDY_ID_REMOVED]), X -linked 
myotubular myopathy ([STUDY_ID_REMOVED]), homozygous familial hypercholesterolemia ([STUDY_ID_REMOVED]), 
Pompe disease ([STUDY_ID_REMOVED]), mucopolysaccharidosis disease ([STUDY_ID_REMOVED]), and achromatopsia 
([STUDY_ID_REMOVED] and [STUDY_ID_REMOVED]).  
The study product, DTX301, contains a codon-optimized human wild-type OTC gene with expression driven by both a liver -specific enhancer element and a liver-specific  promoter encapsidated within a 
nonreplicating AAV8 vector. In spf
ash mice, which is an established nonclinical model of OTC 
deficiency that results from a missense mutation in exon 4 of the OTC gene [Hodges  1989], this 
vector showed a sustained, dose-dependent improvement in both OTC expression and activity following a single intravenous (IV) injection that was comparable to wild -type mice [Wang  2012]. 
These data provide support for the feasibility of this therapeutic approach in humans.  
This clinical study differs from previous gene transfer studies for OTC in a number of ways:  
Ultragenyx Pharmaceutical Inc.  DTX301  
Protocol: 301OTC01   
Page 31 of 126 
Version 06   25 February 2020 1. Adeno -associated virus is used as the vehicle for gene delivery. Unlike adenovirus, which had 
limited eff icacy and significant toxicity at high doses in previous OTC gene transfer studies 
[Raper 2002; Raper  2003], AAV vectors have shown impressive safety and long -term 
efficacy in a number of diseases [Kay 2011; Nathwani  2011a ; Nathwani  2014];  
2. The liver is the natural site of ureagenesis. The AAV8 serotype demonstrates h igh liver 
tropism and can achieve efficient liver gene transfer following IV infusion [ Gao 2002];  
3. The AAV8 serotype is not thought to be endemic in the human population and, therefore, the 
prevalence of pre-existing neutralizing antibodies to AAV8 in patie nts with OTC deficiency 
is expected to be lower than other AAV serotypes, such as AAV2 [Calcedo  2013 ]. 
1.3 Study Rationale  
Ornithine transcarbamylase gene transfer is expected to be effective for the treatment of OTC deficiency since the disease is caused by mutations within a single gene [Caldovic  2015 ]. Unlike 
current medical treatment options (dietary restriction and ammonia scavengers), OTC gene transfer offers the potential to  correct the underlying deficiency for a prolonged period with a single IV 
infusion. Currently, no gene transfer product has been approved for the treatment of OTC deficiency. 
Increasing OTC activity and promoting the removal of ammonia through the urea cy cle should allow 
patients with OTC deficiency to avoid hyperammonemic crises in the context of a well -controlled 
diet, while reducing or stopping ammonia scavenger therapy. Furthermore, depending on the level of 
OTC expression and activity achieved, patients may be able to loosen their dietary restrictions, which 
should greatly improve their quality of life (QoL).  
1.3.1 Design Rationale  
The design of this study is consistent with global regulatory guidelines for protocol design, including: 
subject selection, dose estimation, precautions applied between dosing cohorts, risk mitigation, and 
study stopping criteria.  
Study 301OTC01 is a Phase 1/2, open-label, multicenter, safety and dose-finding study to determine 
the safety, tolerability, and preliminary efficacy of  DTX301 in adults with late -onset OTC deficiency. 
The primary objective of the study is to determine the safety and tolerability of single doses of DTX301. A key element  of the study is the identification of the optimal biological dose (OBD) of 
DTX301. The secondary  objective s of the study are the assessment of rate of ureagenesis, reflecting 
the direct in vivo  efficiency of the urea cycle and the assessment of plasma ammonia (AUC
0-24), 
reflecting clinical metabolic control . The target for DTX301 is to achi eve a rate for ureagenesis of 
Ultragenyx Pharmaceutical Inc.  DTX301  
Protocol: 301OTC01   
Page 32 of 126 
Version 06   25 February 2020 approximately 300 µmol/kg/hr (±10%), which is the approximate rate of ureagenesis in healthy adults 
[Matthews 1984; Jahoor  1987; Castillo 1996; Tuchman 2008b].  
With regards to defining clinically meaningful hyperam monemia as ≥  100 µmol/L in this study 
(Section  4), a plasma  ammonia level of ≥ 100 µmol/L is widely accepted in both clinical practice and 
published literature as a clinically significant level where OTC patients are likely to be symptomatic (including neuropsychological impairments) due to hyperammonemia [Lichter -Konecki  2013]. 
Furthermore, plasma ammonia exceeding 100 µmol/L is identified by the United Kingdom Nat ional 
Metabolic Biochemistry Network as clinically elevated [Wright  2010] and is associated with an 
increased risk of death (odds ratio 1.5 or greater) in OTC patients [Ozanne 2012 ]. Published 
guidelines for the management of hyperammonemia in UCDs also recommend restarting enteral feeding once plasma ammonia is < 100 µmol/L [Häberle 2012; Häberle 2019].  
Consistent with the UCDC, we have def ined symptomatic hyperammonemic events, classified as 
hyperammonemic crisis (HAC) throughout the study, as an episode of signs and symptoms associated 
with hyperammonemia (such as frequent vomiting, nausea, headache, lethargy, irritability, 
combativeness, and somnolence) with documented elevated ammonia levels ( ≥ 100 µmol/L) and 
requiring medical intervention [ Kent and Holt 2017; Longo and Holt 2017; Diaz 2019].  
Eligible subjects will receive a single IV infusion of DTX301. Three subjects will be enrolled i n 
Cohort 1 and a minimum of 2 to 3 subjects will be enrolled in each subsequent cohort; the number of subjects in each subsequent dosing cohort will be determined by subject results and availability of 
study product. Subjects in Cohorts  1 and 2 will be dos ed at a minimum of 2  weeks (14  days) apart. 
The initial 3 subjects in Cohort 3 will be dosed at a minimum of 1  week apart (7  days). Additional 
subjects to Cohort 3 (Cohort Expansion) and subjects to Cohort 4 (Dosing Process Optimization) may 
be dosed less than 1 week apart. There will be a minimum of 12 weeks (84 days) followed by DMC 
review of a dosing cohort between the dosing of the last subject in one dosing cohort and the first 
subject in the next dosing cohort up to Cohort 3. Dosing of additional subjects as expansion of Cohort 
3, and initiation of Cohort 4 (Dosing Process Optimization) may occur in parallel, following the 
DMC review of a minimum of 12 weeks of data from the initial 3  subjects in Cohort 3. Subjects may 
be assigned to either expansion of Cohort 3 or Cohort  4, with at least 1 male subject assigned to each. 
A continual reassessment method (CRM) will be used for dose finding to discover the OBD of 
DTX301 ( Section  10.5.1) . Cohort 4 is intended to dose at the OBD.  
The proposed dosing interval of 14 days between subjects in the first and second dose cohorts, and 7 days between each of the first 3 subjects in Cohort 3, followed by a shorter dosing interval in the 
expansion of Cohort 3 and Cohort 4, is  supported by the safety profile and lack of serious adverse 
Ultragenyx Pharmaceutical Inc.  DTX301  
Protocol: 301OTC01   
Page 33 of 126 
Version 06   25 February 2020 reactions reported in AAV- mediated gene transfer in human subjects, including those using AAV8 
vector in a hemophilia B clinical study [Manno 2006; Nathwani  2011a ; Nathwani  2014] , and the 
ongoing safety review from this study, which includes DMC assessment [Diaz 2019;  Ultragenyx 
Pharmaceutical, data on file ]. Moreover, an ongoing Phase 1/2 clinical study in hemophilia B using 
AAV- mediated gene transfer at a starting dose of 5.0 × 1012 genome copies (GC)/kg (higher than the 
proposed DTX301 starting dose of 3.0 × 1012 GC/kg) at multiple European  study sites is dosing 
subjects within a cohort at a minimum of only 1 day (24 hours) apart [uniQure  2014; 
Clinicaltrials.gov identifier: [STUDY_ID_REMOVED] ; EudraCT Number: 2013-005579- 42]. 
The most common product -related AE observed in clinical studies with AAV- mediated gene transfer 
to subjects with moderate to severe hemophilia B has been an asymptomatic transient rise in liver 
aminotransferases (still within the normal reference range for these laboratory parameters) an d 
concurrent decline in transgene expression approximately 7 to 10 weeks following vector administration [ Manno 2006; Nathwani  2011a ; Nathwani  2014]. In all cases, the transient rise in liver 
aminotransferases resolved without clinical sequelae. It has been hypothesized that this vector -induced hepatitis is due to the activation of capsid -specific cytotoxic T lymphocytes and 
destruction of  transduced liver cells [Mingozzi  2007]. As this is the only identified AE with AAV 
gene transfer and, given that subjects in this study will be closely monitored for vector -induced 
hepatitis and treated with cortic osteroids ( Section  8.2.4.1.2) , having an interval of more than 14 days 
between subjects within Cohorts 1 and 2 and 7 days between the first 3 subjects in Cohort  3 does not 
change either safety evaluations or the medical management of study subjects. To date, no infusion-
related or serious AEs (SAEs) have been reported with DTX301. Aligned with previous experience 
[Manno 2006 ; Nathwani  2011a ; Nathwani  2014], only mild, transient, asymptomatic ris es in liver 
enzymes have been observed in 6 subjects starting approximately 8 days to  7 weeks after vector 
administration that resolved with an oral  corticosteroid taper regimen [Diaz 2019; Ultragenyx 
Pharmaceutical, data on file;]. To allow for refinement in management of asymptomatic transient 
rises in liver aminotransferases (vector-induced hepatitis) and concurrent decline in transgene 
expression following AAV vector administration, Cohort 4 (Dosing Process Optimization) will utilize an alternative regimen of oral corticosteroids. Based on available evidence, it is expected that 
vector -induced hepatitis will be self -limiting. Therefore, oral prednisone (or prednisolone) will be 
employed in a prophylactic regimen initiated before dosing with DTX301, sustained for 4 weeks, 
followed by tapering (Section  8.2.4.1.2). Prophylactic corticosteroid regimens are in use for gene 
transfer therapies [ Audentes 2017 Clinicaltrials.gov identifier: [STUDY_ID_REMOVED] ; Abeona Therapeutics 
2016 ClinicalTrials.gov identifier: [STUDY_ID_REMOVED]].   
Subject safety will be closely monitored throughout the study , including assessment of 
hyperammonemic crises , assessment of metabolic and clinical stability, frequent monitoring of liver 
Ultragenyx Pharmaceutical Inc.  DTX301  
Protocol: 301OTC01   
Page 34 of 126 
Version 06   25 February 2020 enzymes and plasma ammonia levels, and inpatient observation following dosing and at multiple time 
points throughout the 52-week study duration.  
After all subjects in Cohort 1 and Cohort 2, and the initial 3 subjects in Cohort 3 have completed 
Week 12, a data monitoring committee (DMC) will meet to review safety data (ie, AEs/SAEs, 
physical examination findings, vital sign measurements, electrocardiogram [ECG] results, and 
longitudinal clinical laboratory assessments [including assessment of liver function  and plasma 
ammonia ]) and provide a recommendation for progressing to the next dosing level, as applicable 
(Section  9.3), and enrollment of additional subjects to Cohort 3 (Cohort Expansion) and subjects to 
Cohort 4 (Dosing Process Optimization). If an investigator reports an AE/SAE that meets any of the study stopping criteria ( Section  3.2.7 ), the DMC will meet on an ad hoc basis to review and assess the 
event. The DMC  may, at any time, recommend modifying or pausing enrollment due to safety 
concerns based on these periodic data reviews. Addition al DMC meetings may take place, as needed. 
The full scope of each review is outlined in the DMC charter.  
Subjects will be followed for 52 weeks after dosing. After completion of this study, subjects will be asked to enroll in a 4 -year extension study to evaluate the long-term (a total of 5 years after dosing ) 
safety and efficacy of DTX301.  
1.3.2 Dosing Rationale  
The current working estimation to determine the clinical starting dose detailed below is based on available nonclinical data with DTX301, including the  minimal effective dose (MED) and optimal 
effective dose of DTX301 in mice, clinical experience with other AAV8 products, and known limitations when scaling between species.  
Based on preliminary nonclinical study results of DTX301  
 
 
 
 
  
In 
order to estimate the allometric scaling needed for AAV8 -mediated delivery of the OTC transgene 
in this study, two data sets using AAV-mediated transfer of human factor IX were examined: the 
uniQure (Amsterdam, The Netherlands) data set [uniQure 2015] and the Nathwani data set [Nathwani  
2007; Nathwani  2011a ; Nathwani  2011b ]. The AAV5 vector used in the uniQure studies was shown 
to have a 10-fold scaling between mouse and human [uniQure  2015]. The AAV8 vector used in the 

Ultragenyx Pharmaceutical Inc.  DTX301  
Protocol: 301OTC01   
Page 35 of 126 
Version 06   25 February 2020 Nathwani studies supports a 10 -fold scaling from mouse to nonhuman primates and a 4-fold scaling 
between nonhuman primates and humans, for a total of 40-fold between mouse and human [Nathwani  
2007; Nathwani  2011a ; Nathwani  2011b ]. Therefore, when considering a clinical dosing rationale, in 
light of the available comparison data between mice and humans, it seems reasonable to consider a 
10-fold to 40- fold increase in dose from mice to humans to achieve similar target levels for the 
expression and activity of OTC.  
 
 
 
In c
omparison to the clinical development of traditional small molecule and biologic therapies, 
clinical studies for AAV- mediated gene transfer have an additional consideration; after initial dosing, 
it is expected that subjects who are administered DTX301 will develop neutralizing antibodies to 
AAV8 and will receive no benefit from subsequent dosing with this vector. Therefore, unlike classic 
dose-escalation studies, there is a greater focus on targeting efficacy in addition to safety.  
 
 
 
 
 
 consi stent with US Food 
and Drug Administration (FDA) Guidance for Industry on the Considerations for the Design of Early Phase Clinical Trials of Cellular and Gene Therapy Products [ CBER 2015].  
Another consideration is that the maximal feasible dose of vector that can be administered to mice in Good Laboratory Practice toxicology studies (based on dose volume and concentration of vector) is 
7.0 ×  10
13 GC/kg.  
 
 
  
The s
tarting dose for this study (2.0  × 1012 GC/kg)  
 
 which is anticipated to be the no observed 
adver
se effect level.  
belo
w the highest dose used in published nonhuman primate studies with AAV8 (2 × 1013 GC/kg) 
[Jiang  2006 ; McIntosh  2013] and is similar to the doses for other AAV- mediated gene transfer 

Ultragenyx Pharmaceutical Inc.  DTX301  
Protocol: 301OTC01   
Page 36 of 126 
Version 06   25 February 2020 products administered to humans of 2 × 1012 vector genomes/kg (AAV8) [Nathwani  2011a ; 
Nathwani  2014] and 5 × 1012 GC/kg (AAV5) [uniQu re 2014].  
 GC/kg will provide a reasonable 
pro
bability that all subjects in this study have the potential for a clinically substantial benefit from 
DTX301.  
An adaptive design for dose  finding is being used in this study. The CRM will model the probability 
of experiencing a dose -limiting toxicity (DLT) in subsequent dosing cohorts using cumulative safety 
data ( Section  10.5.1 and Figure  10-1).  
 
 
Addi
tionally, depending on the results, additional subjects at the dose of interest may be 
recruited to confirm the OBD.  
Based on existing safety data from clinical studies using AAV- mediated gene transfer (including 
multiple hemophilia programs), substantial toxicity in the predicted therapeutic range is not 
anticipated. Ultragenyx Pharmaceutical is also taking into account the amount of DTX301 Chemistry, 
Manufacturing, and Controls material that can be produced over the anticipated timeline of this 
Phase 1/2 study. Assuming that a maximum tolerated dose (MTD) is not identified in nonclinical 
studies, the proposed dose -finding approach for this Phase 1/2 study is consistent with the FDA 
Guidance for Industry on the Considerations for the Design of Early Phase Clinical Trials of Cellular 
and Gene Therapy Products that achieving a specified target range of exposure is the focus of a 
cellular or gene therapy program when “there are significant practical limits of the dose of the product 
that can be produced or delivered” [CBER 2015].  
For additional nonclinical information, please refer to the DTX301 investigator’s brochure.  

Ultragenyx Pharmaceutical Inc.  DTX301  
Protocol: 301OTC01   
Page 37 of 126 
Version 06   25 February 2020 2 Study Objectives and Endpoints 
Objective  Endpoint  
Primary  
To determine the safety of single IV doses of DTX301 
in adults with late -onset OTC deficiency.  The incidence of AEs, TEAEs, and SAEs for each 
dosing cohort, assessed by severity and relationship to 
study product.  
Secon dary  
To establish a dose of DTX301 that has a meaningful 
increase in the rate of ureagenesis to allow further clinical development.  The change from baseline in the rate of ureagenesis 
(as measured by the generation of [13C]urea over 
4 hours) as determined  by gas chromatography mass 
spectrometry over time to 52  weeks after the IV 
administration of DTX301.  
To evaluate the efficacy of single IV doses of 
DTX301 in adults with late -onset OTC deficiency in 
the setting of tapering or discontinuing ammonia scaven ger medications.  The change from baseline (Day 0) in plasma ammonia 
area under the curve from time zero to 24 hours 
(AUC 0-24) over time to 52 weeks after IV 
administration of DTX301 in the setting of tapering or discontinuing ammonia scavenger medications.  
Exploratory  
To assess the impact of DTX301, by dose, on the 
number of hyperammonemic crises during the study.  The number of hyperammonemic crises observed for 
each dose over time to 52  weeks after IV 
administration of DTX301.  
To evaluate the effect of DTX301, by dose, on urinary 
orotic acid levels.  The change from baseline in urinary orotic acid 
excretion over time to 52 weeks after IV administration of DTX301.  
To evaluate the effect of DTX301, by dose, on plasma 
glutamine and glutamate levels.  The cha nge from baseline in serum glutamine and 
glutamate over time to 52  weeks after IV 
administration of DTX301 .  
To assess the impact of DTX301, by dose, on the 
subject’s neuropsychological functioning.  Changes in responses to the following, summarized by 
dose level of DTX301:  
  
  
 
 
 
 
To assess the impact of DTX301, by dose, on the subject’s quality of life.  Responses to the PROMIS questionnaire, summarized by dose level of DTX301 over time to Week 52. 
To assess the impact of DTX301, by dose, on the use of ammonia scavengers.  Use of ammonia scavengers, summarized by dose 
level of DTX301. 
To assess the impact of DTX301, by dose, on dietary protein restriction.  Change in dietary protein intake, summarized by dose level of DTX301. 
To describe the immune response to AAV8 capsid • The development of neutralizing antibodies to 

Ultragenyx Pharmaceutical Inc.  DTX301  
Protocol: 301OTC01   
Page 38 of 126 
Version 06   25 February 2020 Objective  Endpoint  
proteins after IV administration of DTX301.  AAV8 (as determined by a cell -based assay), 
summarized by time point and dose level of 
DTX301.  
• The development of anti -AAV8 binding antibodies 
(as determined by ELISA), summarized by time point and dose level of DTX301.  
To describe the immune response to OTC after IV administration of DTX301.  • The development of anti -OTC antibodies (as 
determined by ELISA) summarized by time point and dose level of DTX301.  
Abbreviations: AAV8, adeno-associated virus serotype 8; AE , adverse event; AUC 0-24, area under the curve from time zero 
to 24 hours; ELISA, enzyme -linked immunosorbent assay; IV, intravenous; OTC, ornithine transcarbamylase; 
PROMIS, Patient -Reported Outcomes Measurement Information System; SAE, serious adverse ev ent; 
TEAE,  treatment -emergent adverse event.  
Ultragenyx Pharmaceutical Inc.  DTX301  
Protocol: 301OTC01   
Page 39 of 126 
Version 06   25 February 2020 3 Investigational Plan  
3.1 Study Overview  
Study 301OTC01 is a Phase 1/2, open-label, multicenter, safety and dose-finding study to determine 
the safety, tolerability, and preliminary efficacy of DTX301 in adults with  late-onset OTC deficiency. 
A key element of the study is the identification of  the OBD for DTX301. The primary objective of the 
study is to determine the safety of single doses of DTX301. The secondary  objective s of the study are 
the assessment of rate of ureagenesis, reflecting the direct in vivo  efficiency of the urea cycle and the 
assessment of plasma ammonia (AUC 0-24), reflecting clinical metabolic control. The target for 
DTX301 is to achieve a rate for ureagenesis of approximately 300 µmol/kg/hr (±10%) , which is the 
approximate rate of ureagenesis in healthy adults [Matthews 1984; Jahoor  1987; Castillo  1996 ; 
Tuchman  2008b].  
Eligible subjects will receive a single IV infusion of DTX301. Three subjects will be enrolled in 
Cohort 1 and a minimum of 2 to 3 subjects will be enrolled in each subsequent cohort. Dose 
escalation will be conducted according to a model that uses safety data to predict the OBD 
(Section  10.5.1, Figure  10-1, and Figure 10–2 ).  
The following candidate  doses (per kilogram of body weight) will be used to determine the OBD 
(Section  10.5.1): 
• 2.0 × 1012 GC/kg  
• 6.0 × 1012 GC/kg  
• 1.0 × 1013 GC/kg  
There will be a minimum of 14 days between dosing of each subject in Co horts 1 and 2 and 7  days 
between dosing of the initial 3 subjects in Cohort 3. Additional subjects to Cohort 3 (Cohort Expansion) and subjects to Cohort 4 (Dosing Process Optimization) may be dosed less than 1 week 
apart.  
Dose escalation will be conducted  according to a model that uses the collected data to predict the 
safety profile of the dose in order to determine the OBD. There will be a minimum of 12 weeks followed by data monitoring committee (DMC) review ( Section  9.3) of a dosing cohort between the 
dosing of the last subject in one dosing cohort and the first subject in the next dosing cohort up to 
Cohort 3. Dosing of additional subjects as expansion of Cohort 3, and initiation of Cohort 4 (Dosing 
Process Optimization) may occur in parallel, following the DMC review of a minimum of 12 weeks 
Ultragenyx Pharmaceutical Inc.  DTX301  
Protocol: 301OTC01   
Page 40 of 126 
Version 06   25 February 2020 of data from the initial 3 subjects in Cohort 3. A CRM will be used for dose finding to discover the 
OBD of DTX301. Cohort 4 is intended to dose at OBD. There will be no intra-cohort dose 
escalations.  
Subjects treated in Cohort 4 (Dosing Process Optimization) will utilize an alternative regimen of 
corticosteroids, aiming at prophylaxis of vector -induced hepatitis. Therefore, oral prednisone (or 
prednisolone) will be initiated before dosing with DTX301, sustained for 4 weeks, followed by tapering  (Section  8.2.4.1.2) . 
Enrollment will be stopped , and the regulators will be notified if, at any time during the study, any of 
the safety stopping criteria are met ( Section  3.2.7). 
Subjects will be followed for 52 weeks after dosing. After completion of this study, subjects will be 
asked to enroll in a 4 -year extension study to evaluate the long -term (a total of 5 years after dosing ) 
safety and efficacy of DTX301.  
3.2 Overall Study Duration and Follow -Up 
The duration of the study is defined for each subject as the date that written informed consent is provided through the visit at Week 52. Subjects will be in the study for approximately 56 weeks 
(including the screening period).  
The study is anticipated to enroll up to 18 subjects at approximately  20 study sites globally.  
All study visits, clinic or home visits, and the timing of assessments are detailed in  Table  15-1 and 
Table  15-2. Subjects will be asked to participate in  20 outpatient clinic or home visits (approximately 
1.5 to 5 hours in length depending on the ass essments performed at the visit) and 5  inpatient clinic 
visits (approximately 24  to 48 hours in length).  Where available, agreed upon by the investigator and 
allowed by local regulation, an outpatient clinic visit may take place as home health s ervices. 
Investigators will be responsible for maintaining effective lines of communication between the 
investigator and the personnel who manage the subjects at home to guarantee that the 
investigator is constantly kept informed of subject safety, including metabolic and clinical 
status.  
A schematic of the study design is provided in Figure  3-1. 
Ultragenyx Pharmaceutical Inc.  DTX301  
Protocol: 301OTC01   
Page 41 of 126 
Version 06   25 February 2020 Figure  3-1 Study Design 
Screening Period (Day –35 to Day –1) 
Determine subject elig ibility  
Clinical and specialty labs and ECG  
Determine rate of ureagenesis (administer [1-13C]sodium acetate)  
Review ammonia scavenger use and dietary protein restrictions  
Subjects participating in Cohort 4 (Dosing Process Optimization) will start prophylactic corticosteroid regimen at least 5 days prior 
to dosing with DTX301  
Baseline (Day 0 through Day 1) – Inpatient  
Approximately 48 -hour inpatient stay  
• Clinical and specialty labs and ECG  
• PROMIS questionnaire and neuropsychological tests, including a brie f IQ test (WASI- II vocabulary and matrix reasoning 
subtests)  
• AUC 0-24 plasma ammonia and 24- hour urinary orotic acid determination (Day 0)  
• Determine rate of ureagenesis (administer [1-13C]sodium acetate on Day 1)  
• Administer DTX301 (on Day 1 following completion of ureagenesis measurement)  
• Discharge (24 hours after DTX301 administration)  
Subjects participating in Cohort 4 (Dosing Process Optimization) will start prophylactic corticosteroid regimen at least 5 da ys prior 
to dosing with DTX301.  
Treatment Period  
Dose 
Cohort  Outpatient Clinic Visits  
(Weeks 2, 4, 10, 16, 20, and 36)  Inpatient Visits (approximately 28 -hour)  
(Weeks 6, 12, and 24)  
1 to 3  Clinical and specialty labs  Clinical and specialty labs  
Viral shedding  
(saliva, urine, and stool)  Viral sheddin g 
(saliva, urine, and stool)  
Vector genome sample (blood)  Vector genome sample (blood)  
Orotic acid spot urine  PROMIS questionnaire  
Rate of ureagenesis (administer  
[1-13C]sodium acetate at Week 20 only).   Plasma ammonia AUC 0-24 
Urinary orotic ac id 
(every 6 hours over 24 hours)  
Determine rate of ureagenesis (administer  
[1-13C]sodium acetate)  
4 and 
expansion 
of 3 Outpatient Clinic or Home Health Service Visits  
(Weeks 2, 4, 10, 16, and 36)  Inpatient Visits (approximately 28 -hour)  
(Weeks 6, 12, and 24)  
Clinical labs  Clinical and specialty labs  
Orotic acid spot urine  Viral shedding  
(saliva, urine, and stool)  
Outpatient Clinic or Home Health Service Visits  
(Weeks 10, 16, and 36)  PROMIS questionnaire  
Viral shedding  
(saliva, urine, and stool ) Plasma ammonia AUC 0-24 
Outpatient Clinic  
(Weeks 20)  Urinary orotic acid  
(every 6 hours over 24 hours)  
Rate of ureagenesis (administer  
[1-13C]sodium acetate); clinical labs, orotic acid spot 
urine, and viral shedding 
(saliva, urine, and stool)  . 
 
 
• There will be a minimum of 14 days between subjects in Cohorts 1 and 2, and a minimum of 7 days between subjects between 
dosing of the initial 3 subject s in Cohort 3. Additional subjects to Cohort 3 (Cohort Expansion) and subjects to Cohort 4 
(Dosing Process Optimization) may be dosed less than 1 week apart.  
• There will be a minimum of 12 weeks followed by data monitoring committee (DMC) review of a dosing cohort between the 
dosing of the last subject in one dosing cohort and the first subject in the next dosing cohort up to Cohort 3.  
• Dosing of additional subjects as expansion of Cohort 3, and initiation of Cohort 4 (Dosing Process Optimization) may occur in 
parallel, following the DMC review of a minimum of 12 weeks of data from the initial 3 subjects in Co hort 3.  
Ultragenyx Pharmaceutical Inc.  DTX301  
Protocol: 301OTC01   
Page 42 of 126 
Version 06   25 February 2020 • Subjects treated in Cohort 4 (Dosing Process Optimization) will utilize an alternative regimen of corticosteroids, aiming at 
prophylaxis of vector -induced hepatitis. Therefore, oral prednisone (or prednisolone) will be initiated at least 5 days bef ore 
dosing with DTX301, sustained for 4 weeks, followed by tapering.  
• Where available, agreed upon by the investigator , and allowed by local regulation, an outpatient clinic visit may take place as 
home health services.  
End of Study (Week 52)/Early Withdr awal – Inpatient  
Approximately 28 -hour inpatient stay  
• Clinical and specialty labs and ECG  
• PROMIS questionnaire and neuropsychological tests  
• AUC 0-24 plasma ammonia and 24- hour urinary orotic acid determination 
• Determine rate of ureagenesis (administer [1-13C]sodium acetate)  
• Discharge following completion of ureagenesis measurement  
• Subject will be asked to enroll in a long- term (4 -year) extension study  
• Review ammonia scavenger use and dietary protein restrictions  
Abbreviations: AUC 0-24, area under the curve from time zero to 24 hours; DMC, data monitoring committee; IQ,  intelligence quotient; 
PROMIS, Patient- Reported Outcomes Measurement Information System; WASI -II, Wechsler Abbreviated Scale of Intelligence, 
Second Edition.  
3.2.1 Screening Period  
After a subject has provided written informed consent, the investigator or other qualified study 
personnel will determine if the subject is eligible for the study. This will be accomplished by 
reviewing the inclusion and exclusion criteria ( Section  4) and completing all of the screening 
assessments outlined with corresponding timeframe guidance in the Schedule of Events (Table  15-1). 
Screening should be concluded within 35 days before Da y 0. NOTE: The screening assessments may 
be performed on more than 1 day; all assessments must be completed and results available and reviewed prior to Day 0.  
At Screening , blood and urine will be collected. Subjects will be administered [ 1-
13C]sodium acetate 
orally for the determination of ureagenesis as outlined in Section  8.3.1 . The assessment of rate of 
ureagenesis may be repeated during Screening if discrepant with subject’s clinical status and severity .  
The subject’s plasma ammonia level should be < 100 µmol/L or within the range of historical 
ammonia levels obtained when the subject was clinically stable in order to receive [1 -13C]sodium 
acetate. If the ammonia level is inconsistent with a subject’s clinical status, the ammonia level may be 
repeated to ensure accurate results. If the subject is deemed clinically unstable, administration of 
[1-13C]sodium acetate dosing will be held. Blood samples for determination of ureagenesis will be 
collected, via an in dwelling catheter, before dosing (time 0) and at approximately 0.5, 1, 1.5, 2, 3, and 
4 hours after dosing with [1-13C]sodium acetate.  
Subjects who screen fail due to one or more criteria that may potentially be resolved or reversed over time in the opinio n of the investigator (for example, certain laboratory  values or presence of active 
infection) , or whose OTC deficiency is temporarily metabolically or clinically unstable, may be 
Ultragenyx Pharmaceutical Inc.  DTX301  
Protocol: 301OTC01   
Page 43 of 126 
Version 06   25 February 2020 rescreened one time . Subjects may be rescreened after being clinically and m etabolically stable for at 
least 28 days.  
If rescreening is within 3 months of the original screening, the following must be repeated: 
hematology, coagulation and urinalysis, serum pregnancy test (if applicable), clinical chemistry, 
plasma ammonia, amino acid panel, AAV8 neutralizing antibody test, weight, and vital signs. 
Additional tests may be requested on a case-by -case basis, depending on the original reason for 
screen failure. The AAV8 screening neutralizing antibody results must be available and reviewed before IP administration. If the rescreening occurs more than 3 months after the original screening, all 
tests must be repeated except the following: OTC genotyping, HBV, HCV, and HIV.  
3.2.2 Baseline Period  
Subjects will be admitted to the inpatient clinic on Day 0 and will be required to stay for 
approximately 48 hours. While the timing of assessments during the Baseline Visit outlined below 
reflects the most time efficient approach, individual centers may conduct alternate or extended timing 
and sequence of assessments that meet requirements, prior to dosing with DTX301. 
3.2.2.1  Baseline Visit – Day 0  
The timing of all assessments and procedures for Day 0 is outlined in the Schedule of Events (Table  15-1). On Day 0, the baseline determination of plasma ammonia for area under the curve from 
time zero to 24 hours (AUC
0-24) and urinary orotic acid levels (over 24 hours) will be performed. 
Samples for the determination of plasma ammonia (AUC 0-24) and urinary orotic acid levels o ver 
24 hours will be collected prior to the oral administration of [1-13C]sodium acetate on Day 1. Blood 
and urine will be collected as outlined in Section  8.3.  
3.2.2.2  Baseline – Day 1 
The timing of all assessments an d procedures for Day 1 is outlined in the Schedule of Events 
(Table  15-1). The collection of samples for the determination of plasma ammonia (AUC 0-24) and 
urinary orotic acid levels over 24 hours need to be completed prior to the determination of ureagenesis. Subjects will be administered [1 -
13C]sodium acetate orally for the determination of 
ureagenesis. Blood and urine will be collected as outlined in Section  8.3. 
Follow ing completion of sampling for ureagenesis (ie, the 4-hour time point), subjects will then 
receive a single, peripheral IV infusion of DTX301. Safety (eg, vital sign measurements [Section  8.2.2 ], ECGs [ Section  8.2.3] , clinical laboratory assessments [ Section  8.2.4 ], and AEs 
Ultragenyx Pharmaceutical Inc.  DTX301  
Protocol: 301OTC01   
Page 44 of 126 
Version 06   25 February 2020 [Section  9.1]) will be monitored for 24 hours following infusion of DTX301 (Table  15-1). Subjects 
will be discharged after a 24 -hour observation period. Any AEs that occur during this 24-hour 
observation period will be treated with appropriate supportive and medical care  deemed necessary for 
the well -being of the subject.  
Prior to the start of DTX301 infusion, the study site must confirm that the subject’s plasma ammonia 
level on Day 1 (predose) is < 100 µmol/L for patients who historically maintain normal ammonia 
levels,  and the subject is clinically stable; OR subject’s plasma ammonia level on Day 1 (predose) is 
< 200 µmol/L, for patients who historically are not able to fully control ammonia levels with baseline 
management, and the subject is clinically stable. If the Day 1 (predose) ammonia level is inconsistent 
with the subject’s clinical status, the ammonia level may be repeated to ensure accurate results.  The 
24-hour time point (T 24) from local laboratory (STAT sample) for (AUC 0-24) of plasma ammonia can 
serve as th e DTX301 predose plasma ammonia result, if drawn within 12 hours or less of dosing with 
DTX301. If not, a new plasma ammonia (STAT sample) is to be collected prior to dosing with 
DTX301.  The predose plasma ammonia used to determine DTX301 dosing must be dr awn 
within 12 hours or less of dosing. If the subject is deemed clinically unstable, dosing will be held, 
and the subject can be rescreened once the subject is determined to be clinically stable.  Repeat of 
screening assessments or rescreen process may take place depending on timing and subject clinical 
status ( Section  3.2.1  and Table  15-1). 
3.2.3 Treatment Period  
Subjects will be evaluated  approximately every 4 days through W eek 12 at home, at outpatient clinic 
visits, or as inpatient visits (Table  15-1 and Table  15-2). Following the Week  12 visit, subjects will 
visit the study site once approximately every 4 weeks through Week 24, at Week 36, and at Week 52 
or their early withdrawal from the study (Table  15-1 and Table  15-2). Where available, agreed upon 
by the investigator and allowed by local regulation, an outpatient c linic visit may take place as home 
health services. Week 20 visit remains a mandatory outpatient clinic visit for all subjects. 
At any point between scheduled visits, additional unscheduled asses sment of LFTs, plasma ammonia , 
or any other biomarker to assess subject safety and clinical status may be performed, at the discretion 
of the investigator.  
3.2.3.1  Home or Clinic Visits  
Subjects will be asked to provide clinical laboratory samples approximately ev ery 4 days through 
Week 12 of the study. Through Week 12, one sample for spot ammonia will be collected 
Ultragenyx Pharmaceutical Inc.  DTX301  
Protocol: 301OTC01   
Page 45 of 126 
Version 06   25 February 2020 approximately once a week, and sent to the local laboratory (STAT sample). If subjects cannot visit 
the study site in person, they may have the option of being visited by clinically trained and qualified 
personnel (if available) approximately every 4 days at their home through Week 12 (Table  15-2), the 
exception being required study site visits when the subject must visit the study site (Table  15-1). 
Saliva, urine, and stool samples will also be collected at these visits (through Week  12) for 
assessment of viral shedding (Table  15-2) and will continue to be collected until 3  consecutive 
negative results are obtained from each matrix ( Section  8.2.5.3). 
3.2.3.2  Outpatient Clinic or Home Health Service Visits  
Subjects will visit the study site on an outpatient basis at Weeks 2, 4, 10, 16, 20, and 36 for efficacy 
and safety assessments as well as the determination of ureagenesis (at Week 20 only) as outlined in 
the Schedule of Events (Table  15-1). Where availab le, agreed upon by the investigator and allowed 
by local regulation, an outpatient clinic visit may take place as home health Services. Week 20 visit 
remains a mandatory outpatient clinic visit for all subjects.  
3.2.3.3  Inpatient Visits  
Subjects will be admitted to the study site at Weeks 6, 12, 24, and 52 for the determination of plasma 
ammonia (AUC 0-24), urinary orotic acid levels, and ureagenesis. Samples for the determination of 
plasma ammonia (AUC 0-24) and urinary orotic acid levels will be collected over the 24-hour period 
prior to the oral administration of [1-13C]sodium acetate. Blood and urine will be collected as outlined 
in Section  8.3. 
The timing of all assessments and procedures for each visit is outlined in the Schedule of Events (Table  15-1). Subjects will be discharged following the 4 -hour time point for ureagenesis, after all 
assessments/samples have been completed/collected. Subjects will be housed for approximately 28 hours.  
3.2.4 Tapering of Ammonia Scavenger Therapy  
There are multiple types of ammonia scavenger medications available globally and patients with OTC 
deficiency typically have a personalized prescription of one more ammonia scavenger medications to 
optimiz e the management of their disease.  
Adjustments to ammonia scavenger therapy may be considered following the Week 12 and Week 24 visits. Changes to baseline treatment (ie, ammonia scavenger therapy and protein -restricted diet) 
Ultragenyx Pharmaceutical Inc.  DTX301  
Protocol: 301OTC01   
Page 46 of 126 
Version 06   25 February 2020 cannot occur until there is e vidence of transgene expression reflected by continued evidence of 
metabolic stability with ammonia levels in the normal range or  improved ammonia control if subjects 
have a history of ammonia levels above the upper limit of normal and supported by improve ment in 
clinical signs and symptoms. The subject must be clinically stable and under good metabolic control 
before changes can be initiated or progressed. The risks of making adjustments to baseline treatment 
on their own, without express guidance from the  site, will be reinforced with the subject at site visits. 
Changes to baseline treatment cannot occur while the subject is treated with corticosteroids or within a 2-week period of completing a corticosteroid taper.  
Modification of ammonia scavenger thera py cannot occur at the same time as changes in 
protein -restricted diet. Once medications or diet are adjusted or discontinued , the subject must 
demonstrate good metabolic control prior to adjustments in the other type of baseline treatment.  
Modification o f baseline treatment will be individualized, dependent on the clinical judgment of the 
investigator, and based on review of the totality of longitudinal clinical and laboratory data for each 
subject, including spot plasma ammonia levels, plasma ammonia (AUC
0-24), subject clinical 
stability/asymptomatic status, neurocognitive status, and subject -reported outcomes. Rate of 
ureagenesis can not be used for decision -making in modification of ammonia scavenger therapy 
or protein -restricted diet  and results will not be made available to the investigative sites until 
the end of the study . During periods of adjustment to baseline treatment subjects will be closely 
monitored.  
At any time after modification and/or discontinuation of ammonia scavenger therapy, reinstitution of 
therapy may take place based on the subject ’s clinical and metabolic status (elevated ammonia levels 
or signs and symptoms consistent with hyperammonemia), and under evaluation of the investigator.  
Reinstitution of a mmonia scavenger therapy should be considered if: 
1. Subjects demonstrate 2 or more documented consecutive laboratory results of 
hyperammonemia ( plasma ammonia level ≥ 100 µmol/L). NOTE: If the subject is clinically 
stable, spot ammonia may be repeated if discrepant with subject’s clinical status and severity , 
OR 
2. Subjects demonstrate upward trending plasma  ammonia levels less than 100 µmol/L , 
associated with clinical signs or symptoms suggestive of worsening underlying disease , OR  
Ultragenyx Pharmaceutical Inc.  DTX301  
Protocol: 301OTC01   
Page 47 of 126 
Version 06   25 February 2020 3. Subjects experience a time of increased metabolic demand, such as intercurrent viral infection, 
treatment with steroids, hyperammonemia, or hyperammonemic crisis ( Section  3.2.6 ). 
After reinstitution of ammonia scavenger therapy, once intercurrent illness is resolved (if applicable), 
and the subject is documented as clinically and metabolically stable, a second round of modification 
of baseline treatment can be considered. All provisions for stepwise reduction and disease monitoring 
as described above are to be followed . Additional assessments of plasma ammonia levels, amino acid 
profiles, or any other biomarker to assess subject safety and clinical status may be performed, at the 
discretion of the investigator  and as clinically indicated . Learnings from this study will allow for the 
development of a more standardized protocol for tapering ammonia scavenger medications in future 
studies of  DTX301.  
3.2.5 Modification of Dietary Restrictions  
Patients with OTC deficiency typically have a personalized dietary regimen, which encompasses 
protein -restriction adapted to their metabolic and clinical status to optimize the management of their 
disease.  
Subjects will receive a prescribed diet (grams of protein per 24 hours) on Day 0 of the study and this 
diet will be reviewed at Weeks 6, 12, 24 , and 52. Dietary protein intake by the subject between visits 
and dietary restrictions will be reviewed at each visit ( Section  8.7.2 and Table  15-1).   
Modification of baseline protein-restricted diet cannot occur at the same time and/or visit as 
modification of baseline ammonia scavenger therapy. Once medications or diet are adjusted or 
discontinued, the subject must demonstrate good metabolic control prior to adjustments in the other 
type of baseline treatment. During periods of adjustment to baseline treatment , subject s will be 
closely monitored.  
Changes to baseline treatment cannot occur while the subject is treated with corticosteroids or within 
a 2-week period of completing a corticosteroid taper.  
At any time after protein -restricted diet has been modified or fully liberalized, reinstitution of 
restrictions may take place based on the subject’s  clinical and metabolic status and under evaluation 
of the investigator. If a subject successfully discontinues alternate pathway medication or diet it may 
be necessary to restart standard  of care therapy during a time of increased metabolic demand, such as 
Ultragenyx Pharmaceutical Inc.  DTX301  
Protocol: 301OTC01   
Page 48 of 126 
Version 06   25 February 2020 intercurrent viral infection, treatment with steroids, hyperammonemia, or hyperammonemic crisis 
(Section  3.2.6 ). 
3.2.6 Occurrence of Hyperammonemia  and Hyperammonemi c Crisis (HAC)  
Consistent with the U rea Cycle Disorders Consortium (UCDC), we have defined hyperammonemic 
crisis (HAC) in this study as an episode of signs and symptoms associated with hyperammonemia (such as frequent vomiting, nausea, he adache, lethargy, irritability, combativeness, and somnolence), 
with documented elevated ammonia levels (≥ 100 µmol/L) and requiring medical intervention [ Kent 
and Holt 2017; Longo and Holt 2017; Diaz 2019 ]. 
On-study management of hyperammonemia plasma level or hyperammonemic crises may include, 
but is not limited to, intravenous hydration, discontinuation of all dietary protein intake, increase in 
ammonia scavenger therapy, hemodialysis in addition to treatment of underlying inciting illness or 
event ( eg, acute infection, sepsis, bleeding, drug -related, etc.). Comprehensive, internationally 
accepted guidelines for management of urea cycle disorders are recommended [ Häberle 2012 ; 
Häberle 2019].  
Because there is a wide spectrum of presentation and severity o f symptomatic hyperammonemia 
events, investigator judgment needs to be exercised and each subject’s management individualized (Section  3.2.4 , Section  8.3.2 ). 
3.2.7 Safety Stopping Criteria  
Enrollment will be stopped , and the regulators will be notified if, at any time during the study, any of 
the following occur:  
• Death of a subject following administration of DTX301  
• An event with an intensity ≥  Grade 3 (according to the Common Terminology Criteria for 
Adverse Events (CTCAE) [ Section  9.1.3 ]), but excluding hyperammonemic crises 
(Section  3.2.6 ), develops following administration of DTX301 
• Occurrence of a hepatic malignancy following administration of DTX301  
Following DMC review when a stopping rule is met, if the decision is to restart enrollment, a 
substantial amendment will need to  be approved by the regulatory authority.  
Ultragenyx Pharmaceutical Inc.  DTX301  
Protocol: 301OTC01   
Page 49 of 126 
Version 06   25 February 2020 Abnormal clinically significant laboratory values (clinical chemistry,  plasma ammonia,  hematology, 
urinalysis, and coagulation panel) as assessed by the investigator will be considered AEs. Laboratory 
values that meet any of the above criteria will result in a pause in enrollment until the DMC reviews 
the data and provide a recommendation for subsequent study conduct.  
Any event that meets the above criteria will be reported immediately (within 24 hours) as outlined in 
Section  9.1.2.2 and the appropriate page(s) in the electronic case report form (eCRF) must be 
completed. Enrollment and dosing will be temporarily suspended until the situation can be assessed and risks to the subjects mitigated. The DMC will meet on an ad hoc basis if an investigator reports 
an AE/SAE that meets any of the study stopping criteria to review and assess the event. If study 
enrollment is suspended, all subjects who have been enrolled will remain in the study and will 
continue to be monitored through their completion or withdrawal from the study.  
3.2.8 End of Study  
Subjects who complete all visits up to and including the Week 52 visit will have completed the study. Subjects who discontinue early will be asked to return for an early withdrawal visit, where all safety assessments should be performed (Table  15-1). Subjects with any ongoing AEs at this visit will 
continue to be monitored as outlined in Section  9.1.5.  After completion of this study, subjects will be 
asked to enroll in a 4 -year extension study to evaluate the long -term (a total of 5 years after dosing ) 
safety and efficacy of DTX301.  
4 Subject Selection  
Subjects will be assigned to study treatment only if they meet all of the inclusion criteria and none of 
the exclusion criteria.  
4.1 Inclusion Criteria  
Each subject must meet all of the following criteria at Screening to be enrolled in this study:  
1. Willing and able to p rovide written informed consent.  
Ultragenyx Pharmaceutical Inc.  DTX301  
Protocol: 301OTC01   
Page 50 of 126 
Version 06   25 February 2020 2. Males and females ≥  18 years of age with documented diagnosis of late -onset (defined as first 
manifestation of signs and symptoms at > 30 days  of age) OTC deficiency, confirmed via 
enzymatic, biochemical, or molecular testing. This may include identification of a pathogenic 
mutation, via pedigree analysis, liver OTC activity that is <  20% of normal activity, or 
elevated urinary orotate (> 20 µmol/mmol creatinine) after an allopurinol challenge test [Tuchman  2008a].  
3. Documented history of ≥  1 symptomatic hyperammonemia event with ammonia 
≥ 100 µmol/L. 
4. Subject's OTC deficiency is stable as evidenced by either a) no clinical symptoms of hyperammonemia OR b) plasma ammonia level < 100 µmol/L within the 4 -week period 
preced ing the Screening visit.  
5. Subject’s plasma ammonia level on Day 1 (predose) is < 100 µmol/L, for patients who 
historically maintain normal ammonia levels, and the subject is clinically stable; OR subject’s 
plasma ammonia level on Day 1 (predose) is < 200 µm ol/L, for patients who historically are 
not able to fully control ammonia levels with baseline management, and the subject is clinically stable. If the Day 1 (predose) ammonia level is inconsistent with the subject’s 
clinical status, the ammonia level may be repeated to ensure accurate results.  
6. On ongoing daily stable dose of ammonia scavenger therapy for ≥  4 weeks.  
7. No known allergic reaction to any component of DTX301.  
8. Willing and able to comply with study procedures and requirements, including periodic 
inpatient hospitalizations, frequent blood draws, and urine collections over a 24 -hour period.  
9. Hematology and coagulation panel results are within the normal range or, if outside the normal range, deemed not clinically significant in the opinion of the inve stigator.  
10. Males and all females of childbearing potential must be willing to use effective contraception at the time of administration of gene transfer and for the 52  weeks following administration of 
DTX301 to prevent the potential transmission of the AAV  vector. For male subjects, 
appropriate contraceptive methods include the use of a condom with spermicide. For female 
subjects, appropriate contraceptive methods include the use of a condom with spermicide plus 
at least 1 of the following:  
a. Oral contracepti ves, other hormonal contraceptives (vaginal products, skin patches, or 
implanted or injectable products), or mechanical products such as an intrauterine device;  
b. Use of a diaphragm or cervical/vault cap; 
Ultragenyx Pharmaceutical Inc.  DTX301  
Protocol: 301OTC01   
Page 51 of 126 
Version 06   25 February 2020 c. Previous female sterilization (surgical bilateral oop horectomy [with or without 
hysterectomy] or tubal ligation) at least 6 weeks prior to DTX301 administration. In case 
of an oophorectomy alone, the reproductive status of the subject must have been 
confirmed by follow -up hormone level assessment.  
NOTE:  Abst inence is an acceptable form of birth control; however, appropriate contraception 
must be used if the subject becomes sexually active. Abstinence is defined as sexual inactivity 
consistent with the preferred and usual lifestyle of the subject. Periodic abstinence (calendar, 
symptothermal, post -ovulation methods), withdrawal (coitus interruptus), spermicides only, 
and lactational amenorrhea methods are not acceptable methods of contraception. A condom with spermicide is required to be used by all sexually active vasectomized males in the study in order to prevent potential transmission of the vector via seminal fluid.  
NOTE: Females of childbearing potential are defined as all females physiologically capable of 
becoming pregnant, unless they are using highly effective methods of contraception during for 
the duration of the study.  
Females are considered post- menopausal and not of childbearing potential if they have had 
12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (eg, age 
appropriate, history of vasomotor symptoms) or have had surgical bilateral oophorectomy 
(with or without hysterectomy) or tubal ligation at least 6 weeks prior to enrollment. In the 
case of oophorectomy alone, only when the reproductive status of the woman h as been 
confirmed by follow up hormone level assessment is she considered not of childbearing 
potential.  
4.2 Exclusion Criteria  
Subjects who meet any of the following criteria at Screening will be excluded from the study:  
1. At Screening or Baseline (Day 0) , plasma ammonia level ≥ 100 µmol/L for patients who 
historically maintain normal ammonia levels; OR plasma ammonia level ≥ 200 µmol/L for 
patients who historically are not able to fully control ammonia levels with baseline management; OR signs and symptoms of hype rammonemia, with documented elevated 
ammonia level, during the 4 -week period preceding Day 0. If the ammonia level is 
inconsistent with the subject’s clinical status, the ammonia level may be repeated to ensure 
accurate results. 
2. Liver transplant, including hepatocyte cell therapy/transplant.  
Ultragenyx Pharmaceutical Inc.  DTX301  
Protocol: 301OTC01   
Page 52 of 126 
Version 06   25 February 2020 3. History of liver disease as evidenced by any of the following: portal hypertension, ascites, 
splenomegaly, esophageal varices, hepatic encephalopathy, or a liver biopsy with evidence of 
stage 3 fibrosis.  
4. Significant hep atic inflammation or cirrhosis as evidenced by imaging or any of the following 
laboratory abnormalities: alanine aminotransferase (ALT) or aspartate aminotransferase > the 
upper limit of normal (ULN), total bilirubin >  1.5 × ULN, alkaline phosphatase > 2.5 × ULN.  
5. Serum creatinine > 2.0 mg/dL.  
6. Evidence of active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection, documented by current use of antiviral therapy for HBV or HCV or by hepatitis B surface antigen (HBsAg) 
or HCV RNA positivity. NOTE: Subjects with a history of HCV infection must have 
documentation of 2 negative viral assays by polymerase chain reaction (PCR), collected at 
least 6 months apart, to be considered negative for HCV. Subjects with a history of HCV 
infection who test positive for  HCV RNA at Screening can be rescreened once, after they have 
been treated and have documentation of at least 2 negative samples collected at least 6 months 
apart.  
7. History of human immunodeficiency virus (HIV) infection AND any of the following: CD4+ cell count <  350 cells/mm
3, change in antiretroviral therapy regimen within 6 months 
prior to Day 0, or plasma viral load >  200 copies/mL, documented on 2  separate occasions, as 
measured by PCR.  
8. Active infection (viral or bacterial).  
9. Anti-AAV8 neutralizing anti body titer ≥  1:5. 
10. Participation (current or previous) in another gene transfer study.  
11. Participation in another investigational medicine study within 3 months of Screening.  
12. History of a malignancy for which the subject has received treatment in the past 2  years except 
for prostate cancer treated with watchful waiting or surgically removed non -melanoma skin 
cancer.  
13. Has a positive serum pregnancy test at Screening (females of childbearing potential only), a 
positive urine pregnancy test at Baseline (Day 0; fem ales of childbearing potential only), or is 
nursing.  
14. Has any other significant medical condition that the investigator feels would be a risk to the subject or would impede the study.  
Ultragenyx Pharmaceutical Inc.  DTX301  
Protocol: 301OTC01   
Page 53 of 126 
Version 06   25 February 2020 5 Screening and Randomization Procedures  
5.1 Subject Screening  
All potential subjects will sign an informed consent form (ICF) before any study procedures or 
assessments are performed or initiated (Section  11.3) . Subjects will have the opportunity to have any 
questions answered before signing the ICF. All questions raised by the subject must be addressed before the investigator also signs the ICF. A copy of the signed ICF will be given to the subject.  
Subjects will be administered [1 -
13C]sodium acetate orally. Blood samples for determination of 
ureagenesis will be collected, via an indwelling catheter, before dosing (time 0) and at approximately 
0.5, 1, 1.5, 2, 3, and 4 hours after dosing with [1-13C]sodium acetate. During Screening, assessment of 
rate of ureagenesis may be repeated if discrepant with a subject’s clinical status and severity.  
Prior to the start of DTX301 infusion, the study site must confirm that the subject’s plasma ammonia 
level on Day 1  (predose) is < 100 µmol/L for patients who historically maintain normal ammonia 
levels,  and the subject is clinically stable; OR the subject’s plasma ammonia level on Day 1 (predose) 
is < 200 µmol/L, for patients who historically are not able to fully control ammonia levels with 
baseline management, and the subject is clinically stable. If the subject is deemed clinically unstable, 
dosing with DTX301 will be held , and the subject can be rescreened once the subject is determined to 
be clinically stable , with repeat of relevant assessments or rescreened at a later date ( Section  3.2.1). 
Subjects with a history of HCV infection who test positive for HCV RNA at Screening can be 
rescreened once, after they have been treated and have documentation of at least 2 negative samples 
collected at least 6  months  apart. NOTE:  To be eligible to participate in the study, subjects must have 
2 negative HCV viral assays by PCR at least 6 months apart.  
Study sites will maintain documentation of all potential subjects screened for inclusion in the study. If 
a subject is excluded from the study, the reasons for exclusion will be documented in the subject's 
source documents and on the screening log.  
5.2 Subject Randomization  
This is an open-label study; 3 subjects will be enrolled into Cohort 1 and then, sequentially, into 
cohorts of a minimum of 2 to 3  subjects each, up to Cohort 3. D osing of additional subjects in 
expansion of Cohort 3, and initiation of Cohort 4 (Dosing Process Optimization) may occur in 
parallel ( Section  3.1) with at least 1 male subject assigned to each.   
Ultragenyx Pharmaceutical Inc.  DTX301  
Protocol: 301OTC01   
Page 54 of 126 
Version 06   25 February 2020 6 Study Treatment  
6.1 Identity of DTX301  
6.1.1 Description of DTX301  
DTX301 is a nonreplicating, self -complementary, recombinant AAV8 vector that contains a 
codon-optimized, wild-type human OTC coding sequence. DTX301 demonstrates thermal stability, 
which is a general property of AAV and parvoviruses. DTX301 is supplied as a slightly  
 DTX301 is a 
homogeneous, monodisperse solution that is c lear and colorless without visible particulates.  
6.1.2 Components Used for Manufacturing DTX301  
 
  
  
  
 
  
. 
For additional information, 
please refer to the DTX301 investigator’s brochure.  
6.2 Management of Clinical Supplies  
The study site will be provided supplies required for the infusion of DTX301.  
6.2.1 Packaging and Labeling  
Each vial of study product provided to study sites will contain 1 mL of DTX301 frozen in 2 mL 
sterile glass vials with a primary label on the vial. Study product will have secondary packaging with a secondary label. The primary label meets all requirements for blister and small packaging units and 
will contain a unique identifier. The secondary label will contain required text for all countries 
participating in the study and will also contain a unique identifier. Secondary labeling will appear in the appropriate language for the country supplied.  

Ultragenyx Pharmaceutical Inc.  DTX301  
Protocol: 301OTC01   
Page 55 of 126 
Version 06   25 February 2020 6.2.2 Storage of Study Product  
6.2.2.1  Storage of DTX301  
DTX301 must be stored in a secure freezer at a controlled temperature at or below C. The study 
site is to maintain a daily log documenting the temperature.  
6.2.3 Study Product Accountability  
The investigator or designate d personnel will maintain accurate records of receipt of all study product 
(DTX301), including dates of receipt. In addition, accurate records will be kept regarding when and 
how much study product is dispensed and used by each subject in the study. Reasons for departure 
from the expected dispensing regimen must also be recorded. At the completion of the study, all study 
product will be reconciled and retained or destroyed according to instructions provided by the 
sponsor.  
6.2.4 Transmission of Infectious Agents  
Recombinant AAV vectors are nonreplicative and are not expected to pose a risk of transmission. 
However, all sexually active subjects must use approved contraception from the time of DTX301 
dosing and for 52 weeks following administration ( Section  4.1). All subjects enrolled in the study 
should be encouraged to discuss the use of approved contraception with his or her partner in order to prevent possible transmission of vector via seminal or vaginal fluid. The study product and 
posttreatment study samples should be handled using standard universal precautions.  
6.2.5 Exposure to Radiation  
Carbon-13 is a naturally occurring, stable isotope of carbon that emits no radioactivity, has no known 
adverse biological effects, and  is safe to use in children and adults [Koletzko  1997; Tuchman  2008b].  
Detailed instructions for dose preparation and administration of [1 -13C]sodium acetate are provided in  
the ureagenesis manual.  
 

Ultragenyx Pharmaceutical Inc.  DTX301  
Protocol: 301OTC01   
Page 56 of 126 
Version 06   25 February 2020 6.3 Treatment Schedule and Administration  
6.3.1 Administration of [1 -13C]Sodium Acetate  
Subjects will be administered  [1-13C]sodium acetate dissolved in 60 mL of 
water at the time points specified in the Schedule of Events (Table  15-1). 
The dose of [1-13C]sodium acetate administered will be calculated using the subject’s weight recorded 
at Screening. Prior to oral administration, calculations will be checked by the study site pharmacist 
and a member of  medical personnel charged with administration of [1-13C]sodium acetate. 
The subject’s plasma  ammonia level should be < 100 µmol/L or within the range of historical 
ammonia levels obtained when the subject was clinically stable in  order to receive [1 -13C]sodium 
acetate (Section  8.2.4.1; Section  4.1). If the ammonia level is inconsistent with the subject’s clinical 
status, the ammonia level may be repeated to ensure accurate results. If the subject is deemed 
clinically unstable, administration of [1-13C]sodium acetate will be held until the subject is 
determined to be clinically stable. 
Subjects may experience a temporary, mildly unpleasant salty and/or acidic taste from the sodium 
acetate component of the compound. The study site must be equipped with emergency resuscitation 
capabilities. Any event that is considered an AE associated with the administration of [1 -13C]sodium 
acetate (Section  9.1.1)  should be recorded in the appropriate page of the eCRF ( Section  9.1.2).  
Sodium acetate is the sodium salt of acetic acid, a naturally occurring metabolite. Sodium  acetate is a 
commonly used food additive (E 262) .  
Detailed instructions for dose preparation and administration of [1 -13C]sodium acetate are provided in 
the ureagenesis manual.  
6.3.2 Administration of DTX301  
Subjects will receive a single, peripheral IV infusion of DTX301, administered by qualified study 
personnel as designated by the investigator (Table  15-1). The dose will be determined by the cohort 
and candidate dose (Section  3.1). 
The dose of DTX301 to be administered will be calculated using the subject’s weight recorded at 
Screening. The subject’s weight will be verified prior to administration of DTX301 to ensure that 
their current weight is within 10% of their screeni ng weight. NOTE : Any subject weighing > 100 kg 
(> 220 lb) will be dosed as if his or her weight is 100  kg. Prior to infusion, all infusion bag labels will 

Ultragenyx Pharmaceutical Inc.  DTX301  
Protocol: 301OTC01   
Page 57 of 126 
Version 06   25 February 2020 be checked by the study site pharmacist and a minimum of 2 medical personnel charged with 
administrat ion of DTX301. NOTE : Study product should not be prepared for infusion until the 
subject’s plasma ammonia level on Day 1 is confirmed to be less than 100 µmol/L or within the range 
of historical ammonia levels obtained when the subject was clinically stable ( Section  4.1). 
The study site must be equipped with emergency resuscitation capabilities. On Day 1, an IV catheter 
will be inserted into a peripheral vein and flushed with saline.  
Detailed instructions for do se preparation and subsequent infusion of DTX301 are provided in the 
pharmacy manual.  
6.3.3 Treatment Compliance  
[1-13C]sodium acetate will be administered orally at the study site and observed by qualified 
personnel. The dose and time of administration will be recorded in the subject’s eCRF.  Adherence to 
baseline ammonia scavenger medication regimens and modifications to ammonia scavenger 
medication regimens  (Section  3.2.4)  and protein-restricted diet ( Section  3.2.5)  is also considered 
treatment compliance.  
DTX301 will be administered at the infusion center via a single IV infusion administered by qualified 
personnel. The dose, start time, stop time, and volume of infusion wi ll be recorded in the subject’s 
eCRF. 
6.4 Prior and Concomitant Therapy  
Use of all prior and concomitant medications will be recorded in the subject’s eCRF. The minimum requirement is that the drug name, the dates of administration, and the reason for use are to be 
recorded. This will include all prescription drugs, herbal products, vitamins, minerals, and over-the-counter medications. Any changes in concomitant medication use will also be recorded in 
the subject’s eCRF.  
6.4.1 Permitted Medications  
The use of permitted medications (date, dosage, reason for therapy) will be recorded on the concomitant medication page in the eCRF.  
If a subject starts a new medication, including medications to alleviate complications associated with OTC deficiency and herbal supplements,  it should be discussed with the investigator.  
Ultragenyx Pharmaceutical Inc.  DTX301  
Protocol: 301OTC01   
Page 58 of 126 
Version 06   25 February 2020 Any concomitant medication deemed necessary for the welfare of the subject during the study may be 
given. It is the responsibility of the investigator to ensure that details regarding the medication are 
record ed in full in the eCRF. 
6.4.2 Prohibited Medications  
Use of any of the following medications is prohibited, unless the investigator feels these medications 
are medically indicated. If medically indicated, the use of prohibited medications (date, dosage, 
reason f or therapy) will be recorded on the concomitant medication page in the eCRF:  
• Another investigational product to treat OTC deficiency;  
• Another gene therapy product; or  
• Any other medication currently under investigation.  
Ultragenyx Pharmaceutical Inc.  DTX301  
Protocol: 301OTC01   
Page 59 of 126 
Version 06   25 February 2020 7 Withdrawal of Subjects From the Study  
7.1 Study Withdrawal  
Subjects may withdraw from the study at any time and for any reason without prejudice to their future 
medical care by the investigator or at the study site. Any subject who withdraws consent to participate 
in the study will be removed from further treatment and/or study observation immediately upon the 
date of request.  
The investigator must record the reason for withdrawal on the relevant page in the eCRF. The reason for withdrawal may include the following:  
1. Withdrawal of consent  
2. Administ rative decision by the investigator or the sponsor  
3. Ineligibility  
4. Significant protocol deviation  
5. Subject noncompliance  
6. Adverse event  
If a subject is withdrawn due to an AE, the investigator will arrange for the subject to have follow-up visits until the AE has resolved or stabilized ( Section  9.1.5 ).  
If a subject requests or decides to withdraw from the study, all efforts will be made to complete and report the observations as thoroughly as possible up to the date  of withdrawal, and an early 
withdrawal visit will be performed.  
7.2 Subject Replacement 
If a subject withdraws from the study after receiving DTX301, the subject will not be replaced. Subjects who withdraw from the study after signing the ICF, but before receiving DTX301, will be replaced and the replacement subject will be sequentially assigned to treatment with a new subject 
identification number.  
Ultragenyx Pharmaceutical Inc.  DTX301  
Protocol: 301OTC01   
Page 60 of 126 
Version 06   25 February 2020 8 Study Assessments and Procedures  
8.1 Efficacy Assessments  
Planned time points for all efficacy measurements in the study are listed in  Table  15-1.  
8.1.1 Ureagenesis  
The change from baseline in the rate of ureagenesis will be assessed at specified time points 
(Table  15-1). Planned time points for the collection of blood samples to determine the rate of 
ureagenesis are provided in Section  8.3.1 . Subjects will fast for at least 6 hours, including liquids 
containing protein, sugar or carbonate, prior to administration of [1 -13C]sodium acetate. After dosing, 
subjects will continue to fast for at least 4 hours. Water is allowed ad libitum . During Screening, 
assessment of rate of ureagenesis may be repeated if discrepant with subject’s clinical status and 
severity.  
Details for the preparation and shipment of samples are included in the ureagenesis manual and the laboratory manual.  
8.1.2 Plasma Ammonia Area Under the Curve from Time Zero to 24 Hours  
The change from baseline in plasma ammonia (AUC 0-24) will be assessed at specified time points 
(Table  15-1). Planned time points for the collection of blood samples to determine plasma ammonia 
(AUC 0-24) are provided in Section  8.3.2. T wo samples will be collected at each time point for the 
plasma ammonia  (AUC 0-24) determination . One sample will be sent to the local laboratory and 
1 sample will be sent to the central laboratory. Details for the preparation and shipment of samples 
are included in the laboratory manual.  
8.2 Safety Assessments  
Planned time points for all safety assessments are listed in the Schedules of Events (Table  15-1 and 
Table  15-2). Safety will be assessed based on AEs, SAEs, complete and targeted physical 
examination findings, vital sign measurements, ECG results, clinical laboratory assessments (clinical chemistry , plasma ammonia , hematology, urinalysis, and coagulation panel), viral shedding, 
measurement of neutralizing antibody titer to AAV8, measurement of AAV8 binding antibodies, and 
measurement of anti -OTC antibodies.  
Ultragenyx Pharmaceutical Inc.  DTX301  
Protocol: 301OTC01   
Page 61 of 126 
Version 06   25 February 2020 8.2.1 Physical Examination  
A complete or targeted physical examination will be performed at the time points specified in the 
Schedule of Events (Table  15-1). 
A complete physical examination will include assessments of the head, eyes, ears, nose, and throat; skin; and the endocrine metabolic, neurological, respiratory, cardiovascular, gastrointestinal, and 
musculoskeletal systems.  
A targeted physical examination will include assessment of the skin and the respiratory, cardiovascular, and gastrointestinal systems.  
Physical examination findings will be captured on the appropriate page in the  eCRF. 
8.2.2 Vital Sign Measurements  
Vital sign measurements will be made at the time points specified in the Schedule of Events (Table  15-1). During the study, vital sign measurements are to be collected before any stim ulating or 
anxiety -provoking procedures (eg, phlebotomy). Vital sign measurements will include heart rate, 
blood pressure (systolic and diastolic), and respiratory rate. Temperature will be included on days that 
the [1 -
13C] sodium acetate is administered ( Screening, all inpatient visits and Week 20 outpatient 
visit. Height (at the Screening visit only) and weight will also be recorded.   
• On Day 0, weight will be measured to ensure that the weight is within 10% of the screening 
weight used to calculate the d ose of DTX301. Subjects with a confirmed change in weight 
that is >  10% from Screening should be further evaluated to exclude the presence of an acute 
condition or illness; if a benign explanation for the weight change is identified and documented, DTX301 can be given and dosed using the weight obtained on Day 0.  NOTE: 
Any subject weighing > 100 kg (> 220 lb) will be dosed as if his or her weight is 100 kg. 
• Vital signs should be measured with the subject having rested for at least 5 minutes 
beforehand. It i s preferred that the measurement be late with the subject rested, rather than 
on-time with the subject not sufficiently rested. If the subject is not sufficiently rested, this needs to be stated in the source documents.  
• On Day 1, vital signs will be measured at predose, approximately 5 minutes, and 
0.5 (±5 minutes), 1 (±5 minutes), 2, 4, 6, and 8 hours (±15 minutes) after the start of DTX301 
infusion. Vital signs will also be measured at approximately 22  hours (±1  hour)  after the start 
of infusion, prior to  subject discharge. 
Ultragenyx Pharmaceutical Inc.  DTX301  
Protocol: 301OTC01   
Page 62 of 126 
Version 06   25 February 2020 • It is acceptable for heart rate to be captured from the 12 -lead ECG ( Section  8.2.3).  
Vital sign measurements will be recorded in the appropriate page in the eCRF. The medical monitor 
should be notified of any clinically significant changes or abnormal value in vital sign measurements 
(Section  9.1.2 ).  
8.2.3 Electrocardiograms  
An ECG will be performed at the time points specified in the Schedule of Events (Table 15-1). 
• A single 12 -lead ECG will be obtained at Screening, on Day 0 (baseline), at approximately 
1 hour (±15 minutes) after the start of infusion on Day 1, and at Week 52, using an ECG 
machine that automatically calculates the heart rate and measures PR, QRS, QT, and corrected QT intervals.  
Twelve-lead ECGs should be measured with the subject having rested for at least 5 minutes beforehand. It is preferred that the measurement be late with the subject rested , rather than on- time 
with the subject not sufficiently rested. If the subject is not sufficiently rested, this needs to be stated in the source documents. Electrocardiogram results will be recorded in the appropriate page in the 
eCRF. 
8.2.4 Clinical Laboratory Analyses  
Laboratory tests, including LFTs and coagulation panel, will be closely monitored throughout the 
duration of the study. At any point between scheduled visits, additional, unscheduled assessment for 
LFTs, plasma ammonia , or any other biomarker to a ssess subject safety and clinical status may be 
performed, at the discretion of the investigator.  
Investigators will receive flagged notification of any laboratory values that are outside of the normal 
range. Any abnormal laboratory test results (clinical chemistry , plasma ammonia,  hematology, 
urinalysis, coagulation panel, or other laboratory parameters), including those that worsen from baseline or are felt to be clinically significant in the medical and scientific judgment of the 
investigator, are to be  recorded as AEs or SAEs ( Section  9.1.2). 
However, any clinically significant safety assessments that are associated with OTC deficiency are not to be reported as AEs, unless  they are judged by the investigator to be more severe than expected 
for the subject’s condition.  
Ultragenyx Pharmaceutical Inc.  DTX301  
Protocol: 301OTC01   
Page 63 of 126 
Version 06   25 February 2020 All laboratory tests with results that are significantly abnormal during participation in the study 
should be repeated until the values return to normal or baseline. If such values do not return to normal 
within a period judged reasonable by the investigator, the etiology should be identified, and the 
sponsor notified.  
Samples of blood, urine, saliva, and stool will be collected for study assessments. Any samples 
remaining at the end of the study may be stored for up to 15 years and analyzed to better understand 
the effect of DTX301 on OTC deficiency or other UCDs. The choice to allow retention and future 
analysis will be optional. 
8.2.4.1  Clinical Laboratory Parameters  
The clinical laboratory parameters to be measured are listed in  Table  8-1. Samples are to be collected 
at the time points (±5 minutes) specified in the Schedules of Events (Table  15-1 and Table  15-2).  
Ultragenyx Pharmaceutical Inc.  DTX301  
Protocol: 301OTC01   
Page 64 of 126 
Version 06   25 February 2020 Table  8-1 Clinical Laboratory Parameters  
Clinical chemistrya: Sodium, potassium, chloride, carbon dioxide, blood urea nitrogen, creatinine, glucose, 
calcium, phosphate, magn esium, albumin, total protein, creatine kinase, bilirubin (total, 
direct, and indirect), ALT, AST, ALP, gamma -glutamyltransferase, and lactate 
dehydrogenase  
Spot ammonia  Plasma ammonia (STAT sample, local laboratory)b 
Hematology:  Complete blood count wit h differential  
Urinalysis:  Specific gravity, pH, glucose, protein, blood (by dipstick), ketones (by dipstick), and 
microscopic examination (if blood or protein is found)  
Urine chemistry:  Orotic acid  
Coagulation panel:  PT/INR, aPTT  
Amino acid panel : alanine, α-amino -butyric acid, arginine, asparagine, aspartic acid, citrulline, cystine, 
ethanolamine, glutamic acid, glutamine, glycine, histidine, homocysteine, 
hydroxyproline, isoleucine, leucine, lysine, methionine, ornithine, phenylalanine, proline, 
serine, taurine, threonine, tryptophan, tyrosine, and valine  
Otherc: HBV surface antigen (HBsAg), HCV RNA, HIV  
Abbreviations: ALP, alkaline phosphatase; ALT, alanine aminotransferase; aPTT, activated partial thromboplastin time; 
AST, aspartate aminotransfer ase; HBV, hepatitis B virus; HCV, hepatitis C virus; HIV, human immunodeficiency 
virus; LFT, liver function test; PT/INR, prothrombin time/international normalized ratio.  
a. Through Week 12, one sample for LFTs is collected as part of clinical chemistry and s ent to the central laboratory for 
analysis. A second sample for LFTs only is collected and sent to the local laboratory (STAT sample).  
b. Special handling is required for plasma ammonia. At Screening, prior to neuropsychological testing and prior to dosing 
with [1-13C]sodium aceta te, a sample will be collected to confirm the subject’s plasma ammoni a level . The subject’s 
plasma ammonia level should be < 100 µmol/L or within the range of historical ammonia level s obtained when the 
subject was clinically sta ble (Section 4.1). If the ammonia level is inconsistent with the subject’s clinical status, the 
ammonia level may be repeated to ensure accurate results. If the subject is deemed clinically u nstable, the assessments 
will be held until the subject is determined to be clinically stable. (Table 15-1) . The study site may use the local 
laboratory sample from ti me 0 (prior to neuropsychological testing on Day 0 and at Week 52), and t ime 24 hour (prior 
to [1-13C]sodium acetate administration on Day 1 and at Weeks 6, 12, 24, and 52) from the plasma ammonia AUC 0-24 
to confirm the subject’s plasma ammonia (Section  8.3.2 ). 
c. To be collected at Screening only.  
 
Details for the preparation and shipment of samples will be provided by the central or specialty 
laboratory. Reference ranges for all parameters will be provided to the study site by the central or 
specialty laboratory.  
A laboratory param eter may be repeated if there is any concern about the values obtained.  
At any time after in itiation of a prophylactic corticosteroid regimen, additional assessments of plasma 
ammonia levels, amino acid profiles, or any other biomarker to assess subject safety and clinical 
status may be performed, at the discretion of the investigator  and as clinically indicated . 
If additional nonprotocol -specified laboratory assessments are performed at the study site’s local 
laboratory and result in a change in subject management or the results are considered clinically 
Ultragenyx Pharmaceutical Inc.  DTX301  
Protocol: 301OTC01   
Page 65 of 126 
Version 06   25 February 2020 significant by the investigator (eg, SAE, AE, or dose modification), the results must be captured and 
sent to the sponsor along with other study data as defined in Section  9.1.2 . 
8.2.4.1.1  Elevation of Liver Function Tests  
In clinical studies with AAV- mediated gene transfer, a transient rise in liver aminotransferases and 
concurrent decline in transgene expression has been observed [Manno 2006; Nathwani  2011a ; 
Nathwani  2014]. This has been hypothesized to be due to the activation of capsid -specific cytotoxic 
T lymphocytes and destruction of transduced live r cells [Mingozzi  2007] . However, in mice, T-cells 
activated against AAV capsid were not able to target and eliminate transduced hepatocytes 
[Wang  2007; Li C 2007 ; Li H  2007; Siders  2009] unless the transduced hepatocytes co -expressed the 
wild-type AAV capsid protein [Li C 2007 ].  
The inability to reproduce the observed effects in animal models has made it difficult to assess the 
validity of the hypothesis or to develop strategies to overcome or minimize aminotransferase 
elevations. Despite a lack of clear resolution that activation of c ytotoxic T lymphocytes leads to a 
reduction in transgene expression from hepatocytes, appropriate precautions have been incorporated 
into this study. T he use of oral steroids is allowed if a subject experiences elevations in liver 
aminotransferases.  
Liver  function tests will be assessed as part of clinical chemistry ( Section  8.2.4.1 ) at the time points 
specified in the Schedule of Events (Table  15-1 and Table  15-2). Liver function tests will be assessed 
at a central and local (STAT) laboratory approximately every 4 days through Week 12, which will 
allow for a rapid detection of any elevations following administration of DTX301. If  a subject 
experiences an increase in liver function tests following treatment with DTX301, the investigator should consider the initiation of steroid treatment as outlined in Section 8.2.4.1.2 , and taking into 
account dosing Cohort (Cohort 1-3) . The event should be recorded as an AE or SAE, as defined in 
Section  9.1.2,  on the appropriate pages in the eCRF if it is felt to be clinically significant in the 
medical and s cientific judgment of the investigator. 
Cohort 4 (Dosing Process Optimization) will utilize an alternative regimen of corticosteroids, aiming 
at prophylaxis of AAV -mediated, transient ris es in liver aminotransferases as outlined in 
Section  8.2.4.1.2.
 The subject must be assessed as clinically and metabolically stable to initiate the 
prophylactic corticosteroid regimen.  
Ultragenyx Pharmaceutical Inc.  DTX301  
Protocol: 301OTC01   
Page 66 of 126 
Version 06   25 February 2020 8.2.4.1.2  Treatment for Possible Vector -Induced Hepatitis  
The investigator, in conjunction with the Ultr agenyx Pharmaceutical Inc. medical lead will consider 
starting oral steroid treatment, per protocol, for possible vector -induced hepatitis when a subject’s 
ALT is greater than the ULN and is considered by the investigator to be related to treatment with 
DTX301.  The subject  must be assessed as clinically and metabolically stable, and intercurrent 
illnesses (eg , viral infection) or concomitant medications known to affect transaminases, be excluded.   
Repeat liver function testing for confirmation of results should be considered to inform the use of 
steroid treatment. If repeat testing is deemed necessary, every effort should be made to repeat the 
testing within 24 hours from receipt of test results indicating elevated ALT.  
At any point between scheduled visits , additional, unscheduled assessment for LFTs, plasma 
ammonia , or any other biomarker to assess subject safety and clinical status may be performed, at the 
discretion of the investigator.  
Changes to baseline treatment ( ie, ammonia scavenger medications and  protein -restricted diet) 
cannot occur while the subject is treated with corticosteroids or within a 2 -week period of 
completing a corticosteroid taper. 
Based on available evidence, it is expected that vector -induced hepatitis will be self -limiting. 
Therefore, oral prednisone (or prednisolone) will be used per the American Association for the Study 
of Liver Disease guidelines, with a slight modification in Cohorts 1  to 3:  
• Week 1: prednisone 60 mg/day 
• Week 2: prednisone 40 mg/day 
• Week 3 and Week 4: prednisone 30 mg/day 
• Week 5 and thereafter: prednisone will be tapered by 5 mg/week until liver enzymes return to 
baseline levels. The use of prednisone will be recorded on the appropriate page in the eCRF.  
Ultragenyx Pharmaceutical Inc.  DTX301  
Protocol: 301OTC01   
Page 67 of 126 
Version 06   25 February 2020 Cohort 4  (Dosing Process Optimization) will utilize an alternative regimen of corticosteroids, aiming 
at prophylaxis of vector -induced hepatitis. Therefore, oral prednisone (or prednisolone) will be 
initiated before dosing with DTX301, sustained for 4 weeks, followed by tapering as described below . 
Prophylactic corticosteroid regimens are in use for gene transfer therapies [Audentes 201 7 
Clinicaltrials.gov identifier: [STUDY_ID_REMOVED] ; Abeona Therapeutics 2016 ClinicalTrials.gov identifier: 
[STUDY_ID_REMOVED] ].  
• At least 5 days prior to dosing: prednisone 60 mg/day 
• Study Day  1 (Week 1) through Week 4: prednisone 60 mg/day 
• Study Week 5 through Week 8, tapering every 5 days:  
Taper Dose  Duration  
40 mg/ day  5 days  
30 mg/day  5 days  
20 mg/day  5 days  
10 mg/day  5 days  
5 mg/day  5 days  
5 mg every other day  5 days  
 
At any time after in itiation of prophylactic corticosteroid regimen, additional assessments of plasma 
ammonia levels, amino acid profiles, or any other biomarker to assess subject safety and clinical 
status may be performed, at the discretion of the investigator  and a s clinically indicated . 
Utilization of prednisone (or prednisolone) after dosing and after completion of the prophylactic 
regimen, remains available to all subjects when a subject’s ALT is greater than the ULN and is 
considered by the investigator to be re lated to treatment with DTX301. The use of prednisone (or 
prednisolone) will be recorded on the appropriate page in the eCRF.  
Ultragenyx Pharmaceutical Inc.  DTX301  
Protocol: 301OTC01   
Page 68 of 126 
Version 06   25 February 2020 8.2.5 Other Laboratory Parameters  
Where applicable, details for the preparation and shipment of samples are included in the laboratory 
manual. 
8.2.5.1  Neutralizing Antibodies to Adeno -Associated Virus Serotype 8  
Samples for neutralizing antibodies to AAV8 will be collected at the time points specified in the 
Schedule of Events (Table  15-1) to monitor for a humoral immune response to AAV8. The assay will 
be performed using a research method (a cell-based assay).  
8.2.5.2  Adeno -Associated Virus Serotype 8 Binding Antibody 
Immunoglobulin G Assay  
Samples for the AAV8 binding antibody immunoglobulin G (IgG) assay will be collected at the time 
points specified in the Schedule of Events (Table  15-1) to monitor for circulating anti -AAV8 
antibodies. The assay will be performed using a research method (enzyme-linked immunosorbent 
assay [ELISA]).  
8.2.5.3  Anti -Ornithine Transcarbamylase Antibody Assay  
Samples for the anti -OTC antibody assay will be collected at the time points specified in the Schedule 
of Events (Table  15-1) to monitor for circulating anti -OTC antibodies. The assay will be performed 
using a research method (ELISA).  
8.2.5.4  Viral Shedding  
Saliva, urine, and stool will be collected at the time points specified in the Schedules of Events 
(Table  15-1 and Table  15-2) to monitor for the presence of shed virus. The presence of DTX301 will 
be determined . Subjects will be given an appropriate container to collect 
a stool sample at home. Samples for shedding analysis will be collected until the results are negative 
on 3 consecutive occasions for each matrix.  

Ultragenyx Pharmaceutical Inc.  DTX301  
Protocol: 301OTC01   
Page 69 of 126 
Version 06   25 February 2020 8.3 Pharmacokinetics and Pharmacodynamic Assessments  
8.3.1 Ureagenesis  
The conversion of the stable isotope [1-13C]sodium acetate to [13C]urea will be determined by gas 
chromatography mass spectrometry [Tuchman  2008b]. Blood samples will be collected in precooled 
heparinized tubes before dosing (time 0) and at approximately 0.5, 1, 1.5, 2, 3, and 4 hours 
(±5 minutes) after [1 -13C]sodium acetate is administered orally at Screening, Baseline (Day  1), and 
over time to Week 52 after administration of DTX301 (Table  15-1).  
. During Screening, 
assessment of rate of ureagenesis may be repeated if discrepant with subject’s clinical status and severity. Blood samples will be immediately centrifuged to separate the plasma, which will be stored 
frozen at –70°C until shipped for analysis. Details for the preparation and shipment of samples are 
included in the ureagenesis manual and the laboratory manual.  
8.3.2 Plasma Ammonia Area Under the Curve from Time Zero to 24 Hours  
The AUC 0-24 of plasma ammonia will be determined at Baseline (Day 0) and over time to Week  52 
after administration of DTX301 (Table  15-1). Two samples will be collected at time 0 and at 
approximately 2, 4, 8, 12, 16, 20, and 24 hours (±5 minutes). One sample will be sent to the local 
laboratory (STAT sample) and 1 sample will be sent to the central laboratory. If possible, ad hoc 
AUC 0-24 plasma ammonia should be considered if a subject experiences symptomology deemed by 
the investig ator to meet the definition of  an HAC ( Section  3.2.6), driven by the underlying disease or 
at a time of increased metabolic demand, such as intercurrent viral infection, or treatment with 
corticosteroids, and war ranting inpatient monitoring based on investigator discretion.  
The subject’s plasma ammonia level should be < 100 µmol/L or within the range of historical 
ammonia levels obtained when the subject was clinically stable ( Section  4.1) prior to administering 
the neuropsychological tests or [1-13C]sodium acetate and DTX301 (Day 1 only) (Table  15-1). If the 
ammonia level is inconsistent with the subject’s clinical status, the ammonia level may be repeated to ensure accurate results. If the subject is deemed clinically unstable, the assessments will be held until 
the subject is determined to be clinically stable. The study site may use the time 0 and time 24 hour 
plasma ammonia samples to confirm the subject’s plasma ammonia. The samples should be sent to 
the local laboratory (STAT sample) and results available prior to initiating the neuropsychological 
tests or administering [1 -
13C]sodium acetate and DTX301 (Day 1 only).  
Detail s for the preparation and shipment of samples are included in the laboratory manual.  

Ultragenyx Pharmaceutical Inc.  DTX301  
Protocol: 301OTC01   
Page 70 of 126 
Version 06   25 February 2020 8.3.3 Orotic Acid Excretion  
The excretion of orotic acid will be determined over a 24 -hour period. Urine samples will be collected 
approximately every 6 hours (× 4) at Baseline (Day 0) and over time to Week 52 after administration 
of DTX301 (Table  15-1). Details for the preparation and shipment of samples are included in the 
laboratory manual.  
8.4 Quality -of-Life Assessment  
8.4.1 PROMIS Questionnai re 
Subjects will be asked to complete the Patient -Reported Outcomes Measurement Information System 
(PROMIS) questionnaire ( Appendix 15.2.1) on Day 0 (predose) and then at Weeks 6, 12, 24, and 52 
during the study  (Table  15-1). NOTE: The PROMIS questionnaire should be completed prior to the 
neuropsychological tests on Day 0 and at Week 52.  
Patient-reported outcomes will be assessed by components of the PROMIS questionnaire, an 
instrument developed in collaboration with National Institutes of Health, which has been designed, 
calibrated, and validated using a large sample size of participants with chronic diseases for use in 
clinical care and research. PROMIS measures may be used as endpoints in clinical studies to assess 
the effectiveness of treatment. The UCD Consortium also uses the PROMIS questionnaire for the 
evaluation of QoL in their Longitudinal Study participants. 
Domains measured by PROMIS include physical, mental, and social well -being; versions of the 
PROMIS instrument include ones specific for adult and pediatric populations as well as for 
parent -proxy reporting for pediatric patients. The adult versions for the following self -reported 
domains will be included in this study [Reeve 2007; PROMIS  2009 ]: Cognitive Function, Anxiety, 
Depression, and Emotional/Behavioral Dyscontrol.  
8.5 Neuropsychological Tests  
All neuropsychological tests will be administered to English speaking subjects (at a minimum) in a 
nonfasted state. All neuropsychological tests are to be administered by appropriately qualified 
individuals as determined by sponsor or representative. The subject’s plasma ammonia level should 
be < 100 µmol/L ( Section  8.2.4.1 ) or within the range of historical ammonia levels obtained when the 
subject was clinically stable (Section  4.1) in order to perform th e neuropsychological tests. If the 
ammonia level is inconsistent with the subject’s clinical status, the ammonia level may be repeated to 
ensure accurate results. The study site may use the time 0 (T 0) plasma ammonia sample (from 
Ultragenyx Pharmaceutical Inc.  DTX301  
Protocol: 301OTC01   
Page 71 of 126 
Version 06   25 February 2020 AUC 0-24 plasma ammonia) analyzed by the local laboratory (STAT sample) to determine the subject’s 
plasma ammonia level. The result must be available prior to initiating the tests. If the subject is 
deemed clinically unstable, the neuropsychological tests will be held until the subject is determined to 
be clinically stable. Subjects may request pauses to rest during administration of the 
neuropsychological test battery, but the entire battery should be completed in 1 session. Additional 
details are provided in the neuropsychological  section of the manual of operations.  
The neuropsychological assessments have been selected in close consultation with Dr. Susan 
Waisbren and are based on assessments where OTC participants in the UCD Consortium 
Longitudinal Study have shown cognitive defi cits thus far (refer to the neuropsychological section of 
the manual of operations for further details). The most informative neuropsychological tests, as 
determined by these Phase 1/2 study data, may be included in further clinical studies with DTX301 .  
Neuropsychological deficits, especially in memory and executive functioning, are considered to be 
important aspects of the OTC deficiency condition and have widespread effects on daily functioning and relationships. Improving or normalizing plasma ammonia and other blood biomarkers (glutamate 
and glutamine) is hypothesized to potentially improve neuropsychological functioning. Therefore, it 
is important to establish neuropsychological functioning prior to dosing with DTX301 as well as 
evaluate the trajectory  of this functioning longitudinally, ideally over several years. During the 4- year 
extension study, subjects will take this same neuropsychological battery of tests every 2 years to assess changes over time in motor, executive, and memory function.  
8.5.1 Intelligence  
Subjects will be asked to complete the Vocabulary and Matrix Reasoning subtests from the Wechsler 
Abbreviated Scale of Intelligence, Second Edition (WASI-II) at Baseline only (Table  15-1). The 
WASI -II provides general measure of cognitive function in subjects aged 6 to  89 years. The 
Vocabulary and Matrix Reasoning subtests provides an accurate, validated assessment of IQ that is 
highly correlated (r=0.86) with results from the Wechsler Adult Intelligence Scale, Fourth Edition 
(WAIS-IV) [Wechsler  2011 ]. The estimated time needed for completion of the WASI -II is 
30 minutes.  
Ultragenyx Pharmaceutical Inc.  DTX301  
Protocol: 301OTC01   
Page 72 of 126 
Version 06   25 February 2020 8.5.2 Motor Function  
8.5.2.1   
 
 
 
 
 
 
 
8.5.3 Executive Function  
8.5.3.1   
 
 
  
  
 
  
 
 
 
 
8.5.4 Memory  
8.5.4.1   
 
 
 
  
  
 

Ultragenyx Pharmaceutical Inc.  DTX301  
Protocol: 301OTC01   
Page 73 of 126 
Version 06   25 February 2020  
 
8.6 Genotyping  
8.6.1 Ornithine Transcarbamylase Genotyping  
At Baseline, subjects will be asked to provide a single whole-blood sample for OTC genotyping. The 
objective of this research is to provide a background understanding to the etiology of the subject’s 
OTC deficiency and to investigate any relationship between genetic factors and the subject’s response 
to DTX301. The results do not need to be available prior to dosing with DTX301.  
8.7 Other Assessments  
8.7.1 Demographic, Medical, and Ornithine Transcarbamylase Deficiency 
History Assessments  
As allowed by local laws and regulations, the following demographic data may be captured on the 
appropriate page in t he eCRF: date of birth, sex, race, and ethnicity.  
Medical, medication, and OTC deficiency medical history will be assessed as related to the eligibility criteria listed in Section 4.1 and Section  4.2. 
8.7.2 Ammonia Scavenger Use and Dietary Protein Intake  
The use of ammonia scavenger therapy and dietary protein intake will be reviewed and recorded at 
each visit (Table  15-1).  
Changes  to baseline treatment cannot occur until there is evidence of transgene expression reflected 
by continued evidence of metabolic stability with ammonia levels in the normal range or  improved 
ammonia control if subjects have a history of ammonia levels abov e the upper limit of normal and 
supported by improvement in clinical signs and symptoms. The subject must be clinically stable and 
under good metabolic control before changes can be initiated or progressed. The risks of making 
adjustments to baseline treatment on their own, without express guidance from the site, will be 
reinforced with the subject at site visits.  
Changes to baseline treatment cannot occur while the subject is treated with corticosteroids or within a 2-week period of completing a corticoste roid taper.  

Ultragenyx Pharmaceutical Inc.  DTX301  
Protocol: 301OTC01   
Page 74 of 126 
Version 06   25 February 2020 Tapering or discontinuation of ammonia scavenger therapy cannot occur at the same time 
and/or visit as modification of protein -restricted diet.  At any time after modification and/or 
discontinuation of ammonia scavenger therapy, reinstitution of therapy may take place based on the 
subject ’s clinical and metabolic status (elevated ammonia levels, or signs and symptoms consistent 
with hyperammonemia  ), and under evaluation of the investigator.  
Subjects will receive a prescribed diet (grams of prot ein per 24 hours) on Day 0 of the study and this 
diet will be reviewed at Weeks 6, 12, 24 and 52. Dietary protein intake by the subject between visits 
and dietary restrictions will be reviewed at each visit (Table  15-1 ) and recorded in the source 
documentation.  Modification of baseline protein-restricted diet cannot occur at the same time 
and/or visit as modification of baseline ammonia scavenger therapy. At any time after 
protein -restricted diet has been modified o r fully liberalized, reinstitution of restrictions may take 
place based on the subject ’s clinical and metabolic status and under evaluation of the investigator.  
Once medications or diet are adjusted or discontinued, the subject must demonstrate good metabolic 
control prior to adjustments in the other type of baseline treatment.  
9 Safety Monitoring and Reporting  
9.1 Adverse Events and Serious Adverse Events  
Adverse events will be assessed from the time the subject signs the ICF through the end of study/early withdrawal visit.  
At every study visit, subjects will be asked a standard nonleading question to elicit any medically 
related changes in their well -being.  
In addition to subject observations, AEs identified from any study data (eg, laboratory values, physical  examination findings, ECG changes) or identified from review of other documents (eg, 
subject diaries) that are relevant to subject safety will be documented on the AE page in the eCRF.  
9.1.1 Definitions  
9.1.1.1  Adverse Events  
The investigator is responsible for reporting all AEs that are observed or reported during the study, 
regardless of their relationship to study product or their clinical significance.  
Ultragenyx Pharmaceutical Inc.  DTX301  
Protocol: 301OTC01   
Page 75 of 126 
Version 06   25 February 2020 An AE is defined as any untoward medical occurrence in a subject enrolled into this study regardless 
of its causal relationship to study product. Subjects will be instructed to contact the investigator at any 
time after the subject signs the informed consent if any signs or symptoms develop.  
A treatment -emergent AE is defined as any event not present before exposure to  study product or any 
event already present that worsens in either intensity or frequency after exposure to study product.  
9.1.1.2  Serious Adverse Events  
An SAE is defined as any event that:  
• Results in death  
• Is immediately life-threatening  
• Requires inpatient hospitalization or prolongation of existing hospitalization.  
• NOTE:  Hospitalization due to hyperammonemic crisis (HAC  [Section  3.2.6] ) will be 
considered an SAE.  
• NOTE : Nonemergent hospitalizations for subject monitoring in the setting of steroid 
administration for vector -induced hepatitis ( Section  8.2.4.1.2 ) will not be considered an SAE.  
• Results in persistent or significant disability/incapacity  
• Results in a congenital anom aly/birth defect  
Additionally, important medical events that may not result in death, be life threatening, or require 
hospitalization may be considered SAEs when, based upon appropriate medical judgment, they may 
jeopardize the subject or may require medical or surgical intervention to prevent one of the outcomes 
listed in this definition. Examples of such medical events include allergic bronchospasm requiring 
intensive treatment in an emergency room or at home, blood dyscrasias or convulsions that do not 
result in inpatient hospitalization, or the development of drug dependency or drug abuse.  
9.1.2 Safety Reporting  
9.1.2.1  Adverse Events  
All AEs reported or observed during the study will be recorded on the AE page in the eCRF. Information to be collected includes drug tr eatment, dose, event term, time of onset, 
investigator -specified assessment of severity and relationship to study product, corticosteroid 
Ultragenyx Pharmaceutical Inc.  DTX301  
Protocol: 301OTC01   
Page 76 of 126 
Version 06   25 February 2020 regimen, [1 -13C] sodium acetate, OTC deficiency, or hyperammonemia, time of resolution of the 
event, seriousness, any required treatment or evaluations, and outcome. Adverse events resulting from 
concurrent illnesses, reactions to concurrent illnesses, reactions to concurrent medications, or 
progression of disease states must also be reported. All AEs will be followed to adequate resolution. 
The Medical Dictionary for Regulatory Activities (MedDRA) will be used to code all AEs.  
Any medical condition that is present at the time that the subject is screened but does not deteriorate 
should not be reported as an AE. However, if the condition deteriorates at any time during the study, 
it should be recorded as an AE.  
9.1.2.2  Serious Adverse Events  
Any AE that meets SAE criteria ( Section  9.1.1.2 ) or any of the safety stopping criteria ( Section  3.2.7) 
must be reported by the study site to PPD Pharmacovigilance (PVG) Department immediately (ie, 
within 24 hours) after the time study site personnel first learn about the event. The study site should 
recor d all SAE information in the SAE eCRF and submit the report via the electronic data capture 
(EDC) system. An event meeting any of the safety stopping criteria should only be reported as an 
SAE in the EDC system if it meets SAE criteria (Section  9.1.1.2). 
In the event of any fatal or life-threatening SAE, the investigator must immediately inform PPD PVG by telephone ( Table  9-1) and report the SAE in the EDC system. If, for any reason, it is 
not possible to report the SAE in the EDC system (eg, the EDC system is unavailable), the study site should record the SAE on the paper SAE Reporting Form and fax it to PPD PVG 
(Table  9-1). As so on as it is possible, any SAE reported via fax must be entered into the EDC 
system.  
Table  9-1 PPD PVG Contact Information for SAE Reporting  
Region  Contact Information  
Rest of World  Safety hotline :  
Safety faxa:  
North America Safety hotline :  
Safety faxa:  
Abbreviations: PVG, pharmacovigilance; SAE, serious adverse event. 
a. This is the preferred fax number for all regions. The toll -free fax number for North America can be provided upon 
request.  
 

Ultragenyx Pharmaceutical Inc.  DTX301  
Protocol: 301OTC01   
Page 77 of 126 
Version 06   25 February 2020 9.1.2.2.1  Expedited Reporting  
The sponsor is responsible for reporting serious, unexpected, suspected adverse drug reactions 
(SUSARs) involving the study product(s) to all regulatory authorities and participating investigators 
in accordance with International Council for Harmonisation (ICH) guidelines and/or local regulatory 
requirements, as applicable. It is the responsibility of the investigator or designee to promptly notify 
the local institutional review board (IRB)/independent ethics committee (IEC)/institutional biosafety 
committee (IBC) of all SUSARs involving risk to human subjects.  
As there is no prior clinical experience with DTX301, reference safety information for assessing 
whether an AE is a SUSAR is currently not available. Therefore, any SAE considered related to 
DTX301 will be considered a SUSAR and reported immediately as detailed in Section  9.1.2. The 
SAE should be treated with appropriate supportive and medical care deemed necessary for the 
well-being of the subject.  
9.1.3 Assessment of Severity/Toxicity  
The severity/toxicity, or intensity, of an AE refers to the extent to which an AE affects the subject’s 
daily activities. The intensity of the AE will be r ated as Grade 1, 2, 3, 4, or 5 using the most current 
version of the National Cancer Institute (NCI) CTCAE [ NCI CTCAE 2018]. The CTCAE provides 
descriptive terminology that can be used to standardize AE reporting. A severity/toxicity grade is 
provided for each AE term that is grouped by the highest level of MedDRA classification [NCI 
CTCAE 2018 ]. Specific symptoms and medical conditions have a clinical description for each level 
of severity/toxicity. In the event that an AE occurs during the study that is not captured by the CTCAE, the AE should be graded according to the general guidelines outlined in  Table  9-2. 
Ultragenyx Pharmaceutical Inc.  DTX301  
Protocol: 301OTC01   
Page 78 of 126 
Version 06   25 February 2020 Table  9-2 General Guidelines for Grading Events not Captur ed by the CTCAE  
Grade  Criteria  
Grade 1:  Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention 
not indicated.  
Grade 2:  Moderate; minimal, local, or noninvasive intervention indicated; limiting age -appropriate 
instrume ntal ADLa. 
Grade 3:  Severe or medically significant but not immediately life -threatening; hospitalization or 
prolongation of hospitalization indicated; disabling; limiting self -care ADLb. 
Grade 4:  Life-threatening consequences; urgent intervention indica ted. 
Grade 5:  Death related to AE.  
Abbreviations: ADL, activities of daily living; AE, adverse event.  
a. Instrumental ADL refers to preparing meals, shopping for groceries or clothes, using the telephone, managing money, 
etc. 
b. Self-care ADL refers to b athing, dressing and undressing, feeding self, using the toilet, taking medications, and not 
bedridden.  
 
Changes in the severity/toxicity of an AE should be documented to allow an assessment of the 
duration of the event at each level of intensity to be pe rformed. Adverse events characterized as 
intermittent do not require documentation of onset and duration of each episode.  
9.1.4 Assessment of Causality  
The investigator’s assessment of an AE’s relationship to study product is part of the documentation process, b ut it is not a factor in determining what is or is not reported in the study. If there is any 
doubt as to whether a clinical observation is an AE, the event should be reported.  
Ultragenyx Pharmaceutical Inc.  DTX301  
Protocol: 301OTC01   
Page 79 of 126 
Version 06   25 February 2020 The relationship or association of the study product in causing or contributing to the AE will be 
characterized using the following classification and criteria:  
Unrelated:  This relationship suggests that there is no association between the study product and 
the reported event.  
Possible:  This relationship suggests that treatment with  the study product is causing or 
contributing to the AE; ie, the event follows a reasonable temporal sequence from the 
time of the study product administration or follows a known response pattern to the 
study product but could also be produced by other fac tors. 
Probable:  This relationship suggests that a reasonable temporal sequence of the event with the 
study product administration exists and, based upon the known pharmacological action of the study product, known or previously reported adverse reactions to the drug or class of drugs, or judgment based on the investigator’s clinical experience, the association of the event with the study product seems likely. The event disappears or 
decreases on cessation or reduction of the dose of study product.  
Definite:  This relationship suggests that a definite causal relationship exists between the study 
product administration and the AE, and other conditions (concurrent illness, progression/expression of disease state, or concurrent medication reaction) do not appear to explain the event. The event reappears or worsens if the study product is re-administered.  
 
The relationship or association of corticosteroid regimen, [1-
13C] sodium acetate, OTC deficiency, or 
hyperammonemia in causing or contributing to the AE will  also be characterized using the 
classification terms above.  
9.1.5 Follow -Up of Subjects Reporting Adverse Events  
All AEs must be reported in detail on the appropriate page in the eCRF and followed to satisfactory 
resolution, until the investigator deems the eve nt to be chronic or not clinically significant, or until the 
subject is considered to be stable.  
9.2 Procedures for Handling Special Situations  
9.2.1 Pregnancy  
A serum pregnancy test will be performed on all female study subjects of childbearing potential 
during Screening. A urine pregnancy test will be performed on all female study subjects of 
childbearing potential at each visit specified in the Schedule of Events (Table  15-1). 
Ultragenyx Pharmaceutical Inc.  DTX301  
Protocol: 301OTC01   
Page 80 of 126 
Version 06   25 February 2020 Pregnancy is not regarded as an AE unless there is a suspicion that a study drug may have interfered 
with the effectiveness of a contraceptive medication. Any pregnancy in a female study subject that 
occurs during study participation must be reported using the paper Pregnancy Report Form and fax it 
to PPD PVG (Table  9-1). To ensure subject safety, each pregnancy in a female study subject must be 
reported to PPD PVG Department (contact information in Section 9.1.2.2 ) within 2  weeks of learning 
of its occurrence.  
The pregnancy in a female study subject must be followed up to determine outcome (including spontaneous miscarriage, elective termination, normal birth, or congenital abnormality) and status of 
mother and chil d, even if the subject discontinued from the study. Pregnancy complications and 
elective terminations for medical reasons should not be reported as an AE or SAE. Spontaneous 
miscarriages must be reported as an SAE. All neonatal deaths that occur within 28 days of birth 
should be reported as an SAE.  
Any SAE occurring in association with a pregnancy in a female study subject brought to the investigator’s attention after the subject has completed the study and considered by the investigator as 
possibly related  to the study product, must be promptly reported to Ultragenyx Pharmaceutical.  
9.2.2 Treatment Noncompliance  
9.2.2.1  Overdose Management  
An overdose is any dose of study product given to or taken by a subject that intentionally or unintentionally exceeds the dose, based  on body weight (kg), described in Section 3.1. 
Overdoses without signs or symptoms do not need to be recorded as AEs; in case of any AEs 
associated with the overdose, these should be reported on the relevant AE or SAE section in the 
eCRF. The actual dose infused will be recorded on the appropriate page in the eCRF.  
There is no treatment for overdose. All subjects will be closely monitored at the time of infusion for 
any adverse effects and supportive care will be administered at the discretion of the investigator, as 
needed, should an overdose be suspected.  
9.2.2.2  Medication Errors  
A medication error is defined as a mistake made in prescribing, dispensing, administration, or use of 
the study product. The treatment will be open-label and is to be administered by trained medical 
personnel at the study site.  
Ultragenyx Pharmaceutical Inc.  DTX301  
Protocol: 301OTC01   
Page 81 of 126 
Version 06   25 February 2020 9.3 Data Monitoring Committee  
An independent DMC will be responsible for monitoring safety data from the study. The DMC will 
meet after all subjects in Cohort 1, all subjec ts in Cohort 2, and the initial 3 subjects in Cohort 3 have 
completed Week 12 of the study to review the safety data and to provide their recommendation for 
progressing to the next dosing cohort, or expansion of a dosing cohort. There will be no intra -cohort 
dose escalations. The DMC will also hold a meeting at completion of Week 12 for the first 3 subjects dosed in Cohort 4, and at the completion of Week 52 for all subjects. Additional DMC meetings may 
take place, as needed. 
The DMC will meet on an ad hoc basis if an investigator reports an AE/SAE that meets any of the 
safety stopping criteria ( Section  3.2.7 ). The DMC may , at any time, recommend modifying or pausing 
enrollment due to safety concerns based on these periodic data reviews. Following DMC review when a stopping rule is met, if the decision is to restart enrollment, a substantial amendment will need to be 
approved by the regulatory authority. The full scope of each review will be outlined in the DMC 
charter. The DMC will comprise at least either 3 independent medical professionals or 2  independent 
medical professionals and an independent biostatistician who are qualified to review the data and 
provide recommendations for progressing to the next dosing level and progressing to the next dosing 
cohort and cohort expansion. The DMC charter details the members’ roles and  responsibilities as part 
of the DMC as well as the process for each data review (ad hoc or scheduled).  
10 Statistical and Analytical Plan  
A stat istical analysis plan (SAP) will be written and will provide a detailed description of the 
statistical methods and expand on the details provided in this protocol. Additional analyses may be 
added.  
10.1 Dose- Finding Algorithm and Process  
Dose finding for DTX301 will be accomplished through a CRM algorithm as described in 
Section  10.5.1.  The operational process is as follows:  
• Data sources and methodologies used to determine the parameter values of the prior 
distributio ns of the toxicity model  
• Data elements and formats required in order to conduct modeling needed for producing dosing recommendation for the next dose  
Ultragenyx Pharmaceutical Inc.  DTX301  
Protocol: 301OTC01   
Page 82 of 126 
Version 06   25 February 2020 • Validation process of the modeling results and format and data to be provided to the DMC for 
dosing decisi ons 
10.2 Primary Endpoints  
The primary endpoint is the incidence of AEs, treatment -emergent AEs, and SAEs ( Section  9.1). 
10.3 Secondary Endpoints  
The secondary endpoints are: 
• The change from baseline in the rate of ureagenesis (Section  8.1.1)  
• The change from baseline in AUC 0-24 for plasma ammonia ( Section  8.1.2 ) 
10.4 Exploratory Endpoints  
The exploratory endpoints are:  
• The number of hypera mmonemic crises (HAC ) (Section  8.2.4.1)  
• The change from baseline in urinary orotic acid secretion ( Section  8.3.3 ) 
• The change from baseline in serum glutamine and glut amate ( Section  8.2.4.1 ) 
• Changes in responses to neuropsychological tests ( Section  8.4) 
• Responses to the PROMIS questionnaire ( Section  8.4.1) 
• Use of ammonia scavenger therapy (Section  8.7.2)  
• Change in dietary protein intake ( Section  8.7.2 ) 
• The development of neutralizing antibodies to AA V8 (Section  8.2.5.1)  
• The development of anti -AAV8 binding antibodies ( Section  8.2.5.2) 
• The development of anti -OTC antibodies ( Section  8.2.5.3 ) 
10.5 Statistical Analysis Methodology  
Dose-finding modeling will be conducted through specialized software that has been validated by 
PPD. SAS® software (SAS Institute, Inc., Cary, North Carolina, United States) Version 9.2 or later 
Ultragenyx Pharmaceutical Inc.  DTX301  
Protocol: 301OTC01   
Page 83 of 126 
Version 06   25 February 2020 will be used for general data manipulation and statistical analyses. Continuous variables will be 
summarized using the mean, the standard deviation, median, minimum value, and maximum value. 
Categorical variables will be summarized using frequency counts and percentages. Data will be listed 
in data listings. 
Details of the statistical analyses, methods, and data conventions are described in the SAP. 
10.5.1  Determination of the Optimal Biological Dose  
The CRM uses the Bayesian method to model the probability of experiencing a DLT for each given 
dose in order to determine the next dose. A DLT is defined as any AE/SAE ≥  Grade 3 that is 
considered related to DTX301 by the investigator [NCI CTCAE 2018] .  
 
The OBD is defined as the highest dose 
where the predicted probability of experiencing a DLT is less than the target toxicity level.  
 
 
 
A high-level overview of th e decision criteria to be used during dose  finding are presented in 
Figure  10-1. Subjects (n=3) in the first cohort (Cohort 1) will be assigned to Dose 1.  
 
 
 
 Dose finding will continue in this manner 
until one of the following conditions is met:  
1. The MTD is reached.  
 
  
2. The OBD is found.  
 
3. All of the dosing cohorts have been enrolled.  

Ultragenyx Pharmaceutical Inc.  DTX301  
Protocol: 301OTC01   
Page 84 of 126 
Version 06   25 February 2020   
 
Possible dosing paths during dose  
 
 
 
 
 
The protocol will also allow  for adding an 
intermediate dose during either escalation or de-escalation, relative to the candidate doses outlined in 

Ultragenyx Pharmaceutical Inc.  DTX301  
Protocol: 301OTC01   
Page 85 of 126 
Version 06   25 February 2020  
 
  
 
  
 
  
 
  
10.5.2  Efficacy Analysis  
10.5.2.1  Ureagenesis  
The change from baseline in the rate of ureagenesis (presented in µmol/kg/hr  and the relative 
percentage to  normal healthy  adult s [300 µmol/kg/hr ]) will be determine d for all subjects at Weeks 6, 
12, 20, 24, and 52 (Table  15-1). During Screening, assessment of rate of ureagenesis may be repeated 
if discrepant with subject’s clinical status and severity. Full details of the analysis will be provided in 
the SAP. 

Ultragenyx Pharmaceutical Inc.  DTX301  
Protocol: 301OTC01   
Page 86 of 126 
Version 06   25 February 2020 10.5.2.2  Plasma Ammonia Area Under the Curve from Time Zero to 24 Hours  
The change from baseline in the plasma ammonia area under the curve ( AUC 0-24) and the 
time-normalized plasma ammonia, defined as plasma ammonia  AUC 0-24 divided by actual hours from 
zero to 24 hours , after IV administration of DTX301 will be determined for all subjects at Weeks 6, 
12, 24, and 52 (Table  15-1). Full details of the analysis will be provided in the SAP.  
10.5.3  Safety Analyses  
All subjects who receive DTX301 will be included in the safety analysis.  
10.5.3.1  Adverse Events  
All statistical analyses of safety outcomes will be descriptive. The incidence of AEs and 
treatmen t-emergent AEs will be summarized for each dosing cohort by severity and relationship to 
study product. Serious A Es will be presented for each dosing cohort by relationship to study product. 
Summary tables will present incidence estimates and individual event rates by system organ class as 
well as within each system organ class. Subjects experiencing an event more than once with varying 
severity will be counted only once, applying only the maximum severity observed within each system 
organ class and preferr ed term. For incidence of relationship to study product, subjects will be 
counted only once, in the category of the strongest relationship to study product within each system organ class and preferred term.  
10.5.3.2  Physical Examination Findings  
Complete and targeted physical examination findings will be summarized by visit and dosing cohort.  
10.5.3.3  Vital Sign Measurements  
Vital sign measurements (heart rate, blood pressure [systolic and diastolic], and respiratory rate) will 
be summarized over time in terms of absolute values and changes from baseline by visit and dosing 
cohort. Height and weight will be summarized.  
10.5.3.4  Electrocardiogram Results  
Electrocardiogram data will be summarized by visit and dosing cohort. Each ECG will be classified 
as “abnormal” or “normal,” and the relevance of the abnormality will be summarized as “clinically 
significant” or “not clinically significant.”  
Ultragenyx Pharmaceutical Inc.  DTX301  
Protocol: 301OTC01   
Page 87 of 126 
Version 06   25 February 2020 10.5.3.5  Clinical Laboratory Assessment Results  
For all laboratory assessments with continuous results, absolute values and changes from baseline 
will be summarized by visit and dosing cohort. For laboratory tests with categorical results, shifts 
from baseline will be summarized by visit and dosing cohort. Chemistry values from both the central 
laboratory and subjects’ local laboratories will be analyzed.  
10.5.3.6  Other Laboratory Results  
Neutralizing antibodies (AAV8) and AAV8 -binding antibody IgG assay results will be listed by time 
point and dosing cohort. Anti-OTC antibody assay  and viral shedding results will be listed by time 
point and dosing cohort.  
10.5.4  Neuropsychological Tests  
Changes in responses to the PROMIS mental health measurements and  
(Section  8.4) will be summarized by visit and dosing cohort as outlined in the SAP. Results of the 
other neuropsychological tests will be listed by visit and dosing cohort.   
10.5.5  Quality -of-Life Assessment  
Associations between QoL and dose will be undertaken using tabular summaries and appropriate 
statistical methods as outlined in the SAP.  
10.5.6  Other Analyses  
Summary statistical analyses will be provided for demographics, medical history, OTC deficiency 
medical history, prior and concomitant medications, use of ammonia scavengers, and dietary protein intake. A summary of subject disposition will be prepared.  
10.5.7  Interim Analysis  
An interim analysis may be conducted when 12  weeks of data are available for all subjects from at 
least 2  dosing cohorts. Results and their dissemination will be at the sponsor’s discretion. A detailed 
plan for the analysis of the safety and efficacy data will be presented in the SAP.  

Ultragenyx Pharmaceutical Inc.  DTX301  
Protocol: 301OTC01   
Page 88 of 126 
Version 06   25 February 2020 10.6 Data Quality Assurance  
Study sites will maintain source documentation and enter subject data in the eCRF as accurately as 
possible and will rapidly respond to any reported discrepancies. The eCRFs are accessed thr ough 
Medidata Rave® (New York, New York, United States). This EDC system is validated and compliant 
with US Title 21 Code of Federal Regulations (CFR) Part A1. Each person involved with the study 
will have an individual user name and password that allows for record traceability. Thus, the system, 
and subsequently any investigative reviews, can identify coordinators, investigators, and individuals 
who have entered or modified records, as well as the time and date of any modifications. A quality 
review of the data will be performed by the study site with additional reviews by the clinical monitor.  
Each eCRF is presented as an electronic copy, allowing data entry by study site personnel, who can add and edit data, add new subjects, identify and resolve discrepancies, and view records. This system 
provides immediate direct data transfer to the database, as well as immediate detection of 
discrepancies, enabling study site coordinators to resolve and manage discrepancies in a timely 
manner.  
Paper copies of the eCRFs and other database reports may be printed and signed by the investigator. 
This system provides study site personnel, monitors, and reviewers with access to hardcopy audits, 
discrepancy reviews, and investigator comment information.  
After all queries have been resolved, the SAP is approved and signed, and any summary/analysis populations are approved, the database will be locked. All summary and analysis of the data will be 
performed using SAS software Version 9.2 or later.  
10.6.1  Data Management  
As part of the responsibilities assumed by participating in the study, the investigator agrees to 
maintain adequate case histories for the subjects treated as part of the research under this protocol. 
The investigator agrees to maintain accurate eCRFs and source documentation as part of the case 
histories. These source documents may include diary cards, laboratory reports, ECG strips, and other 
materials.  
The sponsor (or sponsor designee) will supply the eCRF. Study personnel must have documented training in the use of the EDC system before the system can be authorized.  
All eCRF information is to be completed. If an item is not available or is not applicable, this fact should be indicated.  
Ultragenyx Pharmaceutical Inc.  DTX301  
Protocol: 301OTC01   
Page 89 of 126 
Version 06   25 February 2020 Investigative study site personnel will enter subject data into the EDC system. The analysis data sets 
will be a combination of these data and data from other sources (eg, laboratory data). All entries and 
changes to the data in the eCRF will be recorded electronically with an audit trail specifying the date 
and time of entry or change  and the name of the authorized person making the entry or change. The 
investigator will answer all queries issued, if applicable. Data queries and query correspondence will be included in the audit trail.  
Clinical data management will be performed in acco rdance with applicable sponsor (or sponsor 
designee) standards and data cleaning procedures to ensure the integrity of the data (eg, removing 
errors and inconsistencies in the data). Adverse events and concomitant medication terms will be 
coded using MedDR A and WHO Drug dictionary terminology, respectively.  
After database lock, each study site will receive an electronic copy of their study site-specific eCRF 
data as entered into the EDC system for the study, including full discrepancy and audit history. 
Additionally, an electronic copy of all of the study site’s data from the study will be created and sent 
to the sponsor for storage. The sponsor (or sponsor designee) will maintain a duplicate electronic copy for their records. In all cases, subject initials will not be collected or transmitted to the sponsor.  
11 Ethics  
11.1 Institutional Review Board, Independent Ethics Committee, and 
Institutional Biosafety Committee  
Federal regulations and the ICH guidelines require that approval be obtained from an IRB/IEC/IBC before participation of human subjects in research studies. Before study onset, the protocol, ICF, 
advertisements to be used for the recruitment of study subjects, and any other written information regarding this study to be provided to the subject or the subject’s legal guardian must be approved by an IRB/IEC/IBC. Documentation of all IRB/IEC/IBC approvals and of the IRB/IEC/IBC compliance 
with ICH harmonised tripartite guideline E6(R2): Good Clinical Practice (GCP) must be maintained 
by the study site and ma de available for review by the sponsor or its designee.  
All IRB/IEC/IBC approvals should be signed by the IRB/IEC/IBC chair or designee and must identify the IRB/IEC/IBC name and address, the clinical protocol by title or protocol number or both, 
and the date approval or a favorable opinion was granted.  
The investigator is responsible for providing written summaries of the progress and status of the study at intervals not exceeding 1  year or otherwise specified by the IRB/IEC/IBC. The investigator must 
Ultragenyx Pharmaceutical Inc.  DTX301  
Protocol: 301OTC01   
Page 90 of 126 
Version 06   25 February 2020 prom ptly supply the sponsor or its designee, the IRB/IEC/IBC, and, where applicable, the institution, 
with written reports on any changes significantly affecting the conduct of the study or increasing the 
risk to subjects.  
11.2 Ethical Conduct of the Study  
The study will be performed in accordance with the ethical principles that have their origin in the 
Declaration of Helsinki, ICH GCP, and all applicable local laws and regulations.  
11.3 Subject Information and Consent  
A written ICF in compliance with regulatory authority regulations and 21 CFR §50 shall be obtained 
from each subject before entering the study or performing any unusual or nonroutine procedure that involves risk to the subject. An ICF template may be provided by the sponsor to study sites. If any 
institution-specific modifications to study -related procedures are proposed or made by the study site, 
the ICF should be reviewed by the sponsor or its designee or both before IRB/IEC/IBC submission. Once reviewed, the ICF will be submitted by the investigator to h is or her IRB/IEC/IBC for review 
and approval before the start of the study. If the ICF is revised during the course of the study, all active participating subjects must sign the revised form.  
Before recruitment and enrollment, each prospective subject or their legal guardian will be given a full explanation of the study and be given the opportunity to read the approved ICF. Once the 
investigator is assured that the subject or their legal guardian understands the implications of participating in the study, the subject or their legal guardian will be asked to give consent to 
participate in the study by signing the ICF. 
The investigator shall retain the signed original ICF(s) and must provide a copy of the signed original 
form to the subject or their legal gua rdian.  
12 Investigator’s Obligations  
The following administrative items are meant to guide the investigator in the conduct of the study but 
may be subject to change based on industry and government standard operating procedures, working 
practice documents, or guidelines. Any change will be reported to the IRB/IEC/IBC but will not 
require a protocol amendment.  
Ultragenyx Pharmaceutical Inc.  DTX301  
Protocol: 301OTC01   
Page 91 of 126 
Version 06   25 February 2020 12.1 Confidentiality  
All laboratory specimens, evaluation forms, reports, and other records will be identified in a manner 
designed to maintain subject confidentiality. All records will be kept in a secure storage area with 
limited access. Clinical information will not be released without the written permission of the subject 
(or the subject’s legal guardian), except as necessary for monitoring and auditing by the sponsor, its 
designee, the FDA, other applicable regulatory agencies, or the IRB/IEC/IBC.  
The investigator and all employees and coworkers involved with this study may not disclose or use 
for any purpose other than performance of the study any data, record, or other unpublished, 
confidential information disclosed to those individuals for the purpose of the study. Prior written 
agreement from the sponsor must be obtained for the disclosure of any said confidential information 
to other parties.  
12.2 Financial Disclosure and Obligations  
Investigators are required to provide financial disclosure information to allow the sponsor to submit 
the complete and accurate certification or disclosure statements required under 21  CFR §54. In 
addition, the investigator must provide to the sponsor a commitment to promptly update this information if any relevant changes occur during the course of the investigation and for 1 year 
following the completion of the study.  
Neither the sponsor nor PPD is financially responsible for further testing or treatment of any medical condition that may be detected during the screening process. In addition, in the absence of specific 
arrangements, neither the sponsor nor PPD is financially responsible for further treatment of the 
subject’s disease.  
12.3 Investigator Documentation  
Prior to beginning the study, the investigator will be asked to comply with ICH E6(R2) 8.2 and Title 
21 of the CFR by providing the following essential documents, including but not limited to:  
• IRB/IEC/IBC approvals;  
• Original investigator -signed investigator agreement page of the protocol;  
• Form FDA 1572 (or equivalent), fully executed, and all updates on a new fully executed 
Form FDA 1572 (or equivalent);  
• Curriculum vitae for the investigator and each subinvestigator;  
Ultragenyx Pharmaceutical Inc.  DTX301  
Protocol: 301OTC01   
Page 92 of 126 
Version 06   25 February 2020 • Financial  disclosure information to allow the sponsor to submit complete and accurate 
certification or disclosure statements required under 21 CFR §54. In addition, the 
investigators must provide to the sponsor a commitment to promptly update this information 
if any relevant changes occur during the course of the investigation and for 1 year after the 
completion of the study;  
• IRB/IEC/IBC-approved ICF, samples of study site advertisements for recruitment for this 
study, and any other written information regarding this study that is to be provided to the 
subject or their legal guardian; and  
• Laboratory certifications and normal ranges for any local laboratories used by the study site, in accordance with 42 CFR §493.  
12.4 Study Conduct  
The investigator agrees that the study will be conducted according to the principles of ICH  E6(R2). 
The investigator will conduct all aspects of this study in accordance with all national, state, and local laws or regulations. Study information from this protocol will be posted on publicly avail able clinical 
study registers before enrollment of subjects begins.  
Where available, agreed upon by the investigator and allowed by local regulation, an outpatient clinic 
visit may take place as home health services. Investigators will be responsible for m aintaining 
effective lines of communication between the investigator and the personnel who manage the 
subjects at home to guarantee that the investigator is constantly kept informed of subject safety, 
including metabolic and clinical status. 
12.5 Adherence to P rotocol 
The investigator agrees to conduct the study as outlined in this protocol in accordance with ICH 
E6(R2) and all applicable guidelines and regulations.  
12.6 Adverse Events and Study Report Requirements  
By participating in this study , the investigator agr ees to submit reports of SAEs according to the time 
line and method outlined in the protocol. In addition, the investigator agrees to submit annual reports to the study site IRB/IEC/IBC as appropriate. 
Ultragenyx Pharmaceutical Inc.  DTX301  
Protocol: 301OTC01   
Page 93 of 126 
Version 06   25 February 2020 12.7 Investigator’s Final Report  
Upon completion of the study, the investigator, where applicable, should inform the institution; the 
investigator/institution should provide the IRB/IEC/IBC with a summary of the study’s outcome and 
the sponsor and regulatory authority(ies) with any reports required.  
12.8 Record Retention  
Essential documents should be retained until at least 2 years after the last approval of a marketing 
application in an ICH region and until there are no pending or contemplated marketing applications in 
an ICH region or at least 2 years have elapsed since the formal discontinuation of clinical 
development of the study product. These documents should be retained for a longer period, however, 
if required by the applicable regulatory requirements or by an agreement with the sponsor. It is the 
responsibility  of the sponsor to inform the investigator/institution as to when these documents no 
longer need to be retained.  
12.9 Publications  
After completion of the study, the data may be considered for reporting at a scientific meeting or for publication in a scientific  journal. In these cases, the sponsor will be responsible for these activities 
and will work with the investigators to determine how the manuscript is written and edited, the number and order of authors, the publication to which it will be submitted, and other related issues. 
The sponsor has final approval authority over all such issues.  
Data are the property of the sponsor and cannot be published without prior authorization from the sponsor, but data and publication thereof will not be unduly withheld.  
13 Study Management  
The administrative structure will include a DMC ( Section  9.3). 
13.1 Monitoring  
13.1.1  Monitoring of the Study  
The clinical monitor, as a representative of the sponsor, has the obligation to closely follow the progression of the study, ensuring that it is being conducted in compliance with the protocol, ICH 
E6(R2), all applicable local laws and regulations, and with current and applicable standard operating 
Ultragenyx Pharmaceutical Inc.  DTX301  
Protocol: 301OTC01   
Page 94 of 126 
Version 06   25 February 2020 procedures. In doing so, the monitor will visit the inv estigator and study site at periodic intervals, in 
addition to maintaining necessary telephone and written contact. The monitor will maintain current 
personal knowledge of the study through observation, review of study records and source 
documentation, and discussion of the conduct of the study with the investigator and study site 
personnel.  
13.1.2  Inspection of Records  
Investigators and institutions involved in the study will permit study -related monitoring, audits, 
IRB/IEC/IBC review, and regulatory inspections by providing direct access to all study records. In 
the event of either an audit or inspection, the investigator agrees to allow the sponsor, representatives 
of the sponsor, or a regulatory agency (eg, FDA or other regulatory agency)  access to all study 
records.  
The investigator should promptly notify the clinical research associate (CRA) of any audits or 
inspections scheduled by any regulatory authorities and promptly forward copies of any reports 
received to the CRA. The CRA will then inform and forward any reports to the sponsor.  
13.2 Management of Protocol Amendments and Deviations  
13.2.1  Modification of the Protocol  
Any changes in this research activity, except those necessary to remove an apparent, immediate hazard to the subject, must be reviewed and approved by the sponsor or its designee. Amendments to 
the protocol must be submitted in writing to the investigator’s IRB/IEC/IBC for approval before subjects can be enrolled into an amended protocol.  
13.2.2  Protocol Deviations  
A deviation from the protocol is a departure f rom the written procedures or processes. A significant 
deviation occurs when there is nonadherence to the protocol by the subject or investigator that results in a significant, additional risk to the subject or important change to the study design. 
Significant deviations can include nonadherence to inclusion or exclusion criteria, nonadherence to 
safety and efficacy -related assessments, or nonadherence to FDA regulations or ICH GCP guidelines, 
that could lead to the subject being withdrawn from the study ( Section  7.1). Protocol waivers or 
exemptions are not permitted. Adherence to the study design requirements, including those specified in the Schedules of Events (Table  15-1 and Table  15-2), is essential for study conduct.  
Ultragenyx Pharmaceutical Inc.  DTX301  
Protocol: 301OTC01   
Page 95 of 126 
Version 06   25 February 2020 The investigator or designee must document and explain in the subject’s source documentation any 
deviation from the approved protocol. The investigator may implement a deviation from, or a change 
of, the protocol to eliminate an immediate hazard to study subjects without prior IRB/IEC/IBC 
approval. As soon as possible after such an occurrence, the implemented deviation or change, the 
reasons for it, and any proposed protocol amendments should be submitted to the IRB/IEC/IBC for 
review and approval, to the sponsor for agreement, and to the regulatory authorities, if required.  
Protocol deviations will be documented by the clinical monitor throughout the course of moni toring 
visits. Principal investigators will be notified in writing by the monitor of deviations. The 
IRB/IEC/IBC should be notified of all protocol deviations in a timely manner, as required.  
13.3 Study Termination  
Although the sponsor has every intention of completing the study, the sponsor reserves the right to 
discontinue the study at any time for clinical or administrative reasons. 
The end of the study is defined as the date on which the last subject completes the last visit (includes 
follow -up visit). 
13.4 Final  Report 
Whether the study is completed or prematurely terminated, the sponsor will ensure that the clinical 
study reports are prepared and provided to the regulatory agency(ies) as required by the applicable 
regulatory requirement(s). The sponsor will also  ensure that the clinical study reports in marketing 
applications meet the standards of the ICH harmonised tripartite guideline E3: Structure and content 
of clinical study reports.  
Where required by applicable regulatory requirements, an investigator signa tory will be identified for 
the approval of the clinical study report. The investigator will be provided reasonable access to 
statistical tables, figures, and relevant reports and will have the opportunity to review the complete 
study results.  
Upon completion of the clinical study report, the sponsor will provide the investigator with a summary of the cumulative study results. The investigator is encouraged to share the cumulative 
summary results and will provide each subject with their individual data. The  study results will be 
posted on publicly available clinical study registers, where required.  
Ultragenyx Pharmaceutical Inc.  DTX301  
Protocol: 301OTC01   
Page 96 of 126 
Version 06   25 February 2020 Declaration of Investigator  
I have read and understood all sections of the protocol titled “A Phase 1/2, Open -Label Safety and 
Dose-Finding Study of Adeno-Associated Virus (AAV) Serotype 8 (AAV8) -Mediated Gene Transfer 
of Human Ornithine Transcarbamylase (OTC) in Adults with Late- Onset OTC Deficiency.” 
I have read and agree to supervise all aspects of the protocol and to conduct the clinical investigation 
in accor dance with the Final Protocol Version 06, dated 25 February 2020, the International Council 
for Harmonisation harmonised tripartite guideline E6(R2): Good Clinical Practice and all applicable government regulations and inform all who assist me in the conduct of this study of their 
responsibilities and obligations.  
   
Signature of Principal Investigator   Date  
   
Printed Name of Principal Investigator    
 
 
Ultragenyx Pharmaceutical Inc.  DTX301  
Protocol: 301OTC01   
Page 97 of 126 
Version 06   25 February 2020 14 Reference List 
Batshaw ML, Monahan PS. Treatment of urea cycle disorders. Enzyme. 1987;38(1 -4):242-50. 
Batshaw ML, MacArthur RB, Tuchman M. Alternative pathway therapy for urea cycle disorders: 
twenty years later. J Pediatr. 2001;138(1 Suppl):S46 -54. 
Batshaw ML, Tuchman M, Summar M, et al. A longitudinal study of urea cycle disorders. Mol Genet 
Metab. 2014;113(1- 2):127 -30. 
Boutin S, Monteilhet V, Veron P, et al. Prevalence of serum IgG and neutralizing factors against 
adeno -associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for 
gene therapy using AAV vectors. Hum Gene Ther. 2010;21(6):704-12.  
Calcedo R, Wilson JM. Humoral immune response to AAV. Front Immunol. 2013;4:341.  
Caldovic L, Abdikarim I, Narain S, et al. Genotype-phenotype correlations in ornithine transcarbamylase deficiency: a mutation update. J Genet Genomi cs. 2015;42(5):181-94.  
Castillo L, Beaumier L, Ajami AM, et al. Whole body nitric oxide synthesis in healthy men determined from [15N]arginine -to[15N]citrulline labeling. Proc Nat Acad Sci U  S A. 
1996;93(21):11460-5.  
Davidoff AM, Gray JT, Ng CY, et al. Com parison of the ability of adeno-associated viral vectors 
pseudotyped with serotype 2, 5, and 8 capsid proteins to mediate efficient transduction of the liver in 
murine and nonhuman primate models. Mol Ther. 2005;11(6):875- 88. 
Deignan JL, Cederbaum SD, Grody WW. Contrasting features of urea cycle disorders in human patients and knockout mouse models. Mol Genet Metab. 2008;93(1):7-14.  
Delis DC, Kaplan E, Kramer JH. Delis- Kaplan Executive Function System (D- KEFS). San Antonio, 
TX: The Psychological Corporation . 2001.  
Diaz GA, Harding CO, Geberhiwot T, et al. Preliminary results from cohorts 1 and 2 of CAPtivate: a phase 1/2 clinical trial of AAV8 -mediated liver -directed gene therapy in adults with late-onset OTC 
deficiency. Molecular Therapy. 2019;27(4S1):2-3.  
Ultragenyx Pharmaceutical Inc.  DTX301  
Protocol: 301OTC01   
Page 98 of 126 
Version 06   25 February 2020 Diaz GA, Schulze A, Longo N, et al. Long -term safety and efficacy of glycerol phenylbutyrate for the 
management of urea cycle disorder patients. 2019;127(4):336- 45. Doi: 
10.1016/j.ymgme.2019.07.004. Epub 2019 Jul 10.  
Gao GP, Alvira MR, Wang L, et al. Novel  adeno -associated viruses from rhesus monkeys as vectors 
for human gene therapy. Proc Natl Acad Sci U S A. 2002;99(18):11854-9.  
Gao G, Vandenberghe LH, Wilson JM. New recombinant serotypes of AAV vectors. Curr Gene Ther. 
2005;5(3):285-97.  
Gao G, Wang Q, Calcedo R, et al. Adeno -associated virus-mediated gene transfer to nonhuman 
primate liver can elicit destructive transgene-specific T cell responses. Hum Gene Ther. 
2009;20(9):930-42.  
Guidance for industry: design of early -phase clinical trials for cellular and gene therapy products. 
CBER. June 2015. Available from:  http://www.fda.gov/downloads/Biologi.../UCM359073.pdf .  
Häberle J, Boddaert N, Burlina A, et al. Suggested guidelines for the diagnosis and management of 
urea cycle disorders. Orphanet J Rare Dis. 2012;7:32.  
Häberle J, Burlina A, Chakrapani A, et al. Suggested guidelines for the diagnosis and management of 
urea cycle disorders: First revision. J Inherit Metab Dis. 2019;42(6):1192- 1230. Doi: 
10.1002/jimd.12100. Epub 2019 May 15.  
Herzog RW, Mount JD, Arruda VR, et al. Muscle-directed gene transfer and transient immune suppression result in sustained partial correction of canine hemophilia B caused by a null mutation. 
Mol Ther. 2001 ;4(3):192- 200. 
Hodges PE, Rosenberg LE. The spfash mouse: a missense mutation in the ornithine transcarbamylase gene also causes aberrant mRNA splicing. Proc Natl Acad Sci U S A. 1989;86(11):4142-6.  
Iasonos A, O’Quigley J. Adaptive dose-finding studies: a review of model -guided phase I trials. 
J Clin Oncol. 2014;32(23):2505- 11. 
Jackson MJ, Beaudet AL, O’Brien WE. Mammalian urea cycle enzymes. Annu Rev Genet. 1986;20:431- 64. 
Jahoor F, Wolfe RR. Reassessment of primed constant -infusion tracer method to measur e urea 
kinetics. Am J Physiol. 1987;252(4 Pt 1):E557 -64. 
Ultragenyx Pharmaceutical Inc.  DTX301  
Protocol: 301OTC01   
Page 99 of 126 
Version 06   25 February 2020 Jiang H, Couto LB, Patarroyo-White S, et al. Effects of transient immunosuppression on 
adeno -associated, virus-mediated, liver -directed gene transfer in rhesus macaques and implications 
for human gene therapy. Blood. 2006;108(10):3321- 8. 
Kay MA. State-of -the-art gene-based therapies: the road ahead. Nat Rev Genet. 2011;12(5):316 -28. 
Kent JD, Holt RJ. Hyperammonemic crises in patients with urea cycle disorders on chronic nitrogen scavenger therapy with  either sodium phenylbutyrate or glycerol phenylbutyrate. Neuropsych. 
2017;7(2):131-6.  
Koletzko B, Sauerwald T, Demmelmair H. Safety of stable isotope use. Eur J Pediatr. 
1997;156(Suppl 1):S12-7.  
Krivitzky L, Babikian T, Lee HS, et al. Intellectual, adaptive, and behavioral functioning in children 
with urea cycle disorders. Pediatr Res. 2009;66(1):96 -101. 
Leonard JV. The nutritional management of urea cycle disorders. J Pediatr. 2001;138(1 Suppl):S40-4.  
Leonard JV, McKiernan PJ. The role of liver transplantation in urea cycle disorders. Mol Genet 
Metab. 2004;81(Suppl 1):S74-8.  
Li C, Hirsch M, Asokan A, et al. Adeno -associated virus type 2 (AAV2) capsid -specific cytotoxic 
T lymphocytes eliminate only vector-transduced cells coexpressing the AAV capsid in vivo . J Virol. 
2007;81(14):7540- 7. 
Li H, Murphy SL, Giles -Davis W, et al. Pre-existing AAV capsid -specific CD8+ T cells are unable to 
eliminate AAV-transduced hepatocytes. Mol Ther. 2007;15(4):792- 800. 
Lichtenberger E, Kaufman A. Essentials of WAIS -IV Assessment, Second Edition. Hoboken, NJ: 
John C Wiley and Sons. 2009.  
Lichter -Konecki U, Caldovic L, Morizono H, Simpson K. Ornithine transcarbamylase deficiency. 
2013 Aug 29 [Updated 2016 Apr 14]. In: Pagon RA, Adam MP, Ardinger HH, et al, editors. GeneReviews
® [Internet]. Seattle (WA): University of Washington, Seattle; 1993- 2016. Available 
from:  http://www.ncbi.nlm.nih.gov/books/NBK154378/ . 
Longo N, Holt RJ. Glycerol phenylbutyrate for the maintenance treatment of patients with 
deficiencies in enzymes of the urea cycle. Expert Opin Orphan Drugs. 2017;5(12):999-1010.  
Ultragenyx Pharmaceutical Inc.  DTX301  
Protocol: 301OTC01   
Page 100 of 126 
Version 06   25 February 2020 Manno CS, Chew AJ, Hutchinson S, et al. AAV- mediated factor IX gene transfer to skeletal muscle 
in patients with severe hemophilia B. Bloo d. 2003;101(8):2963-72.  
Manno CS, Pierce GF, Arruda VR, et al. Successful transduction of liver in hemophilia by 
AAV-factor IX and limitations imposed by the host immune response. Nat Med. 2006;12(3):342-7.  
Matthews DE, Downey RS. Measurement of urea kinet ics in humans: a validation of stable isotope 
tracer methods. Am J Physiol. 1984;246(6 Pt 1):E519- 27. 
McIntosh J, Lenting PJ, Rosales C, et al. Therapeutic levels of FVIII following a single peripheral vein administration of rAAV vector encoding a novel human factor VIII variant. Blood. 
2013;121(17):3335- 44. 
Mingozzi F, Maus MV, Hui DJ, et al. CD8+ T -cell responses to Adeno -associated virus capsid in 
humans. Nat Med. 2007;13(4) :419-22. 
Mingozzi F, High KA. Therapeutic in vivo gene transfer for genetic disease using AAV: progress and 
challenges. Nat Rev Genet. 2011;12(5):341-55.  
Mount JD, Herzoq RW, Tillson DM, et al. Sustained phenotypic correction of hemophilia B with a factor IX null mutation by liver -directed gene therapy. Blood. 2002;99(8):2670- 6. 
Msall M, Batshaw ML, Suss R, et al. Neurologic outcome in children with inborn errors of urea 
synthesis. Outcome of urea -cycle enzymopathies. N Engl J Med. 1984;310(23):1500-5.  
Nakai H, Yant SR, Storm TA, et al. Extrachromosomal recombinant adeno -associated virus vector 
genomes are primarily responsible for stable liver transduction in vivo. J Virol. 2001;75(15):6969- 76. 
Nathwani AC, Gray JT, Ng CY, et al. Self -complementary adeno -associated virus vectors containing 
a novel liver -specific human factor IX expression cassette enable highly efficient transduction of 
murine and nonhuman primate liver. Blood. 2006;107(7):2653-61.  
Nathwani AC, Gray JT, McIntosh J, et al. Safe and efficient transduction of the liver after peripheral 
vein infusion of self -complementary AAV vector results in stable therapeutic expression of human 
FIX in nonhuman primates. Blood. 2007;109(4):1414- 21. 
Nathwani AC, Tuddenham EG, Rangarajan S, et al., Adenovirus-associated virus vecto r-mediated 
gene transfer in hemophilia B. N Engl J Med. 2011a ;365(25):2357- 65. 
Ultragenyx Pharmaceutical Inc.  DTX301  
Protocol: 301OTC01   
Page 101 of 126 
Version 06   25 February 2020 Nathwani AC, Rosales C, McIntosh J, et al. Long-term safety and efficacy following systemic 
administration of a self -complementary AAV vector encoding human FIX pseudotyped with serotype 
5 and 8 capsid proteins. Mol Ther. 2011b;19:876-85.  
Nathwani AC, Reiss UM, Tuddenham EG, et al. Long -term safety and efficacy of factor IX gene 
therapy in hemophilia B. N Engl J Med. 2014;371(21):1994-2004.  
National Institutes of Health. National Cancer Institute (NCI). Common terminology criteria for 
adve rse events (CTCAE). 01 March  2018. Available from: 
https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_50  
National Institutes of Health’s The Patient Reported Outcomes Measurement Information System 
(PROMIS): A walk through the first four years. Jan 2009. Available from: www.nihpromis.org/Documents/PROMIS_The_First_Four_Years.pdf . 
Nichols TC, Raymer RA, Franck HW, et al. Prevention of spontaneous bleeding in dogs with haemophilia A and haemophilia B. Haemophilia. 2010;16(Suppl 3) :19-23. 
Ozanne B, Nelson J, Cousineau J, et al. Threshold for toxicity from hyperammonemia in critically ill children. J Hepatol. 2012;56(1):123-8.  
Raper SE, Yudkoff M, Chirmule N, et al. A pilot study of in vivo liver -directed gene transfer with an 
adenoviral vector in partial ornithine transcarbamylase deficiency. Hum Gene Ther. 
2002;13(1):163-75.  
Raper SE, Chirmule N, Lee FS, et al. Fatal systemic inflammatory response syndrome in a ornithine 
transcarbamylase deficient patient following adenoviral gene transfer. Mol Genet Metab. 
2003;80(1- 2):148-58.  
Reeve BB, Hays RD, Bjorner JB, et al. Psychometric evaluation and calibration of health -related 
quality of life item banks: plans for the Patient-Reported Outcomes Measurement Information System 
(PROMIS). Med Care. 2007;45(5 Suppl 1):S22- 31. 
Siders WM, Shields J, Kaplan J, et al. Cytotoxic T lymphocyte responses to transgene product, not adeno -associated viral capsid protein, limit transgene expression in mice. Hum Gene Ther. 
2009;20(1):11-20.  
Snyder RO, Miao C , Meuse L, et al. Correction of hemophilia B in canine and murine models using 
recombinant adeno -associated viral vectors. Nat Med. 1999;5(1):64-70.  
Ultragenyx Pharmaceutical Inc.  DTX301  
Protocol: 301OTC01   
Page 102 of 126 
Version 06   25 February 2020 Tuchman M, Lee B, Lichter-Konecki U, et al. Cross-sectional multicenter study of patients with urea 
cycle disorders in the United States. Mol Genet Metab. 2008a;94(4):397-402.  
Tuchman M, Caldovic L, Daikhin Y, et al. N-carbamylglutamte markedly enhances ureagensis in 
N-acetyglutamate deficiency and propionic acidemia as measured by isotopic incorporation and bl ood 
biomarkers. Pediatr Res. 2008b;64(2):213-7.  
uniQure Investor Day Presentation Dec 1, 2014. uniQure: Hemophilia – the challenge for gene 
therapy. http://www.uniqure.com/uploads/presentations/3.%2020141201%20MBach%20FINAL.pdf .  
uniQure R&D Day presentation, Oct 15, 2015, uniQure R&D Day – New York City; Gene Therapy 
for Liver Disease and Metabolic Disorder; Deya Corzo, MD. http://www.uniqure.com/uploads/presentations/03%20Gene%20Therapy%20for%20Liver%20Disease%20and%20Metabolic%20Disorder.pdf . 
Vandenberghe LH, Wang L, Somanathan S, et al. Heparin binding directs activation of T cells against adeno -associated virus serotype 2 capsid. Nat Med. 2006;12(8):967 -71. 
Wang L, Calcedo R, Nichols TC, et al. Sustained correction of disease in naïve and AAV2 pretreated hemophilia B dogs: AAV2/8-mediated, liver -directed gene therapy. Blood. 2005;105(8):3079- 86. 
Wang L, Figueredo J, Calcedo R, et al. Cross -presentation of adeno-associated virus serotype 2 
capsids activates cytotoxic T cells but does not render hepatocytes effective cytolytic targets. Hum 
Gene Ther. 2007;18(3):185-94.  
Wang L, Morizono H, Lin J, et al. Preclinical evaluation of a clinical candidate AAV8 vector for ornithine transcarbamylase (OTC) deficiency reveals functional enzyme from each persisting vector 
genome. Mol Genet Metab. 2012;105(2):203-11.  
Wechsler D. Wechsler Abbreviated Scale of Intelligence. San Antonio, TX: The Psychological Corporation. 2011.  
Wright K. UK National Metabolic B iochemistry Network: Guidelines for the Investigation of 
Hyperam monaemia. Version 02. 2010. Available from: http://www.metbio.net/docs/metbio -
guideline -amup100834-21 -07-2010.pdf .  
Yan Z, Zak R, Luxton GW, et al. Ubiquitination of both adeno-associated virus type 2 and 5 capsid 
proteins affects the transduction efficien cy of recombinant vectors. J Virol. 2002;76(5):2043- 53. 
Ultragenyx Pharmaceutical Inc.  DTX301  
Protocol: 301OTC01   
Page 103 of 126 
Version 06   25 February 2020 15 Appendices  
15.1 Appendix: Schedules of Events  
 
 
Ultragenyx Pharmaceutical Inc.  DTX301  
Protocol: 301OTC01   
Page 104 of 126 
Version 06    25 February 2020 Table  15-1 Schedule of Events – Outpatient, Home Health Services,  and Inpatient Clinic Visits  
Procedure  Scree ning  Day 0 
(Baseline)  Day 1 
(DTX301 Dosing)  Treatment Period: Includes Inpatient Clinic (shaded gray) 
and Outpatient Clinic /HHS  visits. For home visits, refer to 
Table  15-2. End of Study/ 
Early 
Withdrawal  
Visit Ty pe OC IC IC 
OC/ 
HHS  OC/ 
HHS  IC OC/ 
HHS  IC OC/ 
HHS  OC (all 
subjects)  IC OC/ 
HHS  IC Prior to 
DTX301 
Infusion  DTX301 
Dosing/ 
Postdose  
Week  – - - – 2 4 6 10 12 16 20 24 36 52 
Day –35 to –1 0 1 1 14 28 42 70 84 112 140 168 252 364 
Visit Window (Days)  – – –  ±2 ±2 ±2 ±2 ±2 ±7 ±7 ±7 ±7 ±7 
Informed consent  X              
Eligibility criteria  X              
Demographics  X              
OTC medical history  X              
Medical history  X              
Prior medication / therapies / 
procedures  X              
HBV, HCV, HIV status  X              
Serum pregnancy test 
(females of childbearing 
potential only)  X              
Clinic admission   Xa Xa    Xb  Xb   Xb  Xb 
Vital sign s (HR, BP, RR)  X X X Xd X X X X X X Xe X X X 
Temperature  f X  X    X  X  X X  X 
Height  X              
Ultragenyx Pharmaceutical Inc.  DTX301  
Protocol: 301OTC01   
Page 105 of 126 
Version 06    25 February 2020 Procedure  Scree ning  Day 0 
(Baseline)  Day 1 
(DTX301 Dosing)  Treatment Period: Includes Inpatient Clinic (shaded gray) 
and Outpatient Clinic /HHS  visits. For home visits, refer to 
Table  15-2. End of Study/ 
Early 
Withdrawal  
Visit Ty pe OC IC IC 
OC/ 
HHS  OC/ 
HHS  IC OC/ 
HHS  IC OC/ 
HHS  OC (all 
subjects)  IC OC/ 
HHS  IC Prior to 
DTX301 
Infusion  DTX301 
Dosing/ 
Postdose  
Week  – - - – 2 4 6 10 12 16 20 24 36 52 
Day –35 to –1 0 1 1 14 28 42 70 84 112 140 168 252 364 
Visit Window (Days)  – – –  ±2 ±2 ±2 ±2 ±2 ±7 ±7 ±7 ±7 ±7 
Weight  X X            X 
Urine pregnancy test 
(females of childbearing 
potential only )  X   X X X X X X Xe X X X 
Orotic acid spot urine      X X  X  X Xe  X  
24-hour urine orotic acidg, h  X     X  X   X  X 
Sample for OTC genotyping   Xc             
Clinical chemistry 
(including LFTs)i X Xc X Xj X X Xc X Xc X Xe Xc X Xc 
LFTs (STAT sample at local 
laboratory)i X X X Xj X X X X X   X  X 
Spot ammonia (STAT 
sample at local laboratory ) X Xc X Xn X X Xc X Xc X Xe Xc X Xc 
Hemat ology / coagulation 
panel  X X   X  X  X   X  X 
Urinalysis  X X     X  X   X  X 
Ultragenyx Pharmaceutical Inc.  DTX301  
Protocol: 301OTC01   
Page 106 of 126 
Version 06    25 February 2020 Procedure  Scree ning  Day 0 
(Baseline)  Day 1 
(DTX301 Dosing)  Treatment Period: Includes Inpatient Clinic (shaded gray) 
and Outpatient Clinic /HHS  visits. For home visits, refer to 
Table  15-2. End of Study/ 
Early 
Withdrawal  
Visit Ty pe OC IC IC 
OC/ 
HHS  OC/ 
HHS  IC OC/ 
HHS  IC OC/ 
HHS  OC (all 
subjects)  IC OC/ 
HHS  IC Prior to 
DTX301 
Infusion  DTX301 
Dosing/ 
Postdose  
Week  – - - – 2 4 6 10 12 16 20 24 36 52 
Day –35 to –1 0 1 1 14 28 42 70 84 112 140 168 252 364 
Visit Window (Days)  – – –  ±2 ±2 ±2 ±2 ±2 ±7 ±7 ±7 ±7 ±7 
Samples for plasma 
ammonia (AUC 0-24)g,k  Xl, m     Xm  Xm   Xm  Xl,m 
Amino acid panel   Xc     Xc  Xc   Xc  Xc 
AAV8 neutralizing antibody 
test (cell -based assay)  X Xc            Xc 
AAV8 binding antibody IgG 
assay (ELISA)  X Xc            Xc 
Anti-OTC antibody assay 
(ELISA)  X       X     X 
Saliva, urine, and stool for 
viral shedding   Xc     Xc X Xc X Xe Xc X Xc 
Complete PE  X             X 
Targeted PE   X     X  X   X   
12-Lead ECG  X X  Xp          X 
PROMIS questionnaireq  X     X  X   X  X 
WASI -II vocabulary and 
matrix reasoning subtests   Xl             

Ultragenyx Pharmaceutical Inc.  DTX301  
Protocol: 301OTC01   
Page 107 of 126 
Version 06    25 February 2020 Procedure  Scree ning  Day 0 
(Baseline)  Day 1 
(DTX301 Dosing)  Treatment Period: Includes Inpatient Clinic (shaded gray) 
and Outpatient Clinic /HHS  visits. For home visits, refer to 
Table  15-2. End of Study/ 
Early 
Withdrawal  
Visit Ty pe OC IC IC 
OC/ 
HHS  OC/ 
HHS  IC OC/ 
HHS  IC OC/ 
HHS  OC (all 
subjects)  IC OC/ 
HHS  IC Prior to 
DTX301 
Infusion  DTX301 
Dosing/ 
Postdose  
Week  – - - – 2 4 6 10 12 16 20 24 36 52 
Day –35 to –1 0 1 1 14 28 42 70 84 112 140 168 252 364 
Visit Window (Days)  – – –  ±2 ±2 ±2 ±2 ±2 ±7 ±7 ±7 ±7 ±7 
 
  Xl            Xl 
  Xl            Xl 
 
 
  Xl            Xl 
Oral [1 -13C]sodium acetater Xm  Xm    Xm  Xm  Xm Xm  Xm 
Samples for ureagenesisg, s X  X    X  X  X X  X 
IWRS  Xt Xt             
DTX301 infusion     Xm, u           
AE/SAE monitoring  X X X X X X X X X X X X X X 
Concomitant medications / 
therapies / procedures   X X  X X X X X X X X X X 
Review personalized, 
prescribed diet   X     X  X   X  X 
Review of dietary protein 
intake  X X X  X X X X X X X X X X 

Ultragenyx Pharmaceutical Inc.  DTX301  
Protocol: 301OTC01   
Page 108 of 126 
Version 06    25 February 2020 Procedure  Scree ning  Day 0 
(Baseline)  Day 1 
(DTX301 Dosing)  Treatment Period: Includes Inpatient Clinic (shaded gray) 
and Outpatient Clinic /HHS  visits. For home visits, refer to 
Table  15-2. End of Study/ 
Early 
Withdrawal  
Visit Ty pe OC IC IC 
OC/ 
HHS  OC/ 
HHS  IC OC/ 
HHS  IC OC/ 
HHS  OC (all 
subjects)  IC OC/ 
HHS  IC Prior to 
DTX301 
Infusion  DTX301 
Dosing/ 
Postdose  
Week  – - - – 2 4 6 10 12 16 20 24 36 52 
Day –35 to –1 0 1 1 14 28 42 70 84 112 140 168 252 364 
Visit Window (Days)  – – –  ±2 ±2 ±2 ±2 ±2 ±7 ±7 ±7 ±7 ±7 
Review of ammonia 
scavenger use  X X X  X X X X X X X X X X 
Consider tapering ammonia 
scavenger therapyv         X   X   
Abbreviations: AAV8, adeno-associated virus serotype 8; AE, adverse event; AUC 0-24, area under the curve from time zero to 24 hours; BP, blood pressure; 
 ECG, electrocardiogram; ELISA, enzyme -linked immunosorbent assay; HBV, hepatitis B virus; HCV, hepatitis C virus; 
HHS, home health services; HIV, human immunodeficiency virus; HR, heart rate; IC, inpatient clinic; IgG, immunoglobulin G; IP, investigational product; IWRS, interactive 
web response system; LFT, liver function test; OC,  outpatient clinic; OTC,  ornithine transcarbamylase; PE, physical examination; PROMIS, Patient -Reported Outcomes 
Measurement Information System;   RR, respiratory rate; SAE, serious adverse event; WASI -II, Wechsler Abbreviated Scale of 
Intelligence, Second Edition; WAIS -IV, Wechsler Adult Intelligence Scale, Fourth Edition; WMI, Working Memory Index.  
Note 1: If rescreen ing is within 3 months  of the original screening or if dosing is expected to occur more than 3 months after completion of original screening assessments, 
the following must be repeated: hematology, coagulation and urinalysis, serum pregnancy test (if appli cable), clinical chemistry including LFTs, spot plasma ammonia, amino 
acid panel, AAV8 neutralizing antibody test, weight, and vital signs. Additional tests may be requested on a case-by -case basis, depending on the original reason for screen 
failure or de lay in dosing. The AAV8 screening neutralizing antibody results must be available and reviewed before IP administration.  If the rescreening occurs more 
than 3 months after the original screening, all tests must be repeated except the following: OTC genotyping, HBV, HCV, and HIV.  
Note 2: At any point between scheduled visits, additional, unscheduled assessment for LFTs, plasma ammonia , or any other biomarker to assess subject safety and clinical status 
may be performed, at the discretion of the investigator. 
Note 3: At any time after in itiation  of prophylactic corticosteroid regimen, additional assessments of plasma ammonia levels, amino acid profiles , or any other biomarker to assess 
subject safety and clinical status may be performed, at the discretion of the investigator  and as clinically indicated . 
Note 4: Where available, agreed upon by the investigator and allowed by local regulation, an outpatient clinic visit may take place as home health services. Week 20 visit is a 
mandatory Outpatient clinic visit f or all subjects.  

Ultragenyx Pharmaceutical Inc.  DTX301  
Protocol: 301OTC01   
Page 109 of 126 
Version 06    25 February 2020 a. Subjects will be discharged 24 hours after the administration of DTX301 on Day 1. Subjects will be inpatient for approximately 48 consecutive hours.  
b. Subjects will be discharged after the administration of [1-13C]sodium acetate and after al l samples for ureagenesis have been collected; subjects will be inpatient for 
approximately 28 hours. 
c. To be collected/performed before the start of plasma ammonia area under the curve from time zero to 24 hours (AUC 0-24) determination.  
d. Vital signs to be me asured at approximately 5 minutes after the start of DTX301 infusion, and at approximately 0.5 (±5 minutes), 1 (±5 minutes), 2, 4, 6, 8 (±15 minutes), and 
22 hours (±1 hour) after the start of DTX301 infusion.  
e. To be collected prior to the [1-13C]sodium ace tate administration.  
f. Temperature will be measured prior to administration of [1-13C] sodium acetate. If the temperature is >  101°F or >  38°C, the procedure should not be initiated.  
g. Collection of samples for AUC 0-24 of plasma ammonia and urine orotic acid determination is to be performed prior to administration of [1-13C]sodium acetate and sample 
collection for determination of the rate of ureagenesis. 
h. Urine samples to be collected at time 0 and at approximately 6, 12, 18, and 24 hours (relative to the start  of plasma ammonia determination). Urinary orotic acid concentration 
will be standardized to urine creatinine concentration.  
i. Through Week 12, one sample for LFTs is collected as part of clinical chemistry and sent to the central laboratory for analysis. A second sample for LFTs only is collected 
and sent to the local laboratory (STAT sample).  
j. Samples for clinical chemistry to be collected at approximately 0.5, 4, 8, and 22 hours after the start of DTX301 infusion.  
k. Samples to be collected at time 0 and at ap proximately 2, 4, 8, 12, 16, 20, and 24 hours (relative to start of plasma ammonia determination). Two samples for plasma amm onia 
to be collected at each time point; 1 sample will be analyzed at the on -site local laboratory and the second sample will be processed and sent to the central  laboratory.  
l. The subject’s plasma ammonia level should be < 100 µmol/L or within the range of historical ammonia levels obtained when the subject was clinically stable in order to 
perform the neuropsychological tests. The 0-hour plasma ammonia sample (for AUC 0-24 of plasma ammonia) local laboratory result (STAT sample) may be used to confirm 
plasma ammonia levels. The results must be back prior to starting the neuropsychological tests.  
m. The subject’s plasma ammonia level should be < 100 µmol/L or within the range of historical ammonia levels  obtained when the subject was clinically stable in order to 
receive [1-13C]sodium acetate and DTX301 (Day 1 only). If the ammonia level is inconsistent with the subject’s clinical status, the ammonia level may be repeated to ensure 
accurate results. If the subject is deemed clinically unstable, [1 -13C]sodium acetate and DTX301 (Day 1 only) will be held until the subject is determined to be clinically 
stable. Rescreening procedures may apply  (Screening and Day 1 only). On Day  1 and at Weeks 6, 12, 24, and 52, the 24-hour (T 24) plasma ammonia from the local (STAT 
sample ) may be used. The result must be back prior to dosing with [1-13C]sodium acetate and DTX301 (Day 1 only).  On Day 1, the same  T 24 local laboratory (STAT 
sample) can serve as the DTX301 predose plasma ammonia result, if drawn within 12 hours or less of dosing with DTX301. If not , a new plasma ammonia (STAT sample) is 
to be collected prior to dosing with DTX301. 
n. A single sample f or plasma ammonia (STAT sample at local laboratory) to be collected and reviewed prior to discharging the subject after DTX301 infusion. 
Ultragenyx Pharmaceutical Inc.  DTX301  
Protocol: 301OTC01   
Page 110 of 126 
Version 06    25 February 2020 o. Viral shedding determination in saliva, stool, and urine to be performed at Weeks 6, 10, and 12 and on Days 46, 58, 62,  and 78 (Table 15-2) . Samples will be collected until 
negative on 3 consecutive occasions. Subjects will be provided an appropriate container to collect a stool sample at home.  
p. 12-Lead ECG to be performed at approximately 1 hour after the start of DTX301 infusion.  
q. PROMIS questionnaire to be completed prior to neuropsychological tests on Day 0 and at Week 52.  
r. At inpatient clinic visits, [1-13C]sodium acetate is to be administered orally on the second day of inpatient  admission, after all samples for AUC 0-24 plasma ammonia and orotic 
acid determination (over 24 hours) have been collected. Prior to administering [1-13C]sodium acetate, the site must confirm the subject’s plasma ammonia level . The 24 -hour 
(T 24) plasma am monia from the local laboratory (STAT sample) may be used. The subject’s plasma ammonia level should be < 100 µmol/L or within the range of historical 
ammonia levels obtained when the subject was clinically stable. If the ammonia level is inconsistent with  the subject’s clinical status, the ammonia level may be repeated to 
ensure accurate results. If the subject is deemed clinically unstable, [1 -13C]sodium acetate will be held until the subject is determined to be clinically stable. On Day 1, the 
same local  laboratory (STAT sample) can serve as the DTX301 predose plasma ammonia used for this assessment should be drawn within 12 hours or less of dosing with 
DTX301. If not, a new plasma ammonia (STAT sample) is to be collected prior to dosing with DTX301.  Subj ects will fast for at least 6 hours, including liquids containing 
protein, sugar or carbonate, prior to administration of [1-13C]sodium acetate. After dosing, subjects will continue to fast for at least 4 hours. Water is allowed ad 
libitum . 
s. Samples to be collected before dosing with [1-13C]sodium acetate (time 0) and at approximately 0.5, 1, 1.5, 2, 3, and 4 hours after dosing with [1-13C]sodium acetate. Subjects 
will fast for at least 6 hours, including liquids containing protein, sugar or carbonate, prior to administration of [1-13C]sodium acetate. After dosing, subjects will continue to 
fast for at least 4 hours. Water is allowed ad libitum. During Screening, assessment of rate of ureagenesis may be repeated if discrepant with subject’s clinical status and 
severity. 
t. Once eligibility is confirmed, the study site should register the visit with IWRS. Study personnel must schedule the dosing visit in IWRS ideally 7 days but no less than 3 days prior to the actual visit date at the study site in order to allow for adequate shipment  time and delivery of DTX301 to the study site. 
u. The start of DTX301 infusion should be after all samples for the determination of the rate of ureagenesis have been collected. Prior to the start of DTX301 infusion, the study 
site must c onfirm that the subject’s plasma ammonia level on Day 1 (predose) is < 100 µmol/L for patients who historically maintain normal ammonia levels, and the subject 
is clinically stable; O R the subject’s plasma ammonia level on Day 1 (predose) is < 200 µmol/L, for patients who historically are not able to fully control ammonia levels with 
baseline management, and the subject is clinically stable. If the Day 1 (predose) ammonia level is inconsistent with the subject’s clinical status, the ammonia level may be 
repeated to ensure accurate results. NOTE: If the subject is deemed clinically unstable, dosing will be held, and the subject can be rescreened once the subject is determined to 
be clinically stable.  The same 24 -h time point (T 24) from local laboratory (STAT sample) AUC
0-24 of plasma ammonia can serve as the DTX301 predose plasma ammonia 
result, if drawn within 12 hours or less of dosing with DTX301. If not, a new plasma ammonia (STAT sample) is to be collected  prior to dosing with DTX301.  
v. Adjustments to ammo nia scavenger therapy may be considered following the Week 12 and Week 24 visits . The subject must be clinically stable and under good metabolic 
control before changes can be initiated or progressed.  The risks of making adjustments to baseline treatment on  their own, without express guidance from the site, will be 
reinforced with the subject at site visits . Modification of ammonia scavenger therapy cannot occur at the same time as changes in protein -restricted diet.  Changes to baseline 
treatment cannot occur while the subject is treated with corticosteroids or within a 2-week period of completing a corticosteroid taper. Modification of baseline treatment will 
be individualized based on review of the totality of longitudinal clinical and laboratory data for e ach subject , including ammonia levels, plasma ammonia AUC 0-24, subject 
clinical stability/asymptomatic status, neurocognitive status, and subject -reported outcomes.  Rate of ureagenesis cannot be used for decision-making in modification of 
ammonia scavenger  therapy or protein -restricted diet  and results will not be made available to the investigative sites until the end of the study . 
Ultragenyx Pharmaceutical Inc.  DTX301  
Protocol: 301OTC01   
Page 111 of 126 
Version 06    25 February 2020 Table  15-2 Schedule of Events – Clinic or Home Visits During the Initial 12 -Week Treatment Period  
Procedure   Treatment Period  
Week  1 2 3 4 5 6 7 8 9 10 11 12 
Day 5 9 18 22 32 36 46 50 54 58 62 66 74 78 
Visit Window 
(Days)  ±1 ±1 ±1 ±1 ±1 ±1 ±1 ±1 ±1 ±1 ±1 ±1 ±1 ±1 
Clinical chemistry (including LFTs)a X X X X X X X X X X X X X X 
LFTs (local laboratory, STAT sample) a X X X X X X X X X X X X X X 
Spot ammonia (local laboratory STAT 
sample)b X X  X  X  X  X  X X  
Saliva, urine, and stool for viral shedding 
       X   X X   X 
Abbreviations: LFT, liver function test;  . 
Note : At any time after initiation of prophylactic corticosteroid regimen, additional assessments of plasma ammonia levels, amino acid profiles , or any other biomarker 
to assess subject safety and clinical status may be performed, at the discretion of the investigator  and as clinically indicated. 
a. Through Week 12, one sample for LTFs is  collected as part of clinical chemistry and sent to the central laboratory for analysis. A second sample for LFTs only is collected 
and sent to the local laboratory (STAT sample).  
b. Through Week 12, one sample for spot ammonia is collected approximately once a week and sent to the local laboratory (STAT sa mple).  
c. Samples for viral shedding are to be collected at Weeks 6, 10, and 12 (see Table  15-1) and on Days 46, 58, 62, and 78 until negative on at least 3  consecutive occasions for 
each matrix.  
 

Ultragenyx Pharmaceutical Inc.  DTX301  
Protocol: 301OTC01   
Page 112 of 126 
Version 06 25 February 2020 15.2 Quality of Life Questionnaire  
15.2.1  PROMIS Questionnaire  

Ultragenyx Pharmaceutical Inc.  DTX301  
Protocol: 301OTC01   
Page 113 of 126 
Version 06 25 February 2020 

Ultragenyx Pharmaceutical Inc.  DTX301  
Protocol: 301OTC01   
Page 114 of 126 
Version 06 25 February 2020 
 

Ultragenyx Pharmaceutical Inc.  DTX301  
Protocol: 301OTC01   
Page 115 of 126 
Version 06 25 February 2020 
 

Ultragenyx Pharmaceutical Inc.  DTX301  
Protocol: 301OTC01   
Page 116 of 126 
Version 06 25 February 2020 15.3 Protocol Amendment History and Summary of Cha nges  
15.3.1  Amendment 1 (dated 18 August 2016)  
The primary objective of Amendment 1 of the protocol, 301OTC01, is to address feedback received 
from the US Food and Drug Administration, the Medicines and Healthcare Products Regulatory 
Agency, and the National Institutes of Health Recombinant DNA Advisory Committee.  
An overview of changes includes the following:  
• Section 1.3.1 (Design Rationale) has been updated to include rationale for defining 
hyperam monemia as ≥100 µmol/L.  
• The dosing interval between subjects within a cohort (14 days [Cohorts 1 and 2] and 7 days 
[subsequent cohorts]) has been revised. Additionally, Section 1.3.1 (Design Rationale) has been updated to include rationale for this change.  
• Section 1.3.2 (Dosing Rationale) has been revised to provide rationale for the new starting dose of 2.0 × 10
12 genome copies (GC)/kg.  
• The rate of ureagenesis will now be the main efficacy parameter to identify the optimal biological dose (OBD) of DTX301. The AUC
0-24 for serum ammonia will still be evaluated to help 
determine the efficacy of DTX301 (Section 2).  
• The candidate doses to determine the OBD of DTX301 have been revised as follows (Section 3.1): 
• Dose 1: 2.0 × 10
12 GC/kg (new starting dose)  
• Dose 2: 6.0 × 1012 GC/kg  
• Dose 3: 1.0 × 1013 GC/kg  
• The number of inpatient visits has been reduced from 8 to 5 to alleviate undue burden to subjects 
(Section 3.2.3). 
• The timing for tapering or discontinuing ammonia scavenger therapy has been revised. 
Investigators will now consider an adjustment to ammonia scavenger therapy following the visits 
at Week 12 and Week 24, after the most recent monitoring results are available (Section 3.2.4).  
• The study stopping criteria have been revised based on feedback received from regulatory 
authorities (Section 3.2.5).  
Ultragenyx Pharmaceutical Inc.  DTX301  
Protocol: 301OTC01   
Page 117 of 126 
Version 06 25 February 2020 • Inclusion criterion #2 has been updated to include specific examples of enzymatic, biochemical, 
or molecular testing that may be performed to confirm ornithine transcarbamylase (OTC) deficiency (Section 4.1).  
• Inclusi on criterion #5 has been added to ensure that the subject's OTC deficiency is stable prior to 
receiving DTX301 (Section 4.1).  
• Inclusion criterion #10 was removed and incorporated into exclusion criterion #13 to have one cohesive criterion for excluding subjects that are pregnant (Section 4.2).  
• Due to reduction of inpatient visits, the rate of ureagenesis will now be measured at Screening, on 
Day 1, and at Weeks 6, 12, 20, 24, and 52 (Section 8.1.1). Additionally, if clinically indicated, the rate of ureagenesis can be measured at any outpatient visit (scheduled or unscheduled)  
• The decision criteria for determining whether to start steroids for suspected vector-induced hepatitis have been revised (Section 8.2.4.1.2).  
• The overall number of neuropsychological  evaluations that will be performed has been reduced 
based on feedback from regulatory authorities (Section 8.5).  
• Weeks 18 and 22 have been added as a clinic or home visit to collect samples for clinical 
chemistry.  
• Specifying that subjects will receive a prescribed diet during each inpatient stay and that an adjustment may be made to the subject's prescribed diet has been removed from the protocol.  
• Minor editorial revisions.  
15.3.2  Amendment 2 (dated 20 December 2016)  
The primary objective of Amendment 2 of the pr otocol, 301OTC01, is to address feedback received 
from the US Food and Drug Administration.  
An overview of changes includes the following:  
• Clarified that ammonia will be analyzed in plasma, not serum (global protocol revision).  
• Clarified that plasma ammonia levels must be <100 µmol/L prior to both administration of the 
neuropsychological tests (Section 8.5) and [1-13C]acetate administration (Section  6.3.1).  
• Revised the language regarding tapering of ammonia scavenger therapy following feedback from 
the FDA (Section 3.2.4).  
Ultragenyx Pharmaceutical Inc.  DTX301  
Protocol: 301OTC01   
Page 118 of 126 
Version 06 25 February 2020 • Added language regarding retesting of liver function tests in the event that possible vector -
induced hepatitis is suspected following feedback from the FDA (Section  8.2.4.1.2).  
• Added collection of samples to test for antibodies against ornithine transcarbamylase.  
• The schedule of events has been revised, as needed (Table 15 -1). 
• Minor editorial revisions.  
15.3.3  Amendment 3 (dated 07 February  2017) 
The primary objective of Amendment 3 of the protocol, 301OTC01, is to address feedback received 
from t he United Kingdom (UK) Medicines and Healthcare Products Agency (MHRA) and the Gene 
Therapy Advisory Committee (GTAC).  
An overview of changes from Amendment 2 (20 December 2016) to Amendment 3 (07 February 
2017) includes the following:  
• Added UK MHRA-requested language around definition of abstinence as a form of birth control (Section  4.1). 
• Per UK MHRA request, added that following data monitoring committee (DMC) review when a stopping rule is met, if the decision is to restart enrollment, a substantial amendment will need to 
be approved by the regulatory authority (Sections 3.2.5 and 9.3).  
• Per GTAC request, provided further justification and clarification that the neuropsychological 
battery of testing is an important assessment for OTC deficiency patients and beyond this 52 -
week study, it will be performed every 2 years during the 4 -year extension study for each study 
subject (Section 8.5).  
• Per GTAC request, added language allowing study subjects to request rest time during administration of the neuropsychological battery (Section 8.5).  
• Per study sites’ request, clarified that the predose plasma ammonia used to determine DTX301 
dosing must be drawn within 12 hours or less of dosing (Section 3.2.2.2).  
• Per study sites’ request, clarified wording to reflect that  flexibility in performing the ureagenesis 
test first is allowed so long as it does not overlap temporally with the plasma ammonia AUC
0-24 
and urinary orotic acid levels over the 24-hour collection period (Section 3.2.2.1).  
Ultragenyx Pharmaceutical Inc.  DTX301  
Protocol: 301OTC01   
Page 119 of 126 
Version 06 25 February 2020 • Per Dimension Therapeutics (DMTX), deleted inclusion criterion #7 since there is no requirement 
to taper ammonia scavenger medications (Section 4.2). 
• Per DMTX, corrected the exclusion criterion (#9) for the anti -AAV8 neutralizing antibody titer to 
≥ 1:5 from > 1:5 (typographical error) ( Section 4.2).  
• Per DMTX, clarified rescreening of patients (Section 3.2.1).  
• Per DMTX, changed the start of the DMC assessment for dose escalation from all subjects in a dose cohort having completed Week 6, to all subjects in a dose cohort having completed Week 12 (Section 1.3.1). 
• Per DMTX, changed the alanine aminotransferase (ALT) threshold for considering starting steroid treatment from 2.5 × upper limit of normal (ULN), to greater than the ULN (Section 
8.2.4.1.2). Therefore, exclusion criterion #4 adjuste d to ALT or aspartate aminotransferase > 
ULN from > 2.0 × ULN (Section 4.2).  
• Per DMTX, increased enzyme-linked immunospot assessments to approximately weekly during 
already scheduled visits through Week 12 for more frequent monitoring of immune response (Section 8.2.5.2 and Table 15–1). 
• Per DMTX, added liver function tests to be performed at local laboratory (STAT sample) during the  scheduled collections approximately every 4 days up through Week 12 in the interest of 
closer monitoring and faster turnaroun d of liver function testing results (Section 8.2.4.1.1, 
Table  8–1, and Table 15– 1). 
15.3.4  Amendment 4 (dated 11 June 2019)  
The primary objective of Amendment 4 of the protocol, 301OTC01, is to provide details on the inclusion of the additional subjects as expansion of Cohort 3, already foreseen in the original 
protocol, and to add Cohort 4 (Dosing Process Optimization). Subjects in Cohort  4 will receive 
DTX301 at the optimal biological dose and will receive a prophylactic corticosteroid regimen, intended to achieve prophylaxis of vector -induced hepatitis.  
An overview of changes from Amendment 3 (07  February 2017) to Amendment  4 (11  June 2019) 
includes the following:  
Ultragenyx Pharmaceutical Inc.  DTX301  
Protocol: 301OTC01   
Page 120 of 126 
Version 06 25 February 2020 • The sponsor name was updated globally from Dimension Therapeutics, Inc. to Ultragenyx 
Pharmaceutical Inc.  
• The sponsor signatory was updated globally to  MD, PhD.  
• The medical monitor was updated to  MD.  
• An ongoing AAV8 gene transfer clinical study in Crigler -Najjar syndrome, which uses a 
prophylactic steroid regimen, was added as a reference and cited as applicable (Sections 1.2, 
8.2.4.1.2).  
• The generation of fewer empty particles via a DTX301 manufacturing process, which was 
presented as a difference between this clinical study and previous gene transfer studies, was 
removed for accuracy (Section 1.2).  
• The changes detailed in Addendum A to Amendment 3 (dated 02 March 2017) were incorporated. The purpose of Addendum A was to align Figure 3 –1 Study Design with the main text of the 
study protocol (Section 3.2). 
• The changes detailed in the country -specific Addendum B to Amendment 3 (dated 21 April 2017) 
for sites in the United Kingdom were incorporated. The purpose of the UK -specific Addendum B 
was to add the requirement that no subjects from UK sites can be dosed until at least 42 days after the first subject in the study (ie, first subject in Cohort  1) has been dosed. This change was made 
to address feedback received from the Gene Therapy Advisory Committee (GTAC) (Sections  1.3.1, 3.1, Figure 3–1). 
• The process for enrollmen t of additional subjects to Cohort 3 (Cohort Expansion) and an 
additional cohort (Cohort 4 [Dosing Process Optimization] was added (Sections 1.3.1, 3.1, 3.2, 5.2, 10.5.1).  
• A reference to ongoing safety results from this study (Study 301OTC01) was added (Sections 1.3.1, 14).  
• An ongoing AAV gene transfer clinical study in hemophilia B, which is dosing patients at a minimum of 1 day apart, was added as a reference and cited as applicable (Section  1.3.1).  
• The details of the prophylactic corticosteroid regimen to be implemented for Cohort 4 (Dosing 
Process Optimization) were added (Sections 1.3.1, 3.1, 8.2.4.1.1, 8.2.4.1.2).  

Ultragenyx Pharmaceutical Inc.  DTX301  
Protocol: 301OTC01   
Page 121 of 126 
Version 06 25 February 2020 • The screening period was extended and will begin at Day –35 (Sections 3.1, 3.2.1, 15.1, 
Table  15-1, Figure 3–1). 
• The decision to adjust or taper ammonia scavenger medications was updated to be made based on 
the investigator’s review of the totality of clinical and laboratory data (Sections  3.2.4, 15.1, 
Table  15-1 [footnote v]).  
• Instructions for dose preparation and administration of [1-13C] w ere updated according to the 
manufacturer and referenced to the ureagenesis manual (Sections 6.2.5, 6.3.1).  
• The duration of fasting before and after administration of [1-13C] sodium acetate was added 
(Sections 8.1.1, 15.1, Table 15 -1 [footnotes r and s]).   
• The timing of DMC meetings was updated to account for additional subjects and 1 additional 
cohort (Sections 9.3, 10.5.1).  
• Text was removed that stated the statistical analysis plan will be finalized prior to the start of the 
study (Section 10).  
• The def inition of the baseline rate of ureagenesis was updated (Section 10.5.2.1).  
• The presentation of other laboratory results and neuropsychological tests was updated to reflect 
the planned data presentation (Sections 10.5.3.6, 10.5.4)  
• Flexibility was added to the timing of the interim analysis. The statement that interim analyses 
would not bias the conduct of the study was removed (Section 10.5.7).  
15.3.5  Amendment 5 (dated 25 February 2020)  
The primary objective of Amendment 5 of the protocol, 301OTC01, is to address  written requests 
from the US Food and Drug Administration to provide more comprehensive guidance on monitoring 
of ammonia levels throughout the study, guidance to investigators on monitoring hyperammonemic 
crises, and more explicit guidance to investigato rs regarding tapering and discontinuation of ammonia 
scavenger medications and protein-restricted diet.  
An overview of changes from Amendment 4 (11  June 2019) to Amendment  5 (25 February  2020) 
includes the following:  
Ultragenyx Pharmaceutical Inc.  DTX301  
Protocol: 301OTC01   
Page 122 of 126 
Version 06 25 February 2020 • The medical monitor was updated to  MD to accurately reflect study personnel 
(Title Page). 
• The protocol amendment history and summary of changes were move d from the beginning of the 
protocol (ie, directly after the protocol approval page) to Appendix 15.3. This change was 
administr ative in nature and does not change the content of the protocol  (Section 15.3). 
• The age cutoff for presentation of disease signs and symptoms, which is used to delineate neonatal-onset from late-onset ornithine transcarbamylase (OTC) deficiency , was updated from 
≤ 1 month of age (neonatal onset) and ≥ 1 month of age (late onset) to ≤ 30 days of age (neonatal 
onset) and > 30 days of age (late onset). This change was made to align with the DTX301 clinical 
development documents and cited literature (Sections 1 , 4.1).  
• The term hyperammonemic crisis (HAC) was introduced and defined explicitly to align with the 
Urea Cycle Disorders Consortium definition. This addition will ensure standardized monitoring 
of HACs throughout the remainder of this study (Sections 1, 1.3.1. 2, 3.2.6, 10.4) . 
• The list of AAV8 clinical studies that are referenced in the introduction were updated to align with the Investigator’s Brochure and the most recent information (Section 1.3.1)  
• The timing of dosing for subjects in the United Kingdom in Cohort 1 was removed because 
Cohort 1 enrollment is now completed (Section 1.3.1, Figure  3-1). 
• The observed timing of elevations in liver enzymes following DTX301 administration was 
updated from “5 to 7 weeks” to “8 days to 7 weeks” after vector administration to reflect ongoing 
data from this Phase 1/2 study (301OTC01; Section 1.3.1).  
• An additional clinical trial (ClinicalTrials.gov identifier: [STUDY_ID_REMOVED]) was referenced as 
justification for the prophylactic steroid regimen to be introduced in Cohort 4 (Dosing Process 
Optimization; Sections 1.3.1, 8.2.4.1.2).  
• The definition of baseline for the rate of ureagenesis was removed globally with the intent that 
baseline definitions will be presented in the statistical analysis plan (Section s 2, 10.5.2.1). 
• The text, “in the setting of tapering or discontinuing ammonia scavenger medications,” was 
removed from exploratory endpoints 2 and 3 (ie, urinary orotic acid excretion and glutamine and 
glutamate). The change was made because the intent is to assess these endpoints in all subjects , 
regardless of baseline treatment status (Section 2).  

Ultragenyx Pharmaceutical Inc.  DTX301  
Protocol: 301OTC01   
Page 123 of 126 
Version 06 25 February 2020 • The specified timing, “weekly ,” was removed from the exploratory endpoint that evaluates use of 
ammonia scavengers. This change was made to reflect the manner by which the data are being 
captured and reported  and to reflect subject management, which requires daily intake of 
scavengers at a prescribed dose (Sections 2, 8.7.2, 10.4).  
• The exploratory endpoints and corresponding assessments determined by the enzyme-linked 
immunospot  [ELISPOT] assay and related to cell- mediated immune response to AAV8 and OTC 
were removed globally. These assays are exploratory in nature and to date have not revealed 
informative results, and require notable blood volume to be collected from subjects (S ections 2, 
8.2, 8.2.4.1.1, 10.4 , 10.5.3.6, Table 15 -1).  
• The sample size was updated from “approximately 6 to 18 subjects” to “up to 18  subjects” to 
reflect the current enrollment status of 9 subjects and plans to continue enrollment (Section 3.2).  
• It was added that “where available, agreed upon by the investigator and allowed by local 
regulation, an outpatient clinic visit may take place as home health services.” The Week  20 visit 
remains a mandatory outpatient clinic visit. This change was made to allow increased flexibility 
for protocol -specified abbreviated visits that may be performed as home health visits and have the 
potential to reduce subject burden in certain situations (Sections  3.2, 3.2.3, 3.2.3.2, 12.4, 
Figure  3-1, Table 15 -1).  
• More comprehensive guidance and testing specifications were added to the rescreening procedure 
to ensure consistent testing and evaluations prior to enrollment and dosing (Section 3.2.1, 
Table  15-1). 
• The rules for administering [1-13C]sodium acetate and neuropsychologica l tests were updated as 
follows: The subject’s plasma ammonia level should be < 100 µmol/L or within the range of 
historical ammonia levels obtained when the subject was clinically stable in order to receive 
[1-13C]sodium acetate. If the ammonia level is inconsistent with a subject’s clinical status, the 
ammonia level may be repeated to ensure accurate results. This change was made to better reflect 
patient status with long-standing metabolic and clinical management (Sections 3.2.1, 6.3.1, 8.3.2, 
8.5, Table  8-1, Table  15-1) . 
• Inclusion criterion #5 and global ly affected text presenting the ammonia criteria prior to the start 
of DTX301 administration  were updated as follows: Subject’s plasma ammonia level on Day 1 
(predose) is < 100 µmol/L, for patients who hi storically maintain normal ammonia levels, and the 
subject is clinically stable; OR the subject’s plasma ammonia level on Day 1 (predose) is 
Ultragenyx Pharmaceutical Inc.  DTX301  
Protocol: 301OTC01   
Page 124 of 126 
Version 06 25 February 2020 < 200 µmol/L, for patients who historically are not able to fully control ammonia levels with 
baseline management, and the subject is clinically stable. If the Day 1 (predose) ammonia level is 
inconsistent with the subject’s clinical status, the ammonia level may be repeated to ensure 
accurate results. This change was made to better reflect patient status with long -standing 
metabolic and clinical management (Sections  3.2.2.2, 4.1, 5.1, Table 15-1). 
• Exclusion criterion #1 was updated as follows: At Screening or Baseline (Day 0), plasma 
ammonia level ≥ 100 µmol/L for patients who historically maintain normal ammonia level s; OR 
plasma ammonia level ≥ 200 µmol/L for patients who historically are not able to fully control 
ammonia levels with baseline management; OR signs and symptoms of hyperammonemia, with 
documented elevated ammonia level, during the 4-week period preceding Day 0. If the ammonia 
level is inconsistent with the subject’s clinical status, the ammonia level may be repeated to ensure accurate results. This change was made to better reflect patient status with long -standing 
metabolic and clinical management  (Section 4.2) . 
• It was added that the assessment of rate of ureagenesis may be repeated during Screening if 
discrepant with subject’s clinical status and severity . The rate of ureagenesis is a direct in vivo  
assessment of the efficiency of the urea cycle and therefore should be compatible with patient 
severity given the understanding that neither ammonia scavenger therapy nor protein-restricted 
diet directly alter s the cycle (Sections 3.2.1, 8.1.1, 8.3.1, 10.5.2.1, Table  15-1).  
• The details of obtaining spot plasm a ammonia prior to dosing were clarified, and the requirement 
for a plasma ammonia (STAT sample) within 12 hours of DTX301 dosing was added explicitly (Section 3.2.2.2, Table 15 -1).  
• It was added that at any point between scheduled visits (and after initiation of a prophylactic steroid regimen) additional testing of liver function tests, plasma ammonia, or other biomarkers to 
assess subject safety and clinical status may be performed, at the discretion of the investigator. 
This text was added to  make it exp licit that investigators have the flexibility to perform additional 
testing and that subject safety is being monitored closely throughout the study (Sections 3.2.3, 3.2.4, 8.2.4, 8.2.4.1, 8.2.4.1.2, Table 15 -1). 
• Spot ammonia testing was made explicit and added to additional visits to ensure ammonia is 
being monitored closely throughout the clinical study (Sections 3.2.3.1, 8.2, Table 15 -1, 
Table  15-2). 
Ultragenyx Pharmaceutical Inc.  DTX301  
Protocol: 301OTC01   
Page 125 of 126 
Version 06 25 February 2020 • Text was added to explicitly state that subjects will be re-educated on the risks of making 
adjustments to  baseline treatment on their own , without the clear guidance of the study site 
investigator (Sections 3.2.4, 8.7.2, Table 15 -1). 
• Additional rules for changes to baseline treatment (ie, ammonia scavenger medication and 
protein -restricted diet) were added to  ensure standardized implementation. The additional rules 
specify that changes to baseline treatment cannot occurring during or within 2 weeks of corticosteroid treatment. Changes to ammonia scavenger medication and protein -restricted diet 
must not occur a t the same time (Sections 3.2.4, 3.2.5, 8.2.4.1.2, 8.7.2 , Table 15 -1). 
• Explicit text was added that rate of ureagenesis cannot be used for decision -making in 
modification of ammonia scavenger therapy or protein-restricted diet and results will not be made available to the investigative sites until the end of the study (Sections 3.2.4, Table 15 -1). 
• Specific guidance was added for considering reinstitution of ammonia scavenger therapy and for 
implementing a second round of modification of baseline treatment. This guidance was added to 
ensure standardized modifications and assurance of subject safety (Sections 3.2.4) . 
• Additional  guidance was added for modification of protein-restricted diet. This guidance was 
added to ensure standardized modifications and assurance of subject safety (Section  3.2.5).  
• Inclusion criterion #6 was updated to specify that a stable dose of ammonia scavenger therapy 
must be “ongoing daily.” This text was added to ensure the intent of this criterion was explicitly stated (Section 4.1).  
• The number of medical personnel (in addition to the study site pharmacist) who must check the 
dosing calculations for [1-
13C]sodium acetate was updated from “a minimum of 2  medical 
personnel” to “a member of medical personnel” (Section 6.3.1).  
• Treatment compliance was updated to include adherence to ammonia scavenger medication 
regimens and protein -restricted diet (Section 6.3.3).  
• The assessment of vector genome determination was removed globally. The results to date for this parameter , including the highest dose planned to be administered for the DTX301 program,  
have consistently demonstrated sequential reduction of blood viral load without rebound in 
values; therefore, based on medical consideration of results to date and to reduce subject burden , 
addit ional testing and collecti on of subject blood is not warranted (Sections 8.2, 10.5.3.6,  
Table  15-1). 
Ultragenyx Pharmaceutical Inc.  DTX301  
Protocol: 301OTC01   
Page 126 of 126 
Version 06 25 February 2020 • Electrocardiogram testing was removed from predose on Day 1 to reduce subject burden and 
based on medical evaluation of study results to date (Section  8.2.3). 
• It was added that prior to initiating the prophylactic steroid regimen (Cohort 4), the subject must 
be assessed as clinically and metabolically stable, and intercurrent illnesses (eg, viral infection) or 
concomitant medications known to affect transaminases, be excluded (Section 8.2.4.1.2).  
• Additional guidance was added to specify when ad hoc 24 -hour plasma ammonia assessments 
should be considered to ensure subject safety is paramount (Section 8.3.2).  
• It was explicitly stated that hospitalization due to hyperammonemic crisis will be considered a 
serious adverse event (Section 9.1.1.2).  
• It was added that adverse events will be assessed in terms of the relationship to corticosteroid 
regimen, in addition to the previously included assessments of relationship (eg, study product, 
[1-13C] sodium acetate, OTC deficiency, or hyperammonemia). This update was made per a 
request from the Data Monitoring Committee (Sections 9.1.2.1, 9.1.4).  
• The version of the NCI CTCAE to be used was updated from Version 4.03 to the most current version (Sections 9.1.3 , 14). 
• An Data Monitoring Committee meeting was introduced after completion of Week 12 for the first 
3 subjects dosed in Cohort 4. This meeting was ad justed  per a request from the Data Monitoring 
Committee  (Section 9.3 ).  
• The analysis of rate of ureagenesis was updated to include the relative percentage to normal 
healthy adults (Section 10.5.2.1).  
• The analysis of plasma ammonia was updated to include time-normalized plasma ammonia 
(Section 10.5.2.2).  
• Viral shedding, AAV8 neutralizing antibody, and AAV8 binding antibody IgG assay (ELISA) assessments were reduced based on medical consideration of results to date and to reduce subject 
burden (Table 15-1, Table 15-2).  
 
 